var title_f43_26_44448="Antibody development syphilis";
var content_f43_26_44448=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Time course of antibody development during syphilis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 208px; background-image: url(data:image/gif;base64,R0lGODlhcwHQAPcAAP/sFmji/85anIZ4hGi7/9DR0JIjK6hPgop4MxBGVP/sJQAAAnZdpbXItqq5qAAAIagqMNXHJ+vOFdDrzzlotffnQEc2MOnv1GdWMer87V2p/bqpJezo6dC5Fcq5JSVOlOnMJLipM0eH0KiUJVSZ+0U1RicGEaiYNP//Nfnv+dLu6+7/+BAsaMnHuZeHNsDUw/nWFEFDRgknTmoXIycWJ3dndzYzNmhXaOvW7KmqqLq1upaIl/rWJFVUVmhMWP/sNLmsuHhpNRciJaaynFRIWMirI2ZnZS9Xq6iYqCMlJnqCiezONMq2NEF4yEEKFjJwxjQmN1dUNElHMzY3RVhWZNa8IpmmkWxoSdXT6rq6xgMUSWhlM7uqGIuGi5eUmG+Z+1MSHpmJJ3h4fyUlNOe8KcjDyldlWIqGNFxXQ1dGNHl0MkZDUBUUJPjq71OX61pmZDUnJseqNO3WJbaZNdbGFufT1UZEKbm2rDaE54yFlXVpZ0mJ7LaqrLaZJlRHJ3pmKe7v9vrWMzY1JpeVNK65tjhELci8uKqmNe/WFScyM4UUExMAE38gKlpVJ/fNJBg3gao/Z6lzs0SW/BQUF2plcf/7CNTBOJyroairtY6CyRcIIHp1a2kLBouXi6aJN391J8awRfvoEZCY+0lUWViF6AAAGPnOE6KbmYuGKIsVKE5JSpSFi2plKAAENby2IpeZpSQmE6iKJ5WZjRcEAR1Gf+/WMpuVKQITNru1M2ZzZ+fGFIKId/nWCBc6bUpSNqenJRcUMkdVSdGtIG51OSkyKEaM/RhSrVpmLAcSJ3F2dQAAEEg4IAgRFSESAwsSCP//////GAAIGv//If//EP/3GP//KQkAGwkADPf////3EP/3IQAICgoIHPf/9v/3Lf/3////9gkIDvf3///39h0gGPL38y5gogsdYe/TCPXnJAwHK+e9GHdzHYwhEK0QCJwYFu/GNaqcJZycGPfGCE4+CGNSELCwP72174yfovTnMUpSIcY5Wkya35St/62E1qGM8yH5BAAAAAAALAAAAABzAdAAAAj/ABcIHEiwoMGDCBMqXMiwocMFygQqizgRosGJGEuVwqhM48aOHjU+eOCRZEiQIDdqTKkypEuWD1KONGlSZMmQI1221Pky5k2cPGnyvFmzVE2hRpO6pHkUqdKcQ23qLNo0akmSRW3WtAixoleOYFdynBp1ptSfV4XmZDqz7Vq3bY3GXSsVqlK5T63qPZv17F2eKD2CJMny6t6fdsse9htUbt+hapcudXqXLl/IjfU+Hhrtr+LBWiX7LeyZcVDSe4WiFt2SclTUpFcvnjiUtEnYh7Fi1ltY9smXZNGK1C26r2vTRBFP3ox88dmMH2mf7IjS907Ut38D1pnSembnoLcf/5YOlLXvjj6BW2X+XXhZZVmdPiZeunzlo3WTDmY+UX7eoOwZdxlORcVG3U4IalfbYuyx1px7eCUoWYHOCVbhguIp9pp9x9nHWHwXordeUolNVl6ADA5IX3H11YefZoJJR9uMKrF0IFrVxWjjbznluJdtJg5oIYYNnvSYdz/2Zh2QFd7WYWZFOsiihxqe2FiJU2EZJVpqIRlddGDdSN2OQ66EkxRplLKADUGcxAYCVYCAQEzQ1WjmneSpt6GeP/KZIYZl7nbnhcElSSiV7Q3pWoNYeQnZigAqCGGiI4r1ZYy/3Thknhs9cAI00vzRyhI/xGQNfCFUooAC0zDRKWHwqf9D0gJyUdejn5LiFB6d3BE26HW/2hmshTJmF9ifC1pHVZXHYrYaiFAxldtd8CGqn18CYpnff4V6lphuM5IXbpmxcbcRMAqcgEoVQXjzwALRRKNMGgAsAcwtS1QzRRA8gIBBKTZYAoIwUDyghiNV/IsBGRKEwEZ35ebqaLcSAiqsucA62x1QMh3qopTDWlvZs4cK+Chm8cVVpYayjXVgnS01+5qttTjSwQlVzCnYGdl4oqYgUahBTQggKDBGCNmEAIMlaGhTBQ88QMEDDCFMA4p62G285XoTW0wWe13nSu2eD2IXc2Vem1htpfK92JiIbutmlscr4wkdxL/m2F9gyiT/Ykk8rDCxhQJz+HQCNRhEpFEhloTBBQ8WhMDLBiFcMQIMLsTDywkRSNAHKFuICx5MuJZNd4Ydh3xtaen1KfJHZ++UHog9KVere5vxtxtWW6+n7aQtinX3xrCbyWnFH7VSRQgdDALAHBMN0+oDt1jCgwu6nLABCDY0or0uG3igyyEheIDAFSd4YMoGGOsp5ul0M+olkucNu/Z2I4kYqOq7d+qx2/vLC36iRaUOVcUw1nLbjupEI2JlSjvxgk8RQrAFagQBBkyICTIsAY0iVMFqIQDACXQBAzSAAARnkMD1ABCPIvBgGNTYgAtCUaqIdAVTs1Edk+hGOtcha3WWUlBv/yRUE/2lBmRGbB/++AIpwfQldQpiznyCV636cYdvDRTd3ZC3kc4ogxgogMMDcAGNJSSCVqXwmzbS9YBC1EIBIVgCBgoRCAUsIQgPGIQCeICAUuiRB4FAw5g4FbGXrGY1Agkg3gJFPLIVbzua4qHYWoMnisGvUK3jn4t8BRSTEehj2DpUmLY4nUhezE7yUgYyEikENclrGwt4gBCQoSZlRIOWG4llKyWCjFSqspUyC2KISpfL3mWqkONRYthId8iKJVEzmRRRMHnopSl+xy1WMl3wKDMm43WTNzIyEu/UpJFobGMbX1LGNvRWRTvBLICn4Q3ypBm7SSKokZqUkCnNlf+VZkHRY9JZ1g+tcj9iOid3ETKgroD3IEMOKix5086xaKSMIJBBGGTIGZgGqU5LJcET5GDDD6Ano3capWv4NCWZ7OmdwFBoU6jLZ3hE4igb3YiTMX1mk0zTz0xOMkr4qebvLFmjsejoT3wLyalKYYtKeMAVEoAGAuBjgYfBBw40UAkNLECDByBgGi4AhjdO8ABuKIMbbNBIEgr2zSMecmNDdOQjL2mulslUrgaVlE/BA7+uATVFR6wbAm26qaTacyPbsMY2vIq4B2BgGiFoRRymoYA0PEAY0/BGHEqRBlYpAA0R6EAoPFEFF8AjEF5FQRAwoA1owEMdwaypMGfbTsj/WDFtwzxlg6Y517Ct5EhKOR5R60rXDxGUUohq4hXH5bIhfnOfXnQBDDpAhg5EoBVhyMYZ6ECGKAAAAfIAQAk8AINhhAIeagjFGQoBgMxlAxgbAAAaQrGBr/osQRONKLm4uCGbPjGZGfPmnnzTT3gaWJ6/9aH7KiUlbXmSRPdc1CeD50QHbTFcGG6mc5UhXetKwAOt6IAuRkBeNdiiCB2gwxUksFk7RKER0PADN6DhAu9ibwNpoG8sYOCI26BUO60rTJDx6cAeEtl9vBKycG9LYfEImb95BZlnkFREKQ7nQgcsIGBhhbf31ZORNZJXKRAAgC08wAXyLYIuzjCCEJxg/x6DGCEaYFCEB/zhD1uYRhpaQY0RPKBzoYgCBgAQgkHgwh7CPV1cC9XS/r6GV3nlLTzDGazsPHSnSpwOgAMbyuMJ9MpoUxFxolSul0EMN4Tt4oE+NdVDTAMNapDGBhrGsw3oAnHxoIYHoHECKUyjCFuAhiX8WAlvAIMN1VhHPKRxhkQnCjeFLSinR4fUYEUyIxzpCkXCMsqPaLu5EoXyouGa6b5K+X9NPm6QYNpluL7sYjLawg+ioAxWBAKPZ5CDJZLwAKK5gAlBYMMJFACKB0TDEj8IAi5csKYluGAjWwABD+Yg5h4Cx9KTvgkyB6rDfGItTNdQxiJMsAgnmBwMM/9IucpXznKWg8EJYACDCWZO8kUsAsPf9hGRCwoTrf1TrhgXFENTQ7udYtGmmir1aGBnyzGhESN0uuGFY9YfSAewQPcL20vLPdzRgcXmJkA5IwxgAAiY/exoLzvZ1w6Btbud7WiPu9nXnnJGxPzlTqD5Ik7VbbsCUONL9vhC+dTEURsz3cKrpPBKSrJmplOLpfCiYfEracQcJdU6dFKFnP2sIo5p5DCfwdjjbgBGMGIGKHcCDUh+jUVsFCM5H6XISQ5zmJt+7HCXO9lNj/q82zw6OddveRY4IZpWy5h/DW7uxmkhnMZuXEXFGClR/WUInsefmZbmktJNvJk6mVkEmYX/yTmhCEWUPe2nl7kJwgSmHJ6NnbK3xt5HboKTp5zsui99ymOedxOEXPb7RVBAElfW9DU2ARPKxWAeQnwMRFyLpniLF32Vh2AzI4CXREiSYmQD0RE0wAiQ8IEfCAGnxwkmNwuz0G0XsyVBN1DdBHtg0XozF3qil3ttR3b793Ikx3cQJUpDN1N/d2RT0mAfZ0jhNEjtg4GaFgMW0BHq4AIuwAaxhAEhkAaT51DO1icG4nwptX31RBgDUQrnYAx48AVkqAEkcIZnWAx48ATGcA5a8C4bWBoykV/G0y1IOIEtCBbWcA0mQAMxZ3r4J3dtd3q+t4N4JRV2dVDIJ3yAMVHk/5Zo+9SIyiAEUWBHysAGgUAN1AACD3AG1CAN0pA4r7dIIVNNDvRoXNdQuSQQWkALT0AKX5AJDEALMnALtyAStigDtGAOTSACZygCFPAIrUAQcug63QdPTydMWYch8TdyNCCD55d2BpByS6VXJeFbHBIh2Vh8MCJR1WFUGfNO4qIk8FEB0IAOrvJYW/AH2YAAHVAFwIAI8AArBdGCFZYsuQUcieg1A9EKj9AEXyAKkeADMucQ8HELuygCZhiMcAgRVwREvZKP4AQo18Z+ysCH9QcGpmd21oA1DzQtfpVgWLZNFGVUXGgg0qcMNjAMMBAHXjUNNmADoRAC4PMAHvADNP+wAErwDFjQk1gACESARjDFV8GBjQ8ZGwuwCCVwBMUQiz7gBHGoYRXxha2okCRwBOegJkK5aasTeOQCGxO4edkmcjc3lIJ3UGWSSUOlK2ZjH5GIYVCmSfGyAGxADS6JCtAABzLpARKwAQ/ABQoABTr5DBnQDRmQAc8wAEK5cWGpSc6leKbkhSYACf+gASLQCza0lad2TyxREL2gkBpwBHC4NitlJHF5SnaCU0DITNNEYIcnfQNVZUQEMkVCWEX4kYu0T71BDNqwWX8wDRYgBaHgAnRQBK0QASBgVgXBDM+wCYupH6KjIxvnSIl0KAvgBJDgD1/wBDLwhQdGjsUzKwL/8QC0sAcaQAFaUJ1c11afgVtkE4mnSYEqxWiAlRxEJ4TvB31jUkTEZYw2MA1koAyFAA0bUATUEAOihQBJUwroRB0LIATNuZVisVsUyY/S1mROkAoC0A940J0OGWXGmJm94AahOYwOeSBBho/qloG4OXiHGHRAeHEUqGCvox61+XweoZ4/phPykgTecAgdoQYKgALNVghLIA2W8DAe0RkLMAbPoAfJGJ9RVmBexj8X6QTvsA//IAm9oJ4rioW1IRAywA+h+S7H535HxoVg9p7lZpQcVyVPMnQUlic611sNlHFUJxheFEH9AUzllKNO6pz6FGkW2FtcBytgYADucAAE//AEcOiNxXOMlsJ5giEQvaABBPAIXopfC/JS7/ama6o7RDmjDkUoO/R3J5VNdXiFg6popeSgMmESD/qkEqpgFyo2jZYpifoOqcAAGkALiZQd/aSmpLqKH0AATWCidzKsX1qq+7hzikchvVOacrpNBvSajZh4bTWOxWo3H+cbTUqr1yEmUpmSTMcncaUMJsAIEKAIYEABXFqd/zWjQ7QZhcGKGqABmrqYW7Kjh+Wq87R51ialtlWf3sKtRAhJl5awS2c/UzGrggqBt5l4LAo7PpV0dgMGZscJrVAMkpCen8qI40ZpD/gSAkELBLAHw9g/suN+24SaeXIkFOpDJVuqCv94Ont1hQxEaQCFq5warlDqnriSaqaGQ/e0COyaCgvAAiTQBIrjTlbqPzT1UND2HvAiAgTAAl5Kh6VDimZJJl7JT2h6RCrIMdxIE/rDnyGqXz7ikdNBHDJDrprWRUBbq3NFJaDRtrTFRepqdjOwtOdZnXRaefB5j8woTgJhDgRwBJuard+pj6cIqh5JGGprtAtbXK3xaQ6Cqg/Is9ZGuCCZVLtSt+jKSIZFuC01A21nAgtwrF0aS6aqJIYiYCEDhzJAACQwjMT6KyvIiPF0q55rlqZ6T/EprBDCSUVCpdH5QDuCJSb1QM6nHtEQrhELLG+5abILGNdQdowgEMd6C3b/e6cHNlt3y24zI55Yu68puj/ziStgIybRW7AqEb9rSr4lc27dWrHPO6iNma7A0RmAKq7QJ4GombCm1r4acZ1mB5ULcAQa0J2Ch3keN4flqxcnSwAUQE7fN5LU6rgB60x1iLkiTFdLVrjDiyxENpdOGrTZl4oTeacTobEQ4AQRcQ6/arfNhzyiCpsuWxICwQIpq8GY95iH6MJ+4qatCqLVWqNU1GU6oprhlr8uPL0rjMPia3zLqzVJPBHsagAhtwCtQADACh/PJTEfab30q7cdVy20kq+6W4zHxJmR2o1vFVzCa49GrGkFork0ir97FY6l+MEnbMFV3LURHCImUHYz/9ARsUQCFJBItrG8y3Vtk0SysRUUAoG15wAROIUipTuq7dOvPTySW4ZcoeGt+EipoJxTLkG6jEmxSox1JrDADroHbgDJCyaOfHspnMlkZwyHx/oB8kq8XqtI9huXPCe0nDqqvGVldBy30md1ISxuR9x+4KgT4WoEtQqJx1W1OuEEqwsSC0ALGgC+84SNGOvB7DuEPty6iyu4QkSjzQRprLq3UazE/5oixvFklvt404fH0WeadRwTDwAFy+AT6pAGS8gTVByhD8m2sYsni2B2ZakmYay198wbUDzH9CRP8/oRdEIaC3C7j0wrvuxsYKNx00K8OBpgueFgh2oa86PGIf9bsQB1ZtQADYFQCjTAA9LAa0NBvU8HbQOsj9GpN4tQduuXwKXgyFHK0oWaxNoqnXFcwWGqBe8MuwOLeBnts1adz5TXZCQzwlTEX9i3sBXpTDZAoKwADVEQBJWAAFwgDXAgzgTBDeIa0GhNp+YbFQvArjS8Eg1MABq8zEY8uPBWwF/pwuKM1Yy7zfXrzW/zQ2dtMR18n82qbgjltjsXvITqElHg1q0gAScwAgrwADD2L2qSBylQBq6dBc+gzS29mkHErbRxG6oLBjPSuuVs0kZ4ltnK10PbMkWNHSONwbgMyBVplLDRU149LDO70vaJKSXCzzNDfGeszNOBDApgCsL/oAtzAJgPIAXQEASMjA/PkN7PgA2xjcOVlFIbXFTg/LedsgBYDawgjMLaumGM6HnU7LAWjdwSCt+5ebmJDSv4nMdN8sfZCBW+5al3a8L2jCx24Aq4oAuZAwCONQ2JEw0NKRCT8Aw18Jz0A83L9RFJDQHSEUsaYA431KqUjKfnKixpfX1m/CoWHbjePMQIDoH11LlmXFsyDihbg8TKG9AlfNnOuqQqWQV/YAMAkAZqUAlRYAt5aUuWEq4jvmArWlK58tcQYAKV+gQaoDgmDtWvOreQec21PbI+jiDHLcxK19LXKNU3fojfmGnpIdmY+1enWxv+5OVQC8seUQvQkFml/5AEKDAN0OAqRtTQsn2NT/app/bbMbIAqvu3/cHb74JUl1fV6Ho83WdEj9i/IWHfmfqhzoTdYc1SchyjvLWP3RqntPNPWOS7x4xUhzTeW2BVbNAIUpBkpx6oJg3gNppDygDOjAB1YHzDal6nVnSnH4p0d4w6dJhoS5vq8J3rxid0AE7qxPLRpeofP/cgkGKvAIaSZ36E8Sydlo4TDc3C6iaptZ0pE20AN8fIC7AHjzzWNB65LfpIND3jk/o+E8uwF6y1gV7vJkXUxp7f8aTdhRSrHrLZLAupbUpKdyXJ0QnA2fzUzHjFr+oTysCuS51LFHDLXaGFbvuVg8G1jsdOgf9s4GdzGwuguJtcpXR+ycak5CqNHsKNz7vVMQTWHM97yYBezRbYG0exAInQ3nKM1oldahpL3wl8DgQAwSEMw3jiK6YUpbrpxFYquodLdeNMAJvcz2puYGQM8FCNTHlO2ZwUiXbhg3xVdBB9aSwfRJULrf/OEtM7BVBfs2AJTspAdkIJxsXg4lXq95AZqUdHu+5+3QTf7lhz8wSQng+99XMr8sZMvjxb2RCCElsH3QvOjX8hu9Q6ncxrN6LDHk4P9dUst0myABoLBk/XwCSgo+EGzdf8jeve+fnp+URrsTKTyRrQ6Y4vtXpdfc9K7Q9P3FIcsOjsTij51VQnzd3My9j/LPiRniHcZNUgcQ0imBKo3qUunV8dzFxfK/n9sVE+DnmcL/AJvAC+CM/+TbWWz/TrCRClBJZSpmzgwYIDEx4kaFDgQoUMCQp8QLDiwwcGLx7ciLBUR4YOGxZ0SFKkRJQhURoU2fLkRIbRFkx5ZmTBSpUeYaZ8OAOCCYcLFuyhIBQmyYZJcy592PQlwpcueYZ0mPGowoVPBy5Q5uaJUYktwzKdqpOjVrM80Zp92hHkx7JVy048mZWl0ro4oe5UaZevxZk1b1JVmzYpUmsQGN1dwIJAqQUXIXqMerdkU8yUqUr9mzmiZrpYL0dU9uAmgaKDM4/OutQy1s96J+ucfTd2/2HPcN/Ovbgbs9ixeW/HBh46JVrTNKkMRlsyI/CodJ38LDnUnGqllNcOn0v3qcnRTsWHhm688AIZGj5wnRoeqnDihrsfTliSZX2IIiXbNUl2qe+x/vpur4F2Ky1AnGYbKBqZlMOuLAPTUuYaAxajCD0NlLnJvpEG/A2vkcjrD7z7WssruuxEu6w88UzrhQAWsONsxZUOTBEuFGFDKsS7aKABDh9/hAIOIrlZgIY0NKnrLgsseAiKJi0AZiILgkgjI2tWyy2linbMD8QuSbNNq/BcMtOjaAQKrIcNuYvPMJbAoE7NodZDEL/ibgRNxY1yZM0/0mhb7USCFnjxHBm3Y//KPb0eKpO++oKQhhpooKmmGmhggMFSP0r5ARoXHEUoDWi8sWEBTVAAoFJvMCgljmmkgWYJGsLrk6O5tmvLPNxiwu8BNppiwzT31tyQzNvsa84AA0Ra4BENIBvQQ6uO4sy7q5Ci0Snb2uv2Km6He0moJkgwjUA3txRrLfxC1FOZIKgJgxV2PgkjDDokCOMXbuCgBh1atQohlFBcUEYTbyQ4Rg0APEhjmhPGOAMaBATKErbO2vusuS07QzaiIHiQholSJmFCGh6keKrBZ9ikLUdsNyZITjCCUoaE6zrqD2MFAx1zvA/TvS/Fb//MWET6ChWBBMgExTFP7iYjkSsNTaL/uk1Ht6DmDzj8qLUUDxRopSAEQgkBAASoNkkTHiKIQAFruFGAjmUwCCUeKaDpwA8/0GBDmTTni7rEykDE+D9elbFGmTG08SAKarb4JJsTQPBGkwUWF2rzMVpWDb7v3GOM2UWCOsINoeoL9N0CNy5uaKyeC7pRDq1CDsU8L+NKAxHAsva4RnFyosJUGGGEWeONZ3Z5Zq/BDwEeVoXGko/eZmMBNhRwZQwA+nigyWUsSIOGIKCRAoFp4HggEF2gmQaGiodRAJpK5HAycHXh+uhW+XYKXeN0EYQGCgjDAySAgBGk4wGfgIYFDLIAG/QgBmuAAhU857RrfcgyyjABBGr2/8BWaCBGv1nSR2A2NKkB6k7uglMGteQxwyzgFho4Anty9TF2ySl5O+QhD/NTvk8kwQ5JiEwEQgGMBQQBAHQQhgSKkIZqSEOKI5sDOjpABxio4QEKiAAw2AACGGDgDzbghhqmEYeMcIMsPevTttborbcUzSAjIJguLNABEJSCFdBoREEWII5nBFKQqvgcBpeElgXICShq+gAJNPQm/71QQnyJjlQI9TE1Mco8ijqcmhwzwrgITn/a8ePmqqahq6kOXtDwwylLEQEA/K0IofCAByIAgyAUohFRiIIU0IAIOtQSER4YgxzowDcJgAAB0BjBAzAAMYtQhJMeUmVrAqS6kP90CS3bIIgU7uYLXfRhAyB4wB+k4YebLCAYuxDDLnLRiQuOaZriUsbxghJCUM4IXCS8poIgUi28aPJl7PIMfETjmwV8gACICkvREPKgTopmny8siAukwQqFPAAF1QAWCrxhGgRIIxBV44pFQ/WATyHgB9lwnzTQUApLuA8aKPibouaplvz4pWc5cY8aoMEOA4ZgBDAYQxikIYgFMGhzQknCMwgpqBLxdDPTmYHpevcaqFEyqoQTT+GIhhuS6Axm/MyVhBbwBA2cK1cAKug1HVUby0wiCkpSiCCcpAwpCCIhebVPEvzAjYIIcRKCsINdkzARP1ipS24Rpc+M49A/caj/oDplQy2oEQpp2EAf0lAANSLwHMA9IBrJcernCBpJAflkkVwhAS0g+rLf2dRw6lrXZmKGLegQapNcGg1XliaUCBWGYzcU1br8GVUeSZRHO7pt/xAkM3CxqJ+EGY+GkKGGQxTCIFH4hRbDw7KnvqZX/awQSxZAiz08Epvocq5be/YtoK0kTK1bnaji8yXobqUUGrgOfHea38bWyHD/jQsm+QISTkpErNUsLj8flaxBISV1iIxBaed7HH+GpYM1g8wDWltID70VdnLUCv+2StbD2JbAlBxlHIH3ERku9LUAhNPRtOo6+GK4hHe6sFyOA5KKPGAjtmuhcgcnINmI18dq/6LJUxtMWzIVRJEPPIcGZDLRbOF2hSrKrzU5pK38VZe53WJXjhVyXgJo4bUElUx8RZlVRo01wDwBEFtZbMng1Dc3snOzfEjrZBt3LCzHa8gCKPAVg4oJXWdab42yCmFsNvpLGabo7CIiFDegbsYKFhqvqJvgDjV0UXMeJad3AqCogjZBHmFr7uybrsA42ZphXskiPJjOVhDgFlh7seAeTJja4pC9NU5ux0rjUJ6wtgnsOdDraC1Qr/ZFle85i366s2IIQXrVetIOgSQr4OgyZAEVXsNN2hy87OxITotg5FUjmr+f7UUjSH4xNSutJTDvONEMufBWZECAXqzZzu2lXf9u4oBGZViADAiYQxGKIAwEZGQOVRBGxdNQij4s4W/6Q04on2tqrlorcJXkGdCiDGo1VRjQeNpMoxXCLBBqgKHDLa6tPP7uFAe0369WC4Kf3fMAoRlRA5/PgezM1iVAQxClgMc0EHDZH1RjGiF4AAiyIQc5UAMAFqgCNJJgG51lm9QU0ZFBQUdCFnnJ1bdZwBqeEYNj9ZqFIbF1VTV0OmZXd6DbDrSNycxzdNeb7Hu69koWsLRHyv3aS2V84zcXEgvw8QHS2AAUAED1JETPAhtQgDoeEIJKYKAPADgstwfP79Ojns5vffWKNvhx1GrS5VoZ99uZcxkiewyFimzahwn/L+l0x947JE+WQB3FZ2TVtrkn8XmjzkVDG3oG1dnUwi20cP3ry0D722dB93txjslscQMWmAYrNAGNDRSECdnAQDwQ4XAJeIANHiC9MtQoagOr0Ddn6vSIyirs+HKWCoO72Pov0TkezXkEcykkT3s9LdmP8YKkAeM541sI5MuN92IdiUAPGUOtjImO8woAERxBEixBEdQAGyKJgZmDbEgCNkA/gmACaoiCeJAAOUgHXoiHB2CCWPo7lOu7Aju+2HINvZM7ZemQ4kiTwCDAb/u7a7K1xSgIEliPHyzCUaMLBJsWfou32YEd0ysrAJuKBTAHAlArGvOYW6CFBFhDNlxD/xlIgO3bvlt4jQXYAgDQhXx4ADhAPz0EAAUAhiJQACEAhkAIhTHYAACggQfIEtGJDaJrLH0SLyTbN4rSFhdSkxKwPUgyEQzkvQU4hzLkNW8xtqAxMy/cJzOLvVMUDtlqK0nKDK5wg2VLMNF5IMe7xcfbkQVQBwWYhjNIOGmQgPmRhi3YImlQIxSoBAuwBAAAAEoJFZobuxuSs9bYPwwLCTjAAG3EgGUoBT/ogz+YjYpoO010naPxMnvSkCZYtgThQkocxd2apGjqNQgsvhsztbnrC5A4DTtpKOdANxdrvag4gQowjSSoACbwACaIgoIIAUswkhOIABtAgBAIgQ1YAv80eInmO4sA2TkBw68qFLTcYwmLgoZQAABLSINs0AZqiANreSCaIEC2kEC6WAQDqKoF0AISkIG4y6hJk0fmojXq8kCjWb72Uj5p1EjIeIQ027QTmklfi7YUc0BtUqFSI7gLa76gJD64yjP/SYJjKAQ1CIUtoCMb+IVq+BrIWKrOkclJirOHmI6aMbSrerRFU7w3asXxAkm00zP5kiYdWTwKcKQZO7c3gr2ZdD133DPEBMLVi0BoO8WiI4ho0JAHoCUDIicGciCZIIJn+IYUSAEceIYS6EnCc7TjWQTW6kcWKgjDHMrjOs3aCCgBwS8IyzIs84+dshHMEAoCqKG7ACj/bAMUecIVu5TAkJRGxwqX1blEDFI0F4AGOJCbz/qDaWglyIiBDJgA7pyAZ7AAUUyhEKs7DWGBBZSqvntH49w34yPCyHKa2wTAHzSNfwOlCDxH1Ms/S3Mr+oLEiBgystsNIhuRFDK9dtmZ1iSIL/qBB+AGHiCnZVoGwFlLzinH/skgDvIgDaGAWdQzJZMNLnm34xQUgJI7j/Q4PjvD4zg8wkw94nQhe5uz1/S1OYsO/mE9eiK4vMQAaDgBgziEbPgEOvAGwNpAmihNbdq5ByMJn7CGyNCAXeu3GNWVsHjEnwMrQQM3esOVQNuOWCwK+NSgviC75FyU0xIlO9sObeKP/+BgDSqdt5ZDABQIgoKorFJRhW+RCbcrzXADQ2WAucYgzBN1kzEDQBX1wdnEiKmctP/5wDA0RX7LyaYEvKkoUY0JO+IijxANsEE9vVYTF+A5TtlKiCQoUvMgR/D0SpwiCFsDA6F4gqJwvfpiRQzM1Nbju9xMTx11sR1zTMgwh2jBjhv9v+f6Mv/U0ai5ygBV1lH6GalpxAAMQxVBrgOrPT6dxF5ThukwgSflyUh6VrCqQjjzR2T9HTFtzHLN0qb5zegb11zFP04NPNVTzv4Uq4moTBW7QlLyNhjittpzy6MUtxlolk9Mq00LoBJLtAzUzUGRR6hSz3PFv+QTt/q8Pf8S7VePazZprVR+YyyzADLE0TFzFE+/jI/5KjNNstY20bdOmhAIwMkjcLdrSlFKI9RG5Rhog8cP5MpaxUstVccMcUqfVbwyU1cZ5Q0uNSH9uVG145bdbE+ZyTDmU1napDYxmQ4niAwSGKFD6tXhLNeFHdN2BFUVVVRBS1QIwbQO1UKj9UCrJDUhm9fusNIne8rAVIkUxdZnzbF/ZUBs9R9FOi8UZA78dM/9vEZiI1v/8a/WIb6SpcVrfApJnTmzpVH+ZLF4xaHeSL2B81hgmzbYkrSL8B1Fe8mcELKgcDsmnC2vrCcDEAoRANPBc9OS2w8pfbLm4tf0xLPsmNGbxTb/LuxNpfWIMRzc6QvVbHJMvuxPSHQLRQkTz/1Jfa1VtM2MkzU+clxd58qpClmAEPJWuEzFLXVFeLtc4nSNnLrCVGTUyTwzN7gOEL25nEOIqmzOssVHuGXegDotOSPfSEPcaDIImRjAnvSLpEmIDUsomW3CA8OdrxK8x3UjFZI9Nn1byWzcADoIDmSoN9NfT9OLT8XLPtlcjmVe1M1CyZo1Wj3c+6LA2UBVvyXaKROhBynOxAkXuAxTB0ZPxIwyoRQwTDXajynepgmwCgRDLN1U33gLAQXZuG0X+zrQMDXf27SxcVRd0yKOJjyenDTYnCuhFC5Fd7mWquTftJtWVsvY/xqLis2V4C98IGXghw7NYCoVFWvsjLj1VU4KshIuuAe+3C8LtrKDFK3Q0+9MlFWli+6NWaoZMBrhv+gSX3mj1yQjQhA50zJFltHVAhkLSPoa0QL5Wrml5CZGCRRG0Fs1X6m0D244LPZIgsURDhh2QqjMUFfdg0dIwXs8OebMLajUPU1tWxelN8fVjBFlRVM0NBJohYM9Mnnl2M5VzhmNSv9CIb7LYQFWBiiCBrhhA0fgZgfqFkM+FahizkKZjlloBaZZ2XwDjacdZEbDGAaE2kIdNfGSkWdmPnn1EKHQAHYEzI2x1NnNwndF1xfrjWEtEKKrX2ses5JDMZ5SnINRgP8NEARqcAH0QQAJ+IHFIV63I2dzns2C8IlnqcugBDbTDbcd9uXEfSwgrCawQ9gGdGdf64jG6MCeC7H2nVsA0li33Vhq3jJU/EsfxABqQIC6sYG3aQVUkE7KZLzOIef1UkyE4OInsBMDJkV9JVmFLV9VTmRs3mEyfejJOttCAVb1mlZXK1QDtuGILpMwMbNo1t96jLTXORFZZb37qExlQABT0IV0CCM6iIBS+APzeSAkSIEyKAAdyIJnAGnetaQO4gR13jURs19LxBM3zWwNcsARO1DIImT/EzFJBLMw2yoGDltpYdcyrdEl5jSQHWZK5jjh8xIt7kKtAo8gYL8HGGz/PFqgaXAgyGiAZ1gBbFiBDHhstVEbuCoJOZkFBZwwzk6KuFYdiIJUm6qWd/TpkTAQiD3dNk3X+AQMTmbm/HzmTU2LOnvMpmBiTlsyb7HrESu2BvNBMcEraUAAGiiYeAgFKOCCavgbJVwqmjgV7Z7YnnhdWCVcCT7pO7NgYn7LodxXzBU1nhvUC063tqCmw5vjWYPb5khT2PbcSo1bEl/ausWqUzvcrWzN0mACaKCGAJeCy9KGQ6DMS1MF5fZf4zIARVgA39uZI9wT6cpdI5QPScwynU7kDw4e3GmOtTCNWyCAXKbfDPaP+VpiUU7vUgPQebVX2ckpqCnaln2IyNiC/0O4HmUQBHvYAgdfgFHYcW2ri2uAAMpe5hq25NDRzzG2y5OuWY4IMjHv06lu318ztWHViDEkgEc68YM+WhJWYvyd3YmIbRMn0w8XvnisuXx0Ceam74uQiTgH6Z61C6x9hFn0Mi+bKBX+tl8WSNlrqDy+NkkWW4J7csTdiJvwCq4IYiT200lvj1n3cnoV8i6z3xsZcug6JIEYOTUZdV3OdLoY2Fm46rg744it8JxVxUv+QnPl7mTH3V2+y4IOWBjj5Bhh2vv0u/5sbbplKyHjY04Ej+G7bPkOMZHWvaCAdqliRR8vBUnIJxzG7btt25/k5d0C1xt+6wRF77c97/9Qx/8FrF8nL1vH3TcAhW9EL/Gn8WzaXdxHdpaQ/+MbkYkeeAYoIFyyNQhb4wQt0ADz5qryoNbFpclX/CeXdkWXK9bC0Y/+ZfFlVxeAMo0F0IBYLVfnfXiDTuN4J3bZTlPTTnb+Q/C/jbe2gHPl/uxO7yATQK8UzOoYJd+5g9psmXkjC1hKK9Bfp1GBllxaaMpZ71nZPppIlz5id3reSlqOdcJtOWNrbitXx7kLOXmpPi5skpNreALgtO8IV9hYp9Qo/t9eRbdaH67Jd9R5nA8DObzeyfMrN4+N/Fh8PLrFSt6ODVdvW16i6fvtvUfIOHk4YHCtr48ZeActkISYr6TRAC3/0IXXa1Z2mgRX0DlTbweXvN17afReArCTuGdWZa1jeJ9754fbsJPidr4W3ZejAnTo3rKgMTgWFHodA+CED5DZ5pTiTZpvLqN5MUNfVOb0Kb4Ne7X1bmvYZa3wjll08+Y4KwWIB8pKlRpIsJTAgwgVMjRIcOCDBwQlMpRIcSJDhRcRblRoUJnDkANBHnSYseRJlA0fFmyZceACKs+gLPDokuVDZdYMOMHzYYHJlR9BBsXpkuRNlUZtriwpcinTlC2JSlXaMCjJrFWhvpRaU0OTBQs6pjRJFaPGrWrXpuV4kKJEZWSVEj0rsq7VgkinjtSLMmRSlxJjPktSc6reogMX/ylyIknG4b5//UoFLJnyx6hYb+6ljLhrXo9F8/YdXTYq29MLF/QiQCsy19hq556kndH27YqVR2rFeTZnb9AsIS4t7bQiYcOTfZNc4OQdCzwPatbtfRkwS4HXUfu9zHd47e5JseeUTRcz77VxU160ndC0sgVHNEx/2Rl35YWpc+t/i3araVDhlRh3m5V3Umad/ZbRAkYUBlRXlikDhiJHmAPUXooZldV2B3ZY4Hd/SdaZVdiR55mGnCHIVoAHhjfRdMq48cRh+5mV337+VQUXext1dBFvQ3FIomcbqqYikA/QEBhFC1DyzBg1qijiDKns0Qt1TzFHomXDGRhYYC26aP8jmE2teF5oRZ5pJlsLyECAFmMBWGZRuGXWX44YWcSebkJxdadTQY7ZIkhzOEKGAn7QAI80S8CB1EDRlOLkg+lpFdQ17TAiSZzjNXXjUcyJViKRgFZFqJgS4jjmcZj1Nxp8G3U51QJNkCBWnqVyt9WPqeEXEZ5GcvmpSqluOJYcEdjiihQbAHBGKD+0ZI1Y1fbw4JRhmvAOEXjgGmpKNQI64m4hGgfeZBmuORR43p2oZmqg7qrbuLpNt4AGR0iZbVL46UdWQglJZSewweLZnn4kvRfcUel9liZS0USjzBgSbDCCBcDA4EErG2hDA0xj3DByCXlgS+CdH23LAI0DKgj/H2nogQjqrA5BOOyowkH87pH++saUmEYtoIVr+/qa50qyDqwj0wa/xSOBx6Xc7o0UfVkSBtRIEEooQcBwyAMjQCOIMtEscMozaautnIiWgvQcKY8YbSS/QBe75ayfCqnzz2naPep6R7KY4lG2mbaAOQS0UmNHQXsUONJs9dq0RnNx2FbdDgOtLkhs+FLKLRIUQccGD/QhDRwLTMxMIYkk4kwyJ6uIFRgQkLI4eXG5G1u9D7NrU4Ypcr7lw6cRvqJiN25nUsFsrhVfE4rPTSySZXK358H8Md0XbXBBDnxxQfNs1AmOWGBDKGd4UAUUdHgzscTxVfsk2w2LygkkItz8/+XvpJlqvZ9OVZGh6C5BMRNQq6wWOXgtUID34ocGOvWfBcplaaLB3ot2NMEN2o9c9bpaWbBSiGpAAxrpeIAaoAGAamzBJBIzmxieQQMpnWgkioiEMSAkHk8ZUDuiKo5sggfENZHqT3+ji0i+9x8gTS1XaEmRWERAgHPURGBpQtgAHeIz0GCRIwZpntOgxioR9a1ErULiGFAxCDbUZAuHiIKBFhA7NooHUgpZQCoywYJ9Kag8RPJSGRWWswAtqEy06SMAVyXAq5hFXhOB1ZxOIhYKEGCP8AFhuRq4xA36yEetso5dAhnIBDlsYnipTrhiWC37ZGQWkPjCLbLkoT4Sp/863vGQ4JoImltCyji3zNm8Ism3A8ZrLWJJnNymZxNPvsiKufFensT4L6UBz3HUAwlZ/iekAE0nhph4RgyMBigTHIAUk8qk38oIpkKa6o9oKiY6ichBADGsTwKyZkGAxBoCiGBxc+tVi/zVRf+4R4MIQmSQ/sgwbRLRNBeRGKXSxjYTHcQJBwgLzcIUJuFJrXi69KMfj2emD4VUkYm0oOBGOkyPLIAFEDyCP4MyObRgEEw17VPBALZBhwZqSJ5aqbp+mk60mI0GKnhGN1LnvIdwIhMX+iDfNtO/M1pvfAgNVgURCb4QOtGg5pFnaAJmM9a4gQAwFUudNIlSe1ZORz//ssieeLnVk/LGivXc5oqKqjZy6JCHD1FEJl7zGVp2yY4GBM5cL+cqVuYKmxpFDFWCJ6iH2HVX78KNElXzxYeIhQUaIEATqNhXFlHOaTr6n1u9ikSIMRZddQsRkw4iqQUQIW0vsAFaKcqSBRjgC1gyKUgDKFzeJe+xxRTffdaFEOYJM5LEmc1+BAIUGYhAA274gA8zqFZelXYuAQMSMMGFz69CVSVmG4NtxVJbDmCoMgsoJ+6Exc6q3m1DI9Icm25puXfid7Hj1R5qgobWLfJHafdyEyX3CM+UIkiMCuyuW/41KsNqUreJ7AxEHTQBsewgbQ64mYBM4A99LSS7Ck2L/yMvaMeHWGMZcNAOauvrG2tYg3CH3S4D1RnMgqhjDKm9l1weICkw8i4uuPovmQjKVu1mJzeYXKmOjQiuk6wOt9coQNp2ARtQLQAMojgHPX7gCAXwwAVEWUASvIGCScXnN7Z0mTZ5YwEFSEMaZNDEue6bGFQOpBpLgGxCSSoslCEtu2AlyAKwfIMqyk8sA5hJtaR0SGki2bRp8Rk0eVTBg7Wncb5xpma266/4LYAGakNDX3+5gBJ8oRX1gEYEXCEBaVjAGmwoBRxirQkaWAMOpdDEowZCg2XUmAYWAPaS5EIDbsi1IJpQACLsgApoxEEZwwbZQOCwDDyXwhrHBgmv4f+QbFzDAQB/9vajSmEBGrAbz8rQBBveRR5CRm58BVlAC55BiZqIxQc34MYCcPAMLyxgETcowWh3jDQtHs1eNwGvd5sWOEv1LaMI5FdGm7iAGD5DBdj4FnouQts9KKMR0khDKaIAgD+AgAfSQMAGQjACadB5DnSOQyn+UA2awyEE0OABClAwh1J4AAUY4CNfklANXcABDggQBBxIWA0MlGIO0oCGAjThBwWQ8A+a8AYPdh6LB/jcGxazBp2r4QkLSAMG1fhBNayBARSAYp1MIXDjCLzBBRjiGVQACjfaoDZVYOMZKyiB2sqQ8JRWeow4JnLAnkfVC6ME1KGWMmcWkDb/M8TuGh/6yAI+EJZGAKAPYagCNNLgAUT8AgO68EAYYDCIDYQiDFygBhQ84Io0AOAECAhFBLbABQVAgRqWAHSCFmAHbZSwCprYAAjSIIHoT2MEW4DGCToQClaAQAEYmH4jOqAAFwBgAy4IxQgwoA0MjGD9ukDEIDAwDQwgQBpQ+GWqyOWhbOLTyPnugVjEQDd4gRc8Qxd0wUzkwDPoQQOA09x8UYxJXjRVxFspGYxwEjRZ2C4RUz5dBZ24FkGYUgwEwwK8wjN4HpsYGQVEwgI0AgwggjR4wyeoQyh4QCkkQShsQBiEQtgAgDqEgQ+yggQMIQKEATVYgDKoAQCMAABg/4DbeIkmYIAdJMEnhEIVFEEVeIAHRMAcAMAyKAMcWAD6KUMQUIMLSMAIlAL0OQsNPIACxIMmeIAcbCEGhEIfvJsCrE8E8IV1yFgQTZDlfRWi5Vs4FVwZYMMEPIMYIGAJcAA2AEI5PEMyyIl2ERmO4YQlwshALcRzQZczedDxyMveKFegMYhYKCDIgcYCtAIpQMICZA0GsEESKMMkKMAGKIMgpIMOwgAwxEMo0EA8SAAGlN/3IQACHOECwEE66IICgEx+KIMNoEAVKEkNaiEChEAIqEE2/AEcOAICgIDz9QE0BAEixMMDFAEIuAA0YEC5jQATBkE8yAHv9QFBhEAoAP9AGAzXFRlXJb4EXJjEApTBMwwAEZSAAl7CJuhbh1kAliWDLDwDwkmKfdQVfUmgWrjTBR6JYmDQ5bgMZNmd72hWcAXIbH1TqllFS30BIyzAJ0jD0YFE1IGAMtiBNESAB0gDDchBNdBABEBDFChAKCjANGzABpzcQDjL8TkMKKljCVWDDWyBNIQCNLiAGzYlG5zA1Q0lDUCDMDyAHECDDcjBNJSQB6hjKEgDNSAANBzfAvgBAChA6pTGkETWnhWPB7rNpeQZSwme2iSi2mDBQz6DFKhNBmxD2UikW/CINE0gJ2FEJ7JVROTUBWIR1PgLQ+2Q8eBIzTTEAhDCMxzZL03/ygdkgiIsgCDYwixOzCSgQiMswCR8gh/4wSeUQiN8AjfUZikIwgZgQCM0gh18wiSMhdh84XecEkk0wgggQLA1AgL4QUEkwR8o50A0gi1sAUE0Z8rNZhKcwB8EQSOUwhmEgR2ogQWogR2AxDJMw9AlD87MG594YGI+DacpQwwYQQ/0gBGwgQ1cQgyowhtMQid0wgLYwC68AVBITEREQ2QuKEfAVYl5lXtYDWVamp44XH/sCUcCmt6AIOQgVGiyC1YsQBZ8ZlCx1BNEQmm+GYdgCIaARHu5aG75nCW02dUEGipNSqTlqI7uqI7CJApUgyDABj+K1MWZIo8eKZImqZLy/6hOLBVKRRwgbhLmQJ6DKtC5oItS5pJIhma4jOhJAqRYHMEBOMGSlmmO0gM7RBqKINbyPEQJlIANlAC7WQAU2ECd2qkN5GmeQgGf3mmdToENcENBXOV5ktLCXWRDaMLIUAEV9AAR3CcRRCoRrIGkroGlXuqlTmqlUqqkdqqkOmqkgmoPUMGjEgGpmmoPMBvmLNBiUqiEUY4nrUeHYFLK8E+MoZaQgZ6X1tDGFUAZqAAOlEEBYAEWDCuxYgEOcAAOAAKzMmsKAEIKiEMKROu0Vuu0tkEKYME94AC2AuB7lNRUTQobqA25lqu5nqvaEEGW9M6ObdFoLMAaoKu8ziu91v/rvALgpqlW5GCo5PRIhR4URtplMNElzPRXQJJomSTaM1zABExABlwAxEasxE4sxUJsBkyAxDYswzZsIk6iiV2TSywANzxDC9gBGkhBFJgBGqzsFaysy74szEpBQqpr5TVQZniaVyDeLgiCFPRsz/pCFPxsz0YB0AZtFBytLwCt0PqsHTStFDQt1NpBIdjBMjStBdiBIAiCBWRt1sLCLjhghOnrkmVkhHoPGHXaIhXXSQGTxWkpSwlke72EiD7DLJip3e5oMzyDEYjTEd3RJDwDH9ztjqbBM6gCdXAW6ClT44WLBTzDFQgu5ELuFTggYvYIZjVmTWWulGYisEQEzZT/aLakyiGBCm4c7IEyxAvNbTNEruA27t9RE90wxAKMqyGwbrWgwTMAIEZwwwzFxxi0wQAAhUBJU2VyokUsQAw8wyYswDVsg1g4r5I67zZAr/RS7/NWS/VOL/ZGmvYuQEKG0wt1Glx17qtq0GaR7b/OlGTW1LicCOzGy7CQlKTERwGAw+KVTXwI5OrarpkOJr7aUrWoaF2I7DPcAf8uAO6uQYsugB48g/0uwLUALlotaaNNcJki3uMesAbraEJOAVBEWqOdWQBDCJROZvlGGPk+aUYGlTv5FD2NbUgOUqKVg5J65gYvKRw8gwIn6TX0sA9fQ7UA8TU8wxAccOPSBBCL/wUNZMAzsJccpU0ZLMI1LAIVcwMVL4ImLII1aAIXcwMXfzEYhzEbcLEJ7No1IJ4ezEIzmMAam4Abs/Ebx/EsxLEJzIId3zEe57Ee7zEeMzBEXgO8cfEYh3EgawI3ePHaAhhNtcWv7NSZEMqcwMwQlYjCIgEQXDImI4ElAwESAALgAgEf5IAhGEIZlHIpGwIftEAdrHId4AAO1IGwcoAszzIH1EEByPIFKGst1wE2uLIvtwEw40ABWOs3FHMtf0PaIPMzpMAKZMA4lGsKFMAzqw04OPAtg8M4ZPM4tIEjcsA4FDMyLysUA3FCPoM4eLK9pjO6roA6k2sktnPaiAM8l/8DO8Nz2mDCWOhdRjKy5WnuTvXhKBqMI0UWdshKsyGaZ5prNZNrMyNV4a1AN4ADNkx0N7BzM2dAM5dDBjDxCnBAN2w0RmP0MzgsSGeACkwAIk7ASXPsC7BzA7zABLwATDcAEztAA7z0C9w0IuJ0Ach0JMY0x570CxheA3Asx2JDTxdAUuf0EKiNWARD2qzALljBEOTAEDgAVmN1DjjAVXM1Vnd1Voe1TTdAVluBAzxDA3Q1WH/1VYO1LByVFeSAVWt1VW91WN8BVjcgWd80Idy0X/O1Xw/BUeW1WNt0X391WL+AEozWaEQcM6FwYqKtJlLP3SSXcDQbc6HWivKoZzr/g446iGfnqA08A27l6N8aro6qwmfq6GhbwI6apI4W4I4+Qw7E9jMEp44+wymk9jME6Y4mgdrMEDGkjQ7c8I7mMADaLSrebQ57sJnewYNALnetqoVKNmQ6JiGJ4njUKIM5zgCf2YgG5wDHkHif2bW49gAnQu62qIs6CFq1BATrsCzl72ojxQLA9kHM7jMUN1XcN6QlBlDQ9v4swA04oH3DBDksNMAlL2nTUDMR6aTE677ll81AN8BpJKIlr7oipiMpbDiFRkZ1Um0AizUBjGQqWSGdCpci6mVO2bzMVgMG5x3FEB2FIGG49kOYzWj7AGyYzZOAnNlciwLLLtwCpA3b/8y4GnBzLAB0K0dWhIOAw0WDPAOOF4VYMHFpJ4EYhIPjzFRuIK++KRODQDcbQZ4kIR4ADtnS4BvY+iuTSdyvPGYKExT2PFj/4IxILtc9gfiErViOTwqWyXh+m4ygw8S14JbNTMEz8DhKUAoQ75aDGO5RmG5mLMBZ59akAHdxs9mk9B1N+EWAWwGITTmON4Wa4iiEO2ZlRCZtPUMNiDlaKCwbcfiLLIBq/52au9cFPIO61jlOGdJ7Vs4mOqgF5pTSuCd3B6wAXWlxzlKle7Jn75YJyrhBPDHChWzyotpNbFx9c5aDfDjocQCJgh6W9ZV+1zateKZh2MzIGnBJeK98D/9WBw00CGJehq/3Fi1AU6tqJU6HohuugqLvHUG3ByvyCQfLhIYtkZ2vwPfKJ+b5h+bM97SwPJnKAiRCDNzJAgjBKHRGctAQfaoqhyDDupdGNAhBcS4APjRAZMCEEhQAiBWEEHB5SDCDEFyHMlyAGIjLAozCBUwUvRfJyyySZkBI5W7FNjBDBWEWiTODRBw9BymDYU63xElpaW2usGO9f2SpJBuQvEVyQN/T1HyLZIDcWIkL4oILyPnQe5ui1LT9He0Por3oux9utb83u1LOinMiZQ3MvWRP+kqXqzYaQqySr8vnUjTP97Tqvrrqr2OVlrgWJNnYQTHWvAXH7hQRm4X/UsWR0Q/9DiSLVyPdBYg2kZaIVJfL7mGc+iblKI6KxUzFxw10AU0sABSsAsLla3a02WDAPuNn0E01T2MjvvZgkGJ+pJc0EpQ5ab0DB54zEvLkxAMgQBUggMA8Ra0OhQUcyh/o0F3MCQIowNDNN4gABQLMwUAgABlYQhpoNoNNmUM52jfEx6MZ4PTQlriXwQzpwDMARBsoC0oVfFDqYCllC9o8cwjFgsNnXhYkLHhRWSkomkotgDJAU8WLFy0iLDkSpUmUFk8+YHnQpcGSLWEqy2izYEaFOxXi9KkzJU6MQIfmNHqUZ8qcRHvebMrT6Rxo1KTNAWpTp9ORQpVBqQYA/0C1NAST7mR6E6sLaXKgedJqFmlOOH+gKSiVRpo2aCgsvN3616hQpT2RPlhQgo/DBWwcrnhGROTWBeCeZXiWxcezborJovT4jJCNZ5cSm1HMtOCCxEAW3JA4MJpBkisByx5MG6HSmDBh5pZpMmNC1FhRCr5dHHVQjMuvKs2albnTq8rUofDQig4Ka9KTHhScdQO0VsDsbYF+9Dx3BREebPCmzudf4jsrQEO04YE3aWygQNsA1azntOIqudoyWuAUiRag5Jlk4HhGh8hgWkCVZ1RYoA4InwlHlmemWCA2opSJJhgikHjGCA6eWaCAZ8YA0TMoHCJkAYeseKacBZRJyP+iAnvbLSbdbOvtONl4m23HHgFcjqwB4SJsOfmKhGo456KsrSxYpIglFBeeWyqu86qQgAcAwqAyqeR0eiAdGNqTpi80uVqKjRhCqaKUYwp5oIhqgqjyyikFTc2Zclbs4pkYJnmmgM4wYmOUcEp4BpAWF9gFxcg8u/QZbHwAZIUFyvDQUYUwxOYZfBZ5powFDGWDIB5Takm3mWYbKUiZbCWJR1kRwgpY+XRML64ouUPvyS+nI+y8J5lTaoEFpKgGBrf8MjYwhECA4Yx4oAmiqemgEzcIAKSRQIE40yzLrAe0wXMBa6qABgEs2fVt3UEvipayBRCN4ZpnJiCIqWhreGb/hSRUXGCAZygpNacxapgEFkYXHvXF2HZi+JkenlHChGdyWEDFF63R97iTcF2JJl5bvjW++NgtMF/lbC6qOOTWLfAsm9gQxo9WPJCGhmUHe+6BCLR5wAJoTkBZRD9cwGADBeD7yclw2dDGg1Jo8IYaNLybstnmrhw7qMlWNOLjCu+AeKFRJ6BB1GcWSTAGkYhaICJAXCMkQTFO2ypgVrHBxovLXH2Gbo1TRllI3GbF1dfdhnLSOMCIUxPMIpfNqscHjs02zKWUQQYFABAI5QfD3hr3SmXOkEYYGKqxoTNlody9lmlicRpzEY1aIAloQHjgh2kQMUWaEPzKHNCbb1uI/zOJnlEF4gWIsP6ZhhWEe6EbHbpmUYdygREjtbtBtROEK1xxxKMntw1ylVXKTVb7kcxJyczBPMt0ZZOe/3YXvOMwxTs2yEc1IlA0nhFwJ2eoRj6i8CV7GUcZbAgBCkIgOp94EGdCSdoglHGIEBziEBEwD+mCVSwWFskiC+iEAzqiiglkoAcQU8gYHGCFHDhgCJfqxguSQDDnLGAMeYuWM3ogBB0uRFqs4pT50Hcb/cFwZbeaHJGsKBtxSW96sZNSzpDSLMhJyS8LQIYgQAgX4cUlGj4THbbM9jyEsMFZEGTWUwJFRjMGimaZi9aBohWrshVykAvYRrSw5MFB5oSRR/9bADd2ocRcvCCHpYiGyjhJFE5qcWUzuaLkenW5zV0OPQIqYxiFB0ArGQuDYeRjzubTx3DZDIH5OmUBO4ezAbrwjPrS3zC/c0b7nQSKqXkkDOc4x/vhK4v024mtrjjKmD3FlYKa0y/pCKjX0Uxntfzf7vyor2y6kGf2Uqcsm2O2LkZTloMZZnGsmTUsouyT8lRIrmjjK2jiD5m9NNpW3EnGsnAHLc8q53eyJjNavtI3gbQlRkZ5tHP2MpUWPSBEJYdL+bFESOD0XFxiEj19/hOkehzSSXUFT5agRZwyS+gq7wVIozjzoDULJhhnxTltGjSjBpLftcj2zJo20pj/FFT/NXmaVKCyjKVGOiknacLFlQRLWa+LqEHFOc2hnqckJo1n6XbqSpF28axYIlaBouWStN70nVOqqBeV+qtPciVItAIKP2mTJLj4KjiRo9VUBztXYP7vjdh6qBsP+1O6bhSMb8WVZBN7WNTcFZJkaY0PYrVTUOKLqUKa666sutelajF/nq2oNfn5I+RgMJZm9ew+nxpX0ErTpVLlFeXqZ9i6OrajB0FiHWpQSIfcQIeRg+Zoo/mSUkrTJa39EW+I1CsuAim62M3uSpn7z8vmcn6+8c6AYGvBheZ0UD5VJiLZ2173vhe+8ZXvfOlbX/suoHx8iNYQHDKA+/4XwAEW8IDf/6tFsZJkR8KsXF4VWzMR9YxsBT2niGhQAihcGMMXHgOGbZBhD2sYCmPYsIctXAITm5gIJSDCilfsgxu8GMYvrgElalBjG8+4xjTWQ41vcOMbD6DGAxDykIXcBSIbuQtJVnIX8rCKPDx5FUBugENaEC1MPQMINdgBEraMBC9/GQl8EDMQyFzmMusgC2jOQprZrAM3vzkHcY7zl72AhFdseQd51vMqdpDkHTxZz3nIcxd2wOc/d8HQfH7yov+chyTnYQBJJvIAxFBpH+vhBpSQ8Q1oa9B5WtGtue0r6QJE3jEuyVmO/SP1uNdqV78a1rGW9axpXWtbv9oxOIoW2xximf9b/xrYwRb2sK33olFaVZ4vU+5uQWjGrrZzdDp1TmILNopcmMEMb3gDtrmt7W1n29tvMMK2x01ub2P722YYhbrNEIxgjCIGU4hBIRIxhULYQAiJsEEi+J0IYiQiCf8WwsAFQYx/j8HgAQc4wJPQcIY3fAxCaLjEkyDxgV984JOYBBs0znGNf3wSThQNo6JlGpEpkhnMCMc2Vs7ybbycwOx1eTiY4YxoMWMSNyeHENiA8YEngRwTv3jFKU70ge/86DzveciT0HMhhJziRV84v22w76oXIgYuLOWxO4qbwcISShbUKjlbOdu3xBztiYzWNeR7DbqlHe7RIodDvhGtGPT/F5E2Ya/eB6l3rAzr78AqJBShGC0qUCFaULgBrAoP+GHpCPCEj3t9d4QTtMkVn8dEJk5bSVSMCjRA5Zz2OwM726WGAE6aqAYKHoCBarhlJ9bghk9CUA0MQPC5ppcnUBbgDIdYwO6ZWlnlR+rZGj0DuQ55AyLV0ZG2ItL5BLGG40gKUoDOKp+4xd/j+km/0LoM7J9HYwGj5/mnll5+mjuqzo72h2kEIQnZAAAwUAENO5RiGWnYTinggAE4KMNblkEdEAAOSgED/qBoIAvCxG+sFiAR3iA2DIORHoja1smWoqgMZKQbokUPBoDxbmAHBuIGBqAEissHdgC5lOFkCAqn/1KtsUwPsPSJr25LsMaJl7DFmczvjyQHnFTKwDgKsnqieGIBA0IhFNKAC7zhAfoAGqQhEDTBD6RhLyzgE6gBA7QBBaCgCvJCGm6vSgqKpmAHvfZFR/bFo2JnPqwpvBYgByojURhCIq5BBzQD+abMIVaBDjngGirL7O5pUKTrbLgPqn6loWZKndJp/cQQdNDpXvjQJi5PqEDnBzzgBCKADlwABE6ABqYhDNBgGjwhAiTAAugABFxAFyTgB0qBDaChCNIgHVyAWYhFDRsR1SBqdJ7t/M4ioFKjfC7hMJ7BAfTgGXagE16gYfggcV5ACAChexxABWClj8yvsSQrZQrLn/9+wzbWxOvcSHeQJQyLBat8SaLCZByByp0AKCNCAAZ4IAjiAV2k4A9CgQ50oQM8oAo6AASqIAJOgA7QRROU4QRAIBRA4PZSjQ+nx/MEiKbGyhtz41iKKX3u4A0TJANUYAVOAVFeYCISJ4d6QAUcwhByDlnAUP0MAv3wadn+cIvqCm2wajjI66xgp2ykMUB2sYUIKrJeSRnSAAZCwQLUgBdM4QE+ARpGYAv2UQKqIAg8IATCABFOIBvCgAbiIAjUIBtSESfH6RabKjBoEpVskSvND0HekG0IIRcKIEFUoEK8oENySBwwoQccA/FCBEnMKxJvKjl8i6qC4hrXz35iZpf/akuMsFGbTMuczDG9Vm0bdkQapIEbogAaUjE/oCEsLOAMKPNbRkAaoCACpMEFFAAaJEAaEMC8timEoE2Xxu4cbdBzVClZamoBWqBjouUCJEIQatMhOKBFxCA2rYcZqugmfOuoXpJ/dEo4dgXUhDMbyc+eAjOPBuqCXDAad9B01smblmIL1CCDEEAKbCIJzuAM2CAjGmEQ7EAZBCEIooEGtiAJuEENyvMFq3NmlEM4VjM65rM1w2naakkZxuANxDNaeiAZYGUSOiEGbKAHEsEMXmQBzEAWkkEkubIPJwqchompjrOoyMmXbAnCHij0bkk5qJMRlQoi96jUOkJAgMUn/yLPEINQqKCGndJLQs+QDLOikCSwveII+uIzSiARCKnTn7RxojrNs7AGazpnprbJNHuwSAczMcmqIVcJOhFTMPGT/T7HphQKScJKPrMyP6lRZSo0rbLm6/7i07RPqpANt65rXFS0TV+IJINC7Mb0ja5zZwYzL6F0RH/l1EoSsfQTB7tq/A4qsIiPFvNooRKKOKHHT1OSIVswqljyVoSDpZDzK2PRBWVK/WJJQ72S1BZL99JvOIV09MKu/MIkoDpU9A4M82TURYuvSvV0p7gOnj6LlHBrPpxzsQbKodZvSF+UITtnvKYxQy2QnVbtKzmVRjf0PhHxZiBIRHmUSuMUnwpki0hDdVKtKCAAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A comparison of the reactivity of the VDRL and FTA-ABS during the course of untreated syphilis. A substantial proportion of persons with primary syphilis may not have developed a diagnostic antibody response at the time the chancre of primary syphilis appears.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles B Hicks, MD; modified from the VD Program, Centers for Disease Control, US Public Health Service.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_26_44448=[""].join("\n");
var outline_f43_26_44448=null;
var title_f43_26_44449="Patient information: Heart block in adults (The Basics)";
var content_f43_26_44449=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/10/27809\">",
"         Patient information: Coronary heart disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/51/25395\">",
"         Patient information: ECG and stress test (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/58/34722\">",
"         Patient information: High blood pressure in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?10/48/11011\">",
"         Patient information: High cholesterol (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/49/6931\">",
"         Patient information: Pacemakers (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/17/33042\">",
"         Patient information: Vagal maneuvers and their responses (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Heart block in adults (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/heart-block-in-adults-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H7199712\">",
"      <span class=\"h1\">",
"       What is heart block?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Heart block is a condition that affects the electrical system that controls the heartbeat. Mild types of heart block can cause your heart to beat more slowly than normal or to skip beats. More serious types can cause your heart to stop beating. Without emergency treatment, serious heart block can be fatal.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7199727\">",
"      <span class=\"h1\">",
"       What causes heart block?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Heart block happens when the electrical signals that tell the heart to beat either get slowed down or stopped. Most people with heart block get it from a disease, surgery, or medicine that damaged their heart. In rare cases, people are born with heart block.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7199744\">",
"      <span class=\"h1\">",
"       What are the symptoms of heart block?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms depend on the type of heart block a person has. There are 3 types of heart block:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        First degree &ndash; This is the mildest type of heart block. Often, people with this type have no symptoms.",
"       </li>",
"       <li>",
"        Second degree &ndash; This type is more serious than first degree. Symptoms include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Fainting",
"       </li>",
"       <li>",
"        Feeling dizzy",
"       </li>",
"       <li>",
"        Feeling tired",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Chest pain",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Third degree &ndash; This is the most serious type of heart block. It can cause the same symptoms as second degree, but they will be more severe. In some cases, third degree heart block can be life threatening.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7199759\">",
"      <span class=\"h1\">",
"       Is there a test for heart block?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will probably do a test called an electrocardiogram (also called an &ldquo;ECG&rdquo; or &ldquo;EKG&rdquo;). This test measures the electrical activity in your heart.",
"     </p>",
"     <p>",
"      You might also need other tests to see if another condition is causing your slow heartbeat.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7199774\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have trouble breathing or have chest pain that lasts for more than a few minutes, call 9-1-1 for an ambulance.",
"     </p>",
"     <p>",
"      If you do not have these problems, but you often notice your heart beating slowly or skipping beats, talk to your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7199789\">",
"      <span class=\"h1\">",
"       How is heart block treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The treatment depends on the type of heart block you have. Often, people who have first degree heart block do not need treatment. But people who have third degree heart block and some people who have second degree heart block need a pacemaker. A pacemaker is a device that goes under the skin near a person&rsquo;s heart. It sends electrical signals to the heart that help it beat at a normal rate.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7199804\">",
"      <span class=\"h1\">",
"       Can heart block be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People who have heart disease are more likely to get heart block. Doing things that keep your heart healthy can help prevent heart disease. This includes:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Eating a healthy diet. This involves eating lots of fruits and vegetables and low-fat dairy products, but not a lot of meat or fatty foods.",
"       </li>",
"       <li>",
"        Walking or doing a physical activity on most days of the week.",
"       </li>",
"       <li>",
"        Losing weight, if you are overweight.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7199821\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/51/25395?source=see_link\">",
"       Patient information: ECG and stress test (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/49/6931?source=see_link\">",
"       Patient information: Pacemakers (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/10/27809?source=see_link\">",
"       Patient information: Coronary heart disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/48/11011?source=see_link\">",
"       Patient information: High cholesterol (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/58/34722?source=see_link\">",
"       Patient information: High blood pressure in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/17/33042?source=see_link\">",
"       Patient information: Vagal maneuvers and their responses (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?43/26/44449?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17118 Version 6.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-E57427EB1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_26_44449=[""].join("\n");
var outline_f43_26_44449=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7199712\">",
"      What is heart block?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7199727\">",
"      What causes heart block?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7199744\">",
"      What are the symptoms of heart block?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7199759\">",
"      Is there a test for heart block?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7199774\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7199789\">",
"      How is heart block treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7199804\">",
"      Can heart block be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7199821\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/10/27809?source=related_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/58/34722?source=related_link\">",
"      Patient information: High blood pressure in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/48/11011?source=related_link\">",
"      Patient information: High cholesterol (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/49/6931?source=related_link\">",
"      Patient information: Pacemakers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/17/33042?source=related_link\">",
"      Patient information: Vagal maneuvers and their responses (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_26_44450="Streak ovaries";
var content_f43_26_44450=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pelvic organs in a patient with complete failure of gonadal development",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The bilateral streak ovaries can be found attached to the posterior broad ligament.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_26_44450=[""].join("\n");
var outline_f43_26_44450=null;
var title_f43_26_44451="Pancreatograms AIP";
var content_f43_26_44451=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Pancreatograms either by MRCP or ERCP in autoimmune chronic pancreatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 542px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MRCP: magnetic resonance cholangiopancreatography; ERCP: endoscopic retrograde cholangiopancreatography.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn by permission from: Macmillan Publishers, Ltd: Kim KP, Kim MH, Song MH, et al. Autoimmune chronic pancreatitis. Am J Gastroenterol 2004; 99:1605. Copyright &copy; 2004.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_26_44451=[""].join("\n");
var outline_f43_26_44451=null;
var title_f43_26_44452="Lateral airway anatomy";
var content_f43_26_44452=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Midsagittal view of the airway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 541px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_26_44452=[""].join("\n");
var outline_f43_26_44452=null;
var title_f43_26_44453="Ketotifen (ophthalmic): Drug information";
var content_f43_26_44453=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ketotifen (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/1/3092?source=see_link\">",
"    see \"Ketotifen (ophthalmic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/53/25428?source=see_link\">",
"    see \"Ketotifen (ophthalmic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alaway&trade; [OTC];",
"     </li>",
"     <li>",
"      Claritin&trade; Eye [OTC];",
"     </li>",
"     <li>",
"      Zaditor&reg; [OTC];",
"     </li>",
"     <li>",
"      ZyrTEC&reg; Itchy Eye [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F186117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zaditor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F186149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, Second Generation",
"     </li>",
"     <li>",
"      Mast Cell Stabilizer;",
"     </li>",
"     <li>",
"      Piperidine Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F186119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Allergic conjunctivitis:",
"     </b>",
"     Ophthalmic: Instill 1 drop into the affected eye(s) twice daily, every 8-12 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F186132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/53/25428?source=see_link\">",
"      see \"Ketotifen (ophthalmic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     <b>",
"      Allergic conjunctivitis:",
"     </b>",
"     Children &ge;3 years: Ophthalmic: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F186120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F186102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]: 0.025% (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alaway&trade;: 0.025% (10 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Claritin&trade; Eye: 0.025% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zaditor&reg;: 0.025% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ZyrTEC&reg; Itchy Eye: 0.025% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zaditor&reg;: 0.025% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops], preservative free:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zaditor&reg;: 0.025% (0.4 mL) (30s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F186089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5278371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For use in eyes only. Wash hands before use. Do not let tip of applicator touch eye; do not contaminate tip of applicator. Remove contact lenses prior to administration. Wait 10 minutes before reinserting if using products containing benzalkonium chloride. Do not wear contact lenses if eyes are red. Allow at least 5 minutes between applications with other eye drops.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F186103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of eye itching due to allergic conjunctivitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6821374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Claritin&trade; Eye (ketotifen) may be confused with Claritin&reg; (loratadine)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ketotifen may be confused with ketoprofen",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ZyrTEC&reg; Itchy Eye (ketotifen) may be confused with ZyrTEC&reg; (cetirizine)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F186147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Allergic reactions, burning or stinging, conjunctivitis, discharge, dry eyes, eye pain, eyelid disorder, itching, keratitis, lacrimation disorder, mydriasis, photophobia, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Flu syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F186106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ketotifen or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F186093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Ophthalmic solution: Not to treat contact lens-related irritation. After ketotifen use, soft contact lens wearers should wait at least 10 minutes before putting their lenses in. Do not wear contact lenses if eyes are red. Do not contaminate dropper tip or solution when placing drops in eyes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self-medication (OTC), notify healthcare provider if symptoms worsen or do not improve within 3 days. Contact healthcare provider if change in vision, eye pain, or redness occur. Do not use if solution is cloudy or changes color.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5278361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F186099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F186108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical ocular administration has not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F186122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13222680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ketotifen has been identified in rat breast milk. It is not known whether detectable levels of ketotifen would appear in human breast milk following topical ocular administration.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F186107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Alaway Childrens Allergy Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% (5 mL): $7.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Alaway Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% (10 mL): $10.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Claritin Eye Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% (5 mL): $11.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ketotifen Fumarate Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% (5 mL): $12.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Wal-Zyr Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% (5 mL): $12.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Zaditor Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% (5 mL): $11.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (ZyrTEC Itchy Eye Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% (5 mL): $13.12",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F186109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Altriabak (BE);",
"     </li>",
"     <li>",
"      Asdron (BR);",
"     </li>",
"     <li>",
"      Asmalergin (BR);",
"     </li>",
"     <li>",
"      Asmaten (MY);",
"     </li>",
"     <li>",
"      Asmax (BR);",
"     </li>",
"     <li>",
"      Asmen (BR);",
"     </li>",
"     <li>",
"      Asumalife (MY);",
"     </li>",
"     <li>",
"      Bei Ka Ming (CL);",
"     </li>",
"     <li>",
"      Butifeno (MX);",
"     </li>",
"     <li>",
"      Denerel (MY);",
"     </li>",
"     <li>",
"      Dhatifen (MY);",
"     </li>",
"     <li>",
"      Dihalar (HR);",
"     </li>",
"     <li>",
"      Edifen (KP);",
"     </li>",
"     <li>",
"      Hyalcrom NF (MX);",
"     </li>",
"     <li>",
"      Kedrop (MX);",
"     </li>",
"     <li>",
"      Ketaxal (MX);",
"     </li>",
"     <li>",
"      Ketof (LU);",
"     </li>",
"     <li>",
"      Ketohexal (ZA);",
"     </li>",
"     <li>",
"      Ketoptic (VE);",
"     </li>",
"     <li>",
"      Ketotifen-ratiopharm (LU);",
"     </li>",
"     <li>",
"      Ketotifeno MK (CR, DO, GT, NI, PA, SV);",
"     </li>",
"     <li>",
"      Nemesil (BR);",
"     </li>",
"     <li>",
"      Orpidix (GR);",
"     </li>",
"     <li>",
"      Privent DPS (IN);",
"     </li>",
"     <li>",
"      Profilar (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Profilasmin-Ped (BR);",
"     </li>",
"     <li>",
"      Scanditen (ID);",
"     </li>",
"     <li>",
"      Totinal (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Zaditen (AE, AR, AT, AU, BB, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CN, CO, CY, CZ, DE, DK, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GY, HK, HN, HU, IE, IL, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, OM, PE, PH, PL, PT, PY, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UG, UY, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Zatin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Zatofen (PK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F186092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exhibits noncompetitive H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor antagonist and mast cell stabilizer properties. Efficacy in conjunctivitis likely results from a combination of anti-inflammatory and antihistaminergic actions including interference with chemokine-induced migration of eosinophils into inflamed conjunctiva.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F186105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Minimally systemic",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Woerly G, Loiseau S, Loyens M, et al, &ldquo;Inhibitory Effects of Ketotifen on Eotaxin-Dependent Activation of Eosinophils: Consequences for Allergic Eye Diseases,&rdquo;",
"      <i>",
"       Allergy",
"      </i>",
"      , 2003, 58(5): 397-406.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/26/44453/abstract-text/12752326/pubmed\" id=\"12752326\" target=\"_blank\">",
"        12752326",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8699 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-8913731101-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_26_44453=[""].join("\n");
var outline_f43_26_44453=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186116\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186117\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186149\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186119\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186132\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186120\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186102\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950127\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186089\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5278371\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186103\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6821374\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186147\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186106\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186093\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299559\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5278361\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186099\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186108\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186122\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13222680\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186107\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186109\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186092\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186105\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8699\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8699|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/1/3092?source=related_link\">",
"      Ketotifen (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/53/25428?source=related_link\">",
"      Ketotifen (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?38/29/39379?source=related_link\">",
"      Ketotifen (systemic): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_26_44454="Adenosine: Drug information";
var content_f43_26_44454=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Adenosine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/23/3444?source=see_link\">",
"    see \"Adenosine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/59/14261?source=see_link\">",
"    see \"Adenosine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F130686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adenocard&reg; IV;",
"     </li>",
"     <li>",
"      Adenoscan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F130687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Adenocard&reg;;",
"     </li>",
"     <li>",
"      Adenosine Injection, USP;",
"     </li>",
"     <li>",
"      PMS-Adenosine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F130728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiarrhythmic Agent, Miscellaneous;",
"     </li>",
"     <li>",
"      Diagnostic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F130690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Paroxysmal supraventricular tachycardia (Adenocard&reg;):",
"     </b>",
"     I.V. (rapid, over 1-2 seconds, via peripheral line; see",
"     <b>",
"      Note",
"     </b>",
"     ): Initial: 6 mg; if not effective within 1-2 minutes, 12 mg may be given; may repeat 12 mg bolus if needed (maximum single dose: 12 mg). Follow each dose with 20 mL normal saline flush.",
"     <b>",
"      Note:",
"     </b>",
"     Initial dose of adenosine should be reduced to 3 mg if patient is currently receiving carbamazepine or dipyridamole, has a transplanted heart or if adenosine is administered via central line (ACLS, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pharmacologic stress testing (Adenoscan&reg;):",
"     </b>",
"     I.V.: Continuous I.V. infusion via peripheral line: 140 mcg/kg/minute for 6 minutes using syringe or volumetric infusion pump; total dose: 0.84 mg/kg. Thallium-201 is injected at midpoint (3 minutes) of infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute vasodilator testing in pulmonary artery hypertension (unlabeled use) (Adenoscan&reg;):",
"     </b>",
"     I.V.:  Initial: 50 mcg/kg/minute increased by 50 mcg/kg/minute every 2 minutes to a maximum dose of 500 mcg/kg/minute (Schrader, 1992)",
"     <b>",
"      or",
"     </b>",
"     to a maximum dose of 250 mcg/kg/minute (McLaughlin, 2009); acutely assess vasodilator response",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F130709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/59/14261?source=see_link\">",
"      see \"Adenosine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Rapid I.V. push (over 1-2 seconds) via peripheral line, followed by a normal saline flush:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Paroxysmal supraventricular tachycardia (Adenocard&reg;):",
"     </b>",
"     Infants and Children: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Manufacturer's recommendation:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &lt;50 kg: Initial: 0.05-0.1 mg/kg (maximum initial dose: 6 mg). If conversion of PSVT does not occur within 1-2 minutes, may increase dose by 0.05-0.1 mg/kg. May repeat until sinus rhythm is established or to a maximum single dose of 0.3 mg/kg or 12 mg. Follow each dose with normal saline flush.",
"    </p>",
"    <p style=\"text-indent:2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;50 kg: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Pediatric advanced life support (PALS, 2010):",
"     </i>",
"     Treatment of SVT: I.V., I.O.: Initial: 0.1 mg/kg (maximum initial dose: 6 mg); if not effective within 1-2 minutes, administer 0.2 mg/kg (maximum single dose: 12 mg). Follow each dose with &ge;5 mL normal saline flush.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F130691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Elderly may be more sensitive to effects of adenosine.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15671324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling. However, adenosine is not renally eliminated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15671325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling. However, adenosine is not hepatically eliminated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F130666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 3 mg/mL (2 mL, 4 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adenocard&reg; IV: 3 mg/mL (2 mL, 4 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adenoscan&reg;: 3 mg/mL (20 mL, 30 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F130651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F130670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adenocard&reg;: For rapid bolus I.V. use only; administer I.V. push over 1-2 seconds at a peripheral I.V. site as proximal as possible to trunk (not in lower arm, hand, lower leg, or foot); follow each bolus with a rapid normal saline flush (infants and children &ge;5 mL; adults 20 mL). Use of 2 syringes (one with adenosine dose and the other with NS flush) connected to a T-connector or stopcock is recommended. If administered via",
"     <b>",
"      central line",
"     </b>",
"     in adults, reduce initial dose (ACLS, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adenoscan&reg;: For I.V. infusion only via peripheral line",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F130734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Abciximab",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F130669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adenocard&reg;: Treatment of paroxysmal supraventricular tachycardia (PSVT) including that associated with accessory bypass tracts (Wolff-Parkinson-White syndrome); when clinically advisable, appropriate vagal maneuvers should be attempted prior to adenosine administration;",
"     <b>",
"      not effective for conversion of atrial fibrillation, atrial flutter, or ventricular tachycardia",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adenoscan&reg;: Pharmacologic stress agent used in myocardial perfusion thallium-201 scintigraphy",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F1141723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACLS/PALS Guidelines (2010): Stable, narrow-complex regular tachycardias; unstable narrow-complex regular tachycardias while preparations are made for synchronized direct-current cardioversion; stable regular monomorphic, wide-complex tachycardia as a therapeutic (if SVT) and diagnostic maneuver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adenoscan&reg;: Acute vasodilator testing in pulmonary artery hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F130726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Frequency varies based on use; higher frequency of infusion-related effects, such as flushing and lightheadedness, were reported with continuous infusion (Adenoscan&reg;).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Transient new arrhythmia (eg, atrial premature contractions, atrial fibrillation, PVCs) after cardioversion (55%), facial flushing (18% to 44%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (2% to 18%), dizziness/lightheadedness (2% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: GI discomfort (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Discomfort of neck, throat, jaw (&lt;1% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Chest pressure/discomfort (7% to 40%), dyspnea (12% to 28%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: AV block (infusion 6%; third-degree &lt;1%), ST segment depression (3%), hypotension (&lt;1% to 2%), chest pain, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Nervousness (2%), apprehension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Upper extremity discomfort (&le;4%), numbness (&le;2%), paresthesia (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Hyperventilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Asystole (prolonged), atrial fibrillation, bradycardia, bronchospasm, burning sensation, blurred vision, hypertension (transient), injection site reaction, intracranial pressure increased, loss of consciousness, metallic taste, MI, respiratory arrest, seizure, torsade de pointes, ventricular fibrillation, ventricular tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F130673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to adenosine or any component of the formulation; second- or third-degree AV block, sick sinus syndrome, or symptomatic bradycardia (except in patients with a functioning artificial pacemaker); use in patients with atrial fibrillation/flutter with underlying Wolff-Parkinson-White (WPW) syndrome (Fuster, 2006); asthma (ACLS, 2010)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In addition to the above, Adenoscan&reg; should be avoided in patients with known or suspected bronchoconstrictive or bronchospastic lung disease.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F130655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Atrial fibrillation/flutter: There have been reports of atrial fibrillation/flutter when administered to patients with paroxysmal supraventricular tachycardia (PSVT) and may be especially problematic in patients with PSVT and underlying Wolff-Parkinson-White syndrome; has also been reported in patients with or without a history of atrial fibrillation undergoing myocardial perfusion imaging with adenosine infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction disturbances: Adenosine decreases conduction through the AV node and may produce first-, second-, or third-degree heart block. Patients with pre-existing SA nodal dysfunction may experience prolonged sinus pauses after adenosine; use caution in patients with first-degree AV block or bundle branch block; use is contraindicated in patients with high-grade AV block,  sinus node dysfunction, or symptomatic bradycardia (unless a functional artificial pacemaker is in place). Rare, prolonged episodes of asystole have been reported, with fatal outcomes in some cases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May produce profound vasodilation with subsequent hypotension. When used as a bolus dose (PSVT), effects are generally self-limiting (due to the short half-life of adenosine). However, when used as a continuous infusion (pharmacologic stress testing), effects may be more pronounced and persistent, corresponding to continued exposure. Use infusions with caution in patients with autonomic dysfunction, carotid stenosis (with cerebrovascular insufficiency), uncorrected hypovolemia, pericarditis, pleural effusion and/or stenotic valvular heart disease; discontinue infusion in patients who develop persistent or symptomatic hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Proarrhythmic effects: Monitor for proarrhythmic effects (eg, polymorphic ventricular tachycardia) during and shortly after administration/termination of arrhythmia. The benign transient occurrence of atrial and ventricular ectopy is common upon termination of arrhythmia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Arrhythmia (wide-complex tachycardia): Avoid use in irregular or polymorphic wide-complex tachycardias; may cause degeneration to ventricular fibrillation (ACLS, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart transplant recipients: Use with extreme caution in heart transplant recipients; adenosine may cause prolonged asystole; reduction of initial adenosine dose is recommended (ACLS, 2010); considered by some to be contraindicated in this setting (Delacr&eacute;taz, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary artery hypertension: Acute vasodilator testing (not an approved use): Use with extreme caution in patients with concomitant heart failure (LV systolic dysfunction with significantly elevated left heart filling pressures) or pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis; significant decompensation has occurred with other highly selective pulmonary vasodilators resulting in acute pulmonary edema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Avoid use in patients with bronchoconstriction or bronchospasm (eg, asthma); mild-to-moderate exacerbations have been reported following use in a limited number of patients with asthma. Per the ACLS guidelines, use considered contraindicated in patients with asthma. Use caution in patients with obstructive lung disease not associated with bronchoconstriction (eg, emphysema, bronchitis); respiratory compromise has occurred during use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Wolff-Parkinson-White (WPW) syndrome: Use in patients with atrial fibrillation/flutter with underlying WPW syndrome is considered to be contraindicated since ventricular fibrillation may result (Fuster, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Caffeine: Pharmacologic stress testing: Since caffeine antagonizes the activity of adenosine, withhold for 5 half-lives prior to adenosine use; avoid dietary caffeine for at least 12 hours prior to pharmacologic stress testing (Henzlova, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbamazepine: Concomitant use potentiates the effects of adenosine; reduction of initial adenosine dose is recommended when used for SVT (ACLS, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dipyridamole: Concomitant use potentiates the effects of adenosine; reduction of initial adenosine dose is recommended when used for SVT (ACLS, 2010); withhold dipyridamole-containing medications for at least 24 hours prior to pharmacologic stress testing (Henzlova, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drugs which slow AV node conduction: Use with caution in patients receiving other drugs which slow AV node conduction (eg, digoxin, verapamil).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Theophylline (includes aminophylline): Pharmacologic stress testing: Since theophylline antagonizes the activity of adenosine, withhold for 5 half-lives prior to adenosine use whenever possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be at increased risk of hemodynamic effects, bradycardia, and/or AV block.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adenocard&reg;: Transient AV block is expected. When used in PSVT, at the time of conversion to normal sinus rhythm, a variety of new rhythms may appear on the ECG. Administer as a rapid bolus, either directly into a vein or (if administered into an I.V. line), as close to the patient as possible (followed by saline flush). Dose reduction recommended when administered via central line (ACLS, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: ECG monitoring is required during use. Equipment for resuscitation and trained personnel experienced in handling medical emergencies should always be immediately available. Adenosine does not convert atrial fibrillation/flutter to normal sinus rhythm; however, may be used diagnostically in these settings if the underlying rhythm is not apparent.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F130660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caffeine: May diminish the therapeutic effect of Adenosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May enhance the adverse/toxic effect of Adenosine. Specifically, the risk of higher degree heart block may be increased. Management: Consider using a lower initial dose of adenosine in patients who are receiving carbamazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: May enhance the adverse/toxic effect of Adenosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the therapeutic effect of Adenosine. Dose reduction of adenosine may be needed. Management: Reduction of the initial dose of adenosine may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nicotine: May enhance the AV-blocking effect of Adenosine. Nicotine may enhance the tachycardic effect of Adenosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May diminish the therapeutic effect of Adenosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F130684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Adenosine's therapeutic effect may be decreased if used concurrently with caffeine. Management: Avoid food or drugs with caffeine for at least 12 hours prior to pharmacologic stress testing.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F130662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F130675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Adenosine is an endogenous substance and adverse fetal effects would not be anticipated. Case reports of administration during pregnancy have indicated no adverse effects on fetus or newborn attributable to adenosine. ACLS guidelines suggest use is safe and effective in pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F130694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F1620757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid dietary caffeine for at least 12 hours prior to pharmacologic stress testing.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Adenocard Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg/2 mL (2 mL): $39.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12 mg/4 mL (4 mL): $82.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Adenoscan Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg/mL (20 mL): $261.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Adenosine Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg/2 mL (2 mL): $10.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12 mg/4 mL (4 mL): $26.28",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F130664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     ECG, heart rate, blood pressure",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F130676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adenocard (BR);",
"     </li>",
"     <li>",
"      Adenocor (AU, BE, BG, CZ, DK, EE, EG, ES, FI, GB, GR, HN, HU, IE, IL, KP, LU, MY, NL, NO, NZ, PE, PL, PT, SE, SG, TH, TW, UY, VE, ZA);",
"     </li>",
"     <li>",
"      Adenoject (IN);",
"     </li>",
"     <li>",
"      Adenoscan (AU, ES, HK, JP);",
"     </li>",
"     <li>",
"      Adenosina Biol (AR, PY);",
"     </li>",
"     <li>",
"      Adenozer (TW);",
"     </li>",
"     <li>",
"      Adrekar (AT, DE);",
"     </li>",
"     <li>",
"      Cardimax (PE);",
"     </li>",
"     <li>",
"      Cardiovert (PH);",
"     </li>",
"     <li>",
"      Krenosin (FR, IT, LU, MX);",
"     </li>",
"     <li>",
"      Krenosine (CH);",
"     </li>",
"     <li>",
"      Tricor (CN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F130654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Antiarrhythmic actions:",
"     </b>",
"     Slows conduction time through the AV node, interrupting the re-entry pathways through the AV node, restoring normal sinus rhythm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Myocardial perfusion scintigraphy:",
"     </b>",
"     Adenosine also causes coronary vasodilation and increases blood flow in normal coronary arteries with little to no increase in stenotic coronary arteries; thallium-201 uptake into the stenotic coronary arteries will be less than that of normal coronary arteries revealing areas of insufficient blood flow.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F130672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Very brief",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Blood and tissue to inosine then to adenosine monophosphate (AMP) and hypoxanthine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: &lt;10 seconds",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Blomstr&ouml;m-Lundqvist C, Scheinman MM, Aliot EM, et al, &ldquo;ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias--Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 108(15):1871-909.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/26/44454/abstract-text/14557344/pubmed\" id=\"14557344\" target=\"_blank\">",
"        14557344",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Delacr&eacute;taz E, &ldquo;Clinical Practice: Supraventricular Tachycardia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(10):1039-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/26/44454/abstract-text/16525141/pubmed\" id=\"16525141\" target=\"_blank\">",
"        16525141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ellenbogen KA, Thames MD, DiMarco JP, et al, &ldquo;Electrophysiological Effects of Adenosine in the Transplanted Human Heart. Evidence of Supersensitivity,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1990, 81(3):821-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/26/44454/abstract-text/2306833/pubmed\" id=\"2306833\" target=\"_blank\">",
"        2306833",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122 (18 Suppl 3):640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/26/44454/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuster V, Ryden LE, Cannom DS, et al, &ldquo;ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(4):149-246.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/26/44454/abstract-text/16908781/pubmed\" id=\"16908781\" target=\"_blank\">",
"        16908781",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harrison JK, Greenfield RA, and Wharton JM, &ldquo;Acute Termination of Supraventricular Tachycardia by Adenosine During Pregnancy,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 1992, 123(5):1386-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/26/44454/abstract-text/1575160/pubmed\" id=\"1575160\" target=\"_blank\">",
"        1575160",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Henzlova MJ, Cerqueira MD, Mahmarian JJ, et al, &ldquo;Stress Protocols and Tracers,&rdquo;",
"      <i>",
"       J Nuc Cardiol",
"      </i>",
"      , 2006, 13(6):e80-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/26/44454/abstract-text/17174798/pubmed\" id=\"17174798\" target=\"_blank\">",
"        17174798",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al, &ldquo;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):876-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/26/44454/abstract-text/20956230/pubmed\" id=\"20956230\" target=\"_blank\">",
"        20956230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McIntosh-Yellin NL, Drew BJ, and Scheinman MM, &ldquo;Safety and Efficacy of Central Intravenous Bolus Administration of Adenosine for Termination of Supraventricular Tachycardia,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1993, 22(3):741-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/26/44454/abstract-text/8354807/pubmed\" id=\"8354807\" target=\"_blank\">",
"        8354807",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McLaughlin VV, Archer SL, Badesch DB, et al, &ldquo;ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2009, 119(16):2250-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/26/44454/abstract-text/19332472/pubmed\" id=\"19332472\" target=\"_blank\">",
"        19332472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neumar RW, Otto CW, Link MS, et al, &ldquo;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):729-67.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rich S, Kaufmann E, and Levy PS, &ldquo;The Effect of High Doses of Calcium-channel Blockers on Survival in Primary Pulmonary Hypertension,&rdquo;",
"      <i>",
"       N Engl J Med,",
"      </i>",
"      1992, 327(2):76-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/26/44454/abstract-text/1603139/pubmed\" id=\"1603139\" target=\"_blank\">",
"        1603139",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schrader BJ, Inbar S, Kaufmann L, et al, &ldquo;Comparison of the Effects of Adenosine and Nifedipine in Pulmonary Hypertension,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1992, 19(5):1060-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/26/44454/abstract-text/1552096/pubmed\" id=\"1552096\" target=\"_blank\">",
"        1552096",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9359 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-17F8E0A872-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_26_44454=[""].join("\n");
var outline_f43_26_44454=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130686\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130687\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130728\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130690\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130709\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130691\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671324\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671325\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130666\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130651\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130670\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130734\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130669\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1141723\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174500\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130726\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130673\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130655\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298689\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130660\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130684\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130662\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130675\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130694\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1620757\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322965\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130664\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130676\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130654\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130672\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9359\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9359|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/23/3444?source=related_link\">",
"      Adenosine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/59/14261?source=related_link\">",
"      Adenosine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_26_44455="Genetic factors in inflammatory bowel disease";
var content_f43_26_44455=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genetic factors in inflammatory bowel disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/26/44455/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/26/44455/contributors\">",
"     Scott B Snapper, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/26/44455/contributors\">",
"     Daniel K Podolsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/26/44455/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/26/44455/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/26/44455/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/26/44455/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/26/44455/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory bowel disease (IBD) is comprised of two major disorders: ulcerative colitis (UC) and Crohn's disease (CD) with more than 1.4 million affected people in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/1\">",
"     1",
"    </a>",
"    ]. These disorders have both distinct and overlapping pathologic and clinical characteristics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/17/7450?source=see_link\">",
"     \"Definition, epidemiology, and risk factors in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of UC and CD are not well understood. The role of genetic factors will be reviewed here. Immune and microbial mechanisms are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/48/27401?source=see_link\">",
"     \"Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two issues related to genetic factors in IBD: factors that increase the susceptibility to IBD, which will be reviewed here; and genetic syndromes that are associated with an increased risk of IBD. However, more than 85 percent of patients with CD have no family history of IBD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Genetic susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of observations in both humans and animal models suggest that genetically determined factors contribute to IBD susceptibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     &nbsp;Animal models",
"    </strong>",
"    &mdash; The ability to delete or modify genes selectively (such as interleukin [IL]-2) in animal models has contributed to the understanding of the genetic loci that may be involved in IBD pathogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. These experiments have revealed several important observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Colitis is a relatively nonspecific phenotype that can result from alterations in a variety of genes. Genes affecting both the adaptive and innate immune system as well as epithelial function can lead to intestinal inflammation.",
"     </li>",
"     <li>",
"      A single genetic alteration can be associated with a variable clinical presentation, depending upon the specific strain of mice used, suggesting that the actual phenotype results from interactions among multiple genetic loci.",
"     </li>",
"     <li>",
"      The lack of colitis observed in susceptible strains with genetic alterations when maintained in germ-free environments demonstrates that the genes confer disease susceptibility, but actual disease is dependent upon the presence of microorganisms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Human studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;IBD appears to follow a non-Mendelian pattern of inheritance.",
"   </p>",
"   <p>",
"    The most compelling clinical evidence for the heritable risk of IBD has been obtained from twin studies, which also suggest that genetic factors may be more important in CD than in UC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In a study that included 80 twins with IBD, for example, the concordance rate for monozygotic twins was markedly higher in CD than UC (50 versus 19 percent) and continued to rise over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    First-degree relatives of patients with IBD are approximately 3 to 20 times more likely to develop the disease than the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/10-15\">",
"     10-15",
"    </a>",
"    ]. In one report, children in whom both parents had IBD (CD or UC) had up to a 33 percent chance of developing IBD by age 28 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/10\">",
"     10",
"    </a>",
"    ]. All of the affected offspring developed CD and were born to parents who both had CD. In addition, having a sibling with CD can increase the risk of developing CD by 30 times compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/13\">",
"     13",
"    </a>",
"    ]. Approximately two-thirds of sibling pairs are diagnosed within ten years of each other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children of an affected parent who is Jewish may be at a higher risk of developing IBD. One study evaluated the lifetime risks for IBD in offspring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/14\">",
"     14",
"    </a>",
"    ]. The likelihood of developing either CD or UC was significantly higher if the affected parent was Jewish (8 versus 5 percent for CD in the parent and 5 versus 2 percent for UC in the parent).",
"   </p>",
"   <p>",
"    Clinical features of the disease also demonstrate a heritable pattern. Concordance in the location (eg, ileal versus colonic) and type (eg, fibrostenotic, fistulas) of CD has been observed, as illustrated by the following findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/16-21\">",
"     16-21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 554 patients with CD, 17 percent had a family history of CD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/16\">",
"       16",
"      </a>",
"      ]. Concordance of the site of disease in at least two family members was observed in 86 percent of cases, and 82 percent were concordant for the clinical type of disease.",
"     </li>",
"     <li>",
"      Another report evaluated 72 families with two to five or more affected first degree relatives [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/17\">",
"       17",
"      </a>",
"      ]. Concordance for disease location and type were present in 56 and 49 percent in families with two affected members compared to 83 and 76 percent in families with more than two affected members.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is some support for \"genetic anticipation,\" which refers to the development of earlier onset and more severe disease in offspring of affected parents in subsequent generations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/15,22,23\">",
"     15,22,23",
"    </a>",
"    ]. In one study, for example, 48 of 57 children with CD born of parents with CD developed symptoms a median of 16 years earlier than the onset of disease in their parents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/22\">",
"     22",
"    </a>",
"    ]. Rather than reflecting genetic anticipation, the preceding observations may in part be explained by ascertainment bias because children of parents with IBD may be subjected to earlier diagnostic evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/17,24\">",
"     17,24",
"    </a>",
"    ]. In addition, apparent genetic anticipation may be explained in part by bias secondary to the lack of adjustment for different observation times among subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/25\">",
"     25",
"    </a>",
"    ]. Since children of affected parents are typically followed for a much shorter time span than their parents (up to a lower average age), the average age of disease onset in children may be lower than would be found if this group were followed for a longer time. However, this cannot be the entire explanation since the parents may be first diagnosed after the child (12 of 49 cases in one series) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Specific genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although genetic alteration in any one of several individual genes in mice is sufficient to lead to an IBD-like syndrome, in humans, alterations in single genes confer a modest effect by themselves; it is likely that the aggregate effect at several loci contributes to the IBD phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of screening approaches, most notably genome-wide association studies (GWAS), have implicated over 100 distinct susceptibility loci for IBD, some contributing unique",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    combined risk for CD",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    UC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/28-50\">",
"     28-50",
"    </a>",
"    ]. Similar studies in pediatric cohorts have identified many of the same genes associated with adult IBD risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/40,50\">",
"     40,50",
"    </a>",
"    ]. Deep resequencing of genes identified by GWAS in patient cohorts have further identified rare variants within these loci adding to the overall genetic variation associated with IBD risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/51\">",
"     51",
"    </a>",
"    ]. Such gene identification strategies have pinpointed several critical signaling pathways that have been consistently associated with IBD susceptibility. Analysis of the functional properties of the proteins encoded by these various genes has further aided in identifying specific mechanistic pathways that are important in the pathogenesis of these disorders.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Intracellular innate immune pathways recognizing microbial products in the cytoplasm",
"      </strong>",
"      &ndash; The IBD1 gene on chromosome 16 encodes the protein NOD2 (CARD15) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/31-37\">",
"       31-37",
"      </a>",
"      ]. Mutations in IBD1 confer susceptibility to ileal CD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/33-35\">",
"       33-35",
"      </a>",
"      ]. In a prospective cohort of 186 children, the prevalence of NOD2 mutations was 42 percent, suggesting that early onset CD has a strong genetic component [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/37\">",
"       37",
"      </a>",
"      ]. The wild-type NOD2 protein activates nuclear factor kappa B in response to muramyl dipeptide, a fragment of bacterial peptidoglycan [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]; this process is deficient in patients with the mutant form of NOD2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/48/27401?source=see_link\">",
"       \"Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       The autophagy pathway",
"      </strong>",
"      &ndash; Several CD associated genes (ATG16L1, IRGM, and LRRK) regulate the autophagy pathway, an innate homeostatic process that permits recycling of intracellular organelles, as well as contributes to the removal of intracellular microorganisms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/30,44,45,52\">",
"       30,44,45,52",
"      </a>",
"      ]. NOD2 can also regulate autophagy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/53,54\">",
"       53,54",
"      </a>",
"      ], suggesting that these pathways are integrated and defective in some patients with CD.",
"     </li>",
"     <li>",
"      <strong>",
"       Pathways regulating adaptive immunity",
"      </strong>",
"      &ndash; Adaptive immune genes that regulate both the IL-17 and IL-23 receptor pathway have been implicated for IBD risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/42,47\">",
"       42,47",
"      </a>",
"      ] including genes associated with risk for both UC and CD (eg, IL23R, IL12B, STAT3, JAK2, and TYK2) and those implicated in CD only (eg, IL-27, TNFSF15). Some of these genes (STAT3, JAK2, and TYK2) overlap with the IL-10 immunoregulatory pathway that has also been independently linked to both UC and CD.",
"     </li>",
"     <li>",
"      In a study of two unrelated families with children who had CD, homozygous, recessive loss-of-function mutations in the IL-10 receptor gene were identified in four of nine children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/41\">",
"       41",
"      </a>",
"      ]. One of the children had refractory CD and was treated successfully with allogeneic hematopoietic stem cell transplantation. In addition, homozygous IL-10 loss-of-function mutations have been found in patients with early onset CD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Pathways regulating epithelial function",
"      </strong>",
"      &ndash; A number of epithelial barrier genes are specifically associated with ulcerative colitis and not Crohn&rsquo;s disease (eg, OCTN2, ECM1, CDH1, HNF4A, LAMB1, and GNA12) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/49,56\">",
"       49,56",
"      </a>",
"      ]. Genes that control Paneth cell biology and the ER",
"      <span class=\"nowrap\">",
"       stress/unfolded",
"      </span>",
"      protein response have also been identified in CD (eg, Xbp-1; Nod2) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Major histocompatibility complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have evaluated potential associations of IBD with major histocompatibility complex (MHC) loci [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/43,58-73\">",
"     43,58-73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24167?source=see_link\">",
"     \"Human leukocyte antigens (HLA): A roadmap\"",
"    </a>",
"    .) Considered together, these studies have demonstrated that HLA-DR2 is associated with UC, particularly in Japanese patients, and extraintestinal manifestations of CD are more commonly observed in patients with HLA-A2, HLA-DR1, and DQw5. In a genome-wide association study (GWAS) of a Japanese population, HLA-Cw*1202-B*5201-DRB1*1502 haplotype was associated with increased susceptibility to UC but decreased risk for CD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, results among studies have varied. Some variation may be due to the different methods used to assess MHC; only recently have these been determined at the molecular level. Variation among different population groups may also account for the differing results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     GENETIC SYNDROMES ASSOCIATED WITH IBD",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Turner syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Turner syndrome is caused by the absence of an X chromosome (45 XO) or by the presence of an abnormal, dysfunctional X chromosome. One of these abnormalities is present in approximately 1:5000 live female births. Common features of Turner syndrome include short stature, webbed neck, widely spaced nipples, cubitus valgus, and cardiac defects (especially bicuspid aortic valve, coarctation, and aortic stenosis). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33449?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An association with IBD has also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. In one of the largest series, 4 of 135 (3 percent) adults with Turner syndrome developed IBD (two with UC and two with CD), an incidence much higher than an age-matched population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hermansky-Pudlak syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomatous colitis similar to CD has been reported in individuals with Hermansky-Pudlak syndrome (HPS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. HPS is an autosomal recessive disorder characterized by oculocutaneous albinism, abnormal platelet aggregation with bleeding diathesis, and pulmonary fibrosis. Genetic linkage analysis has identified a candidate gene for HPS on chromosome 10q23. In one study, 8 of 49 (16 percent) patients with HPS had IBD; four of the eight had a mutation in this gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Glycogen storage disease type 1b",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with glycogen storage disease type 1b present in infancy with hypoglycemia, growth failure, hepatomegaly, and neutropenia, secondary to a deficiency of the glucose-6-phosphate translocase (transport protein). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/48/16136?source=see_link\">",
"     \"Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These patients develop a granulomatous colitis pathologically similar to CD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/80\">",
"     80",
"    </a>",
"    ], which responds to treatment with granulocyte-macrophage colony stimulating factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/81\">",
"     81",
"    </a>",
"    ]. Interestingly, a case report described the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    to treat fistulae in an adolescent boy with CD, suggesting altered neutrophil function may be a contributing factor to the pathogenesis of idiopathic CD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44455/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/56/10115?source=see_link\">",
"       \"Patient information: Crohn's disease in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/17/42258?source=see_link\">",
"       \"Patient information: Ulcerative colitis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/40/24196?source=see_link\">",
"       \"Patient information: Crohn's disease (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/39/10869?source=see_link\">",
"       \"Patient information: Ulcerative colitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95254869\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Studies of humans and animal models suggest that genetically determined factors contribute to inflammatory bowel disease (IBD) susceptibility. The colitis phenotype results from interactions among multiple genetic loci but actual disease is dependent upon the presence of microorganisms.",
"     </li>",
"     <li>",
"      Clinical evidence for the heritable risk of IBD is suggested by the high concordance rate for Crohn's disease (CD) in monozygotic twins and a 3- to 20-fold increased risk of IBD in first-degree relatives of patients with IBD. Clinical features of the CD also demonstrate a heritable pattern with concordance in disease location (eg, ileal versus colonic) and type (eg, fibrostenotic, fistulas). Furthermore, the presence of \"genetic anticipation,\" which refers to the development of earlier onset and more severe disease in offspring of affected parents in subsequent generations, also suggests a heritable cause for IBD.",
"     </li>",
"     <li>",
"      Genome-wide association studies (GWAS) have implicated over 100 distinct susceptibility loci for IBD. Rare variants within these loci have been identified adding to the overall genetic variation associated with IBD risk. The functional properties of the proteins encoded by these genes has aided in identifying specific mechanistic pathways that are important in the pathogenesis of IBD. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Specific genes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several studies have evaluated potential associations of IBD with major histocompatibility complex (MHC) loci. However, results among studies have varied. Some variation may be due to differences in methods used to assess MHC and in population groups studied. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Major histocompatibility complex'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several genetic syndromes have been associated with IBD. These include Turners syndrome, Hermansky-Pudlak syndrome, and glycogen storage disease type 1b. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Genetic syndromes associated with IBD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/1\">",
"      Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004; 126:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/2\">",
"      Orholm M, Munkholm P, Langholz E, et al. Familial occurrence of inflammatory bowel disease. N Engl J Med 1991; 324:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/3\">",
"      Satsangi J, Jewell DP, Bell JI. The genetics of inflammatory bowel disease. Gut 1997; 40:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/4\">",
"      Mizoguchi A, Mizoguchi E. Animal models of IBD: linkage to human disease. Curr Opin Pharmacol 2010; 10:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/5\">",
"      Saleh M, Elson CO. Experimental inflammatory bowel disease: insights into the host-microbiota dialog. Immunity 2011; 34:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/6\">",
"      Tysk C, Lindberg E, J&auml;rnerot G, Flod&eacute;rus-Myrhed B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988; 29:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/7\">",
"      Thompson NP, Driscoll R, Pounder RE, Wakefield AJ. Genetics versus environment in inflammatory bowel disease: results of a British twin study. BMJ 1996; 312:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/8\">",
"      Orholm M, Binder V, S&oslash;rensen TI, et al. Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand J Gastroenterol 2000; 35:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/9\">",
"      Halfvarson J, Bodin L, Tysk C, et al. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology 2003; 124:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/10\">",
"      Laharie D, Debeugny S, Peeters M, et al. Inflammatory bowel disease in spouses and their offspring. Gastroenterology 2001; 120:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/11\">",
"      Roth MP, Petersen GM, McElree C, et al. Familial empiric risk estimates of inflammatory bowel disease in Ashkenazi Jews. Gastroenterology 1989; 96:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/12\">",
"      Mons&eacute;n U, Brostr&ouml;m O, Nordenvall B, et al. Prevalence of inflammatory bowel disease among relatives of patients with ulcerative colitis. Scand J Gastroenterol 1987; 22:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/13\">",
"      Fielding JF. The relative risk of inflammatory bowel disease among parents and siblings of Crohn's disease patients. J Clin Gastroenterol 1986; 8:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/14\">",
"      Yang H, McElree C, Roth MP, et al. Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut 1993; 34:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/15\">",
"      Satsangi J, Grootscholten C, Holt H, Jewell DP. Clinical patterns of familial inflammatory bowel disease. Gut 1996; 38:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/16\">",
"      Bayless TM, Tokayer AZ, Polito JM 2nd, et al. Crohn's disease: concordance for site and clinical type in affected family members--potential hereditary influences. Gastroenterology 1996; 111:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/17\">",
"      Colombel JF, Grandbastien B, Gower-Rousseau C, et al. Clinical characteristics of Crohn's disease in 72 families. Gastroenterology 1996; 111:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/18\">",
"      Polito JM 2nd, Childs B, Mellits ED, et al. Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology 1996; 111:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/19\">",
"      Peeters M, Nevens H, Baert F, et al. Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology 1996; 111:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/20\">",
"      Henckaerts L, Van Steen K, Verstreken I, et al. Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol 2009; 7:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/21\">",
"      Annese V, Andreoli A, Astegiano M, et al. Clinical features in familial cases of Crohn's disease and ulcerative colitis in Italy: a GISC study. Italian Study Group for the Disease of Colon and Rectum. Am J Gastroenterol 2001; 96:2939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/22\">",
"      Grandbastien B, Peeters M, Franchimont D, et al. Anticipation in familial Crohn's disease. Gut 1998; 42:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/23\">",
"      Lee JC, Lennard-Jones JE. Inflammatory bowel disease in 67 families each with three or more affected first-degree relatives. Gastroenterology 1996; 111:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/24\">",
"      Lee JC, Bridger S, McGregor C, et al. Why children with inflammatory bowel disease are diagnosed at a younger age than their affected parent. Gut 1999; 44:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/25\">",
"      Picco MF, Goodman S, Reed J, Bayless TM. Methodologic pitfalls in the determination of genetic anticipation: the case of Crohn disease. Ann Intern Med 2001; 134:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/26\">",
"      Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/27\">",
"      Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol 2010; 28:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/28\">",
"      Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008; 40:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/29\">",
"      Fisher SA, Tremelling M, Anderson CA, et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet 2008; 40:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/30\">",
"      Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007; 39:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/31\">",
"      Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/32\">",
"      Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/33\">",
"      Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002; 122:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/34\">",
"      Vermeire S, Wild G, Kocher K, et al. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet 2002; 71:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/35\">",
"      Hampe J, Grebe J, Nikolaus S, et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 2002; 359:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/36\">",
"      Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002; 123:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/37\">",
"      Kugathasan S, Collins N, Maresso K, et al. CARD15 gene mutations and risk for early surgery in pediatric-onset Crohn's disease. Clin Gastroenterol Hepatol 2004; 2:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/38\">",
"      Rioux JD, Silverberg MS, Daly MJ, et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet 2000; 66:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/39\">",
"      Rioux JD, Daly MJ, Silverberg MS, et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat Genet 2001; 29:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/40\">",
"      Kugathasan S, Baldassano RN, Bradfield JP, et al. Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. Nat Genet 2008; 40:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/41\">",
"      Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009; 361:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/42\">",
"      Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/43\">",
"      Forcione DG, Sands B, Isselbacher KJ, et al. An increased risk of Crohn's disease in individuals who inherit the HLA class II DRB3*0301 allele. Proc Natl Acad Sci U S A 1996; 93:5094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/44\">",
"      Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007; 39:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/45\">",
"      Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 2007; 39:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/46\">",
"      Noble CL, Nimmo ER, Drummond H, et al. The contribution of OCTN1/2 variants within the IBD5 locus to disease susceptibility and severity in Crohn's disease. Gastroenterology 2005; 129:1854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/47\">",
"      Franke A, Balschun T, Sina C, et al. Genome-wide association study for ulcerative colitis identifies risk loci at 7q22 and 22q13 (IL17REL). Nat Genet 2010; 42:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/48\">",
"      Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010; 42:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/49\">",
"      Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011; 43:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/50\">",
"      Imielinski M, Baldassano RN, Griffiths A, et al. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet 2009; 41:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/51\">",
"      Rivas MA, Beaudoin M, Gardet A, et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet 2011; 43:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/52\">",
"      McCarroll SA, Huett A, Kuballa P, et al. Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nat Genet 2008; 40:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/53\">",
"      Cooney R, Baker J, Brain O, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010; 16:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/54\">",
"      Travassos LH, Carneiro LA, Ramjeet M, et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010; 11:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/55\">",
"      Glocker EO, Frede N, Perro M, et al. Infant colitis--it's in the genes. Lancet 2010; 376:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/56\">",
"      UK IBD Genetics Consortium, Barrett JC, Lee JC, et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet 2009; 41:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/57\">",
"      Kaser A, Lee AH, Franke A, et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 2008; 134:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/58\">",
"      Danz&eacute; PM, Colombel JF, Jacquot S, et al. Association of HLA class II genes with susceptibility to Crohn's disease. Gut 1996; 39:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/59\">",
"      Mathew CG, Easton DF, Lennard-Jones JE. HLA and inflammatory bowel disease. Lancet 1996; 348:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/60\">",
"      Reinshagen M, Loeliger C, Kuehnl P, et al. HLA class II gene frequencies in Crohn's disease: a population based analysis in Germany. Gut 1996; 38:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/61\">",
"      Satsangi J, Welsh KI, Bunce M, et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 1996; 347:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/62\">",
"      Nakajima A, Matsuhashi N, Kodama T, et al. HLA-linked susceptibility and resistance genes in Crohn's disease. Gastroenterology 1995; 109:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/63\">",
"      De La Concha EG, Fernandez-Arquero M, Santa-Cruz S, et al. Positive and negative associations of distinct HLA-DR2 subtypes with ulcerative colitis (UC). Clin Exp Immunol 1997; 108:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/64\">",
"      Duerr RH, Neigut DA. Molecularly defined HLA-DR2 alleles in ulcerative colitis and an antineutrophil cytoplasmic antibody-positive subgroup. Gastroenterology 1995; 108:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/65\">",
"      Sugimura K, Asakura H, Mizuki N, et al. Analysis of genes within the HLA region affecting susceptibility to ulcerative colitis. Hum Immunol 1993; 36:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/66\">",
"      Kobayashi K, Atoh M, Konoeda Y, et al. HLA-DR, DQ and T cell antigen receptor constant beta genes in Japanese patients with ulcerative colitis. Clin Exp Immunol 1990; 80:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/67\">",
"      Asakura H, Tsuchiya M, Aiso S, et al. Association of the human lymphocyte-DR2 antigen with Japanese ulcerative colitis. Gastroenterology 1982; 82:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/68\">",
"      Bouma G, Oudkerk Pool M, Crusius JB, et al. Evidence for genetic heterogeneity in inflammatory bowel disease (IBD); HLA genes in the predisposition to suffer from ulcerative colitis (UC) and Crohn's disease (CD). Clin Exp Immunol 1997; 109:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/69\">",
"      Hesresbach D, Alizadeh M, Bretagne JF, et al. Investigation of the association of major histocompatibility complex genes, including HLA class I, class II and TAP genes, with clinical forms of Crohn's disease. Eur J Immunogenet 1996; 23:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/70\">",
"      Smolen JS, Gangl A, Polterauer P, et al. HLA antigens in inflammatory bowel disease. Gastroenterology 1982; 82:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/71\">",
"      Zetterquist H, Broom&eacute; U, Einarsson K, Olerup O. HLA class II genes in primary sclerosing cholangitis and chronic inflammatory bowel disease: no HLA-DRw52a association in Swedish patients with sclerosing cholangitis. Gut 1992; 33:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/72\">",
"      Biemond I, Burnham WR, D'Amaro J, Langman MJ. HLA-A and -B antigens in inflammatory bowel disease. Gut 1986; 27:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/73\">",
"      Toyoda H, Wang SJ, Yang HY, et al. Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology 1993; 104:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/74\">",
"      Okada Y, Yamazaki K, Umeno J, et al. HLA-Cw*1202-B*5201-DRB1*1502 haplotype increases risk for ulcerative colitis but reduces risk for Crohn's disease. Gastroenterology 2011; 141:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/75\">",
"      Price WH. A high incidence of chronic inflammatory bowel disease in patients with Turner's syndrome. J Med Genet 1979; 16:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/76\">",
"      Weinrieb IJ, Fineman RM, Spiro HM. Turner syndrome and inflammatory bowel disease. N Engl J Med 1976; 294:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/77\">",
"      Hayward PA, Satsangi J, Jewell DP. Inflammatory bowel disease and the X chromosome. QJM 1996; 89:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/78\">",
"      Schinella RA, Greco MA, Cobert BL, et al. Hermansky-Pudlak syndrome with granulomatous colitis. Ann Intern Med 1980; 92:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/79\">",
"      Gahl WA, Brantly M, Kaiser-Kupfer MI, et al. Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak syndrome). N Engl J Med 1998; 338:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/80\">",
"      Visser G, Rake JP, Fernandes J, et al. Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European Study on Glycogen Storage Disease type I. J Pediatr 2000; 137:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/81\">",
"      Roe TF, Coates TD, Thomas DW, et al. Brief report: treatment of chronic inflammatory bowel disease in glycogen storage disease type Ib with colony-stimulating factors. N Engl J Med 1992; 326:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44455/abstract/82\">",
"      Vaughan D, Drumm B. Treatment of fistulas with granulocyte colony-stimulating factor in a patient with Crohn's disease. N Engl J Med 1999; 340:239.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4062 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-A6501CF067-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_26_44455=[""].join("\n");
var outline_f43_26_44455=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H95254869\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Genetic susceptibility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Human studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Specific genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Major histocompatibility complex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      GENETIC SYNDROMES ASSOCIATED WITH IBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Turner syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hermansky-Pudlak syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Glycogen storage disease type 1b",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95254869\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33449?source=related_link\">",
"      Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/17/7450?source=related_link\">",
"      Definition, epidemiology, and risk factors in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/48/16136?source=related_link\">",
"      Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24167?source=related_link\">",
"      Human leukocyte antigens (HLA): A roadmap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/48/27401?source=related_link\">",
"      Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/40/24196?source=related_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/56/10115?source=related_link\">",
"      Patient information: Crohn's disease in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/39/10869?source=related_link\">",
"      Patient information: Ulcerative colitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/17/42258?source=related_link\">",
"      Patient information: Ulcerative colitis in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_26_44456="Cardiorenal syndrome: Prognosis and treatment";
var content_f43_26_44456=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiorenal syndrome: Prognosis and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/26/44456/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/26/44456/contributors\">",
"     Michael S Kiernan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/26/44456/contributors\">",
"     James E Udelson, MD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/26/44456/contributors\">",
"     Mark Sarnak, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/26/44456/contributors\">",
"     Marvin Konstam, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/26/44456/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/26/44456/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/26/44456/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/26/44456/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/26/44456/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H17930178\">",
"    <span class=\"h1\">",
"     DEFINITION AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of important interactions between heart disease and kidney disease. The interaction is bidirectional as acute or chronic dysfunction of the heart or kidneys can induce acute or chronic dysfunction in the other organ. The clinical importance of such relationships is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mortality is increased in patients with heart failure (HF) who have a reduced glomerular filtration rate (GFR). (See",
"      <a class=\"local\" href=\"#H28486377\">",
"       'Reduced GFR and prognosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with chronic kidney disease have an increased risk of both atherosclerotic cardiovascular disease and heart failure, and cardiovascular disease is responsible for up to 50 percent of deaths in patients with renal failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link&amp;anchor=H1#H1\">",
"       \"Chronic kidney disease and coronary heart disease\", section on 'Introduction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute or chronic systemic disorders can cause both cardiac and renal dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The term cardiorenal syndrome (CRS) has been applied to these interactions, but the definition and classification have not been clear. A 2004 report from the National Heart, Lung, and Blood Institute defined CRS as a condition in which therapy to relieve congestive symptoms of HF is limited by a decline in renal function as manifested by a reduction in GFR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/3\">",
"     3",
"    </a>",
"    ]. The reduction in GFR was initially thought to result from a reduction in renal blood flow. However, various studies have demonstrated that cardiorenal interactions occur in both directions and by a variety of mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35223?source=see_link&amp;anchor=H49850194#H49850194\">",
"     \"Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The different interactions that can occur led to the following classification of CRS that was proposed by Ronco and colleagues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 1 (acute) &mdash; Acute HF results in acute kidney injury (AKI, previously called acute renal failure)",
"     </li>",
"     <li>",
"      Type 2 &mdash; Chronic cardiac dysfunction (eg, chronic HF) causes progressive chronic kidney disease (CKD, previously called chronic renal failure)",
"     </li>",
"     <li>",
"      Type 3 &mdash; Abrupt and primary worsening of kidney function due, for example, to renal ischemia or glomerulonephritis causes acute cardiac dysfunction, which may be manifested by HF",
"     </li>",
"     <li>",
"      Type 4 &mdash; Primary CKD contributes to cardiac dysfunction, which may be manifested by coronary disease, HF, or arrhythmia",
"     </li>",
"     <li>",
"      Type 5 (secondary) &mdash; Acute or chronic systemic disorders (eg, sepsis or diabetes mellitus) that cause both cardiac and renal dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognosis and treatment of type 1 and type 2 CRS will be reviewed here. Issues related to the prevalence of a reduced GFR in patients with HF, the diagnosis of type 1 and 2 CRS, and the mechanisms by which acute and chronic HF lead to worsening renal function are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35223?source=see_link\">",
"     \"Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28486377\">",
"    <span class=\"h1\">",
"     REDUCED GFR AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reduced glomerular filtration rate (GFR) is generally associated with a worse prognosis in patients with heart failure (HF), whether present at baseline or developing during therapy for HF. A possible exception may be seen with diuretic therapy in patients with decompensated HF in whom diuretic therapy may improve survival despite a fall in GFR. (See",
"    <a class=\"local\" href=\"#H17931529\">",
"     'Diuretics'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81276792\">",
"    <span class=\"h2\">",
"     Reduced baseline GFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of moderate to severe reductions in glomerular filtration rate (GFR less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2) in patients with HF has ranged from 30 to 60 percent in large clinical studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. This observation is important clinically because the baseline GFR is a predictor of mortality in both acute and chronic HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/6-13\">",
"     6-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review of 16 studies included more than 80,000 patients with HF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/6\">",
"       6",
"      </a>",
"      ]. The patients were categorized as having normal renal function (estimated GFR [eGFR] 90",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      or higher), mildly impaired renal function (eGFR 53 to 89",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      serum creatinine greater than 1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [88.4",
"      <span class=\"nowrap\">",
"       micromol/L],",
"      </span>",
"      or serum cystatin C greater than 1.03 to 1.55",
"      <span class=\"nowrap\">",
"       mg/dL),",
"      </span>",
"      or moderately to severely impaired renal function (eGFR less than 53",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      serum creatinine of 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [133",
"      <span class=\"nowrap\">",
"       micromol/L]",
"      </span>",
"      or higher, or serum cystatin C of 1.56",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or higher). Serum cystatin C may be a better marker of GFR than serum creatinine under certain circumstances because unlike creatinine production, cystatin C production is less dependent upon muscle mass and therefore less influenced by nutritional status [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link\">",
"       \"Assessment of kidney function\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The mortality rate at a follow-up of one year or more was 24 percent in those with a normal eGFR compared with 38 and 51 percent in patients with mild and moderate to severe reductions in eGFR, respectively (adjusted hazard ratio 1.6 and 2.3). It was estimated that mortality increased by approximately 15 percent for every 10",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      reduction in eGFR.",
"     </li>",
"     <li>",
"      Similar findings were noted in a report of 2680 patients with chronic HF in the CHARM program who were followed for a median of almost three years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/8\">",
"       8",
"      </a>",
"      ]. All-cause mortality increased significantly when the baseline eGFR was below 75",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 (adjusted hazard ratio 1.09, 95% CI 1.06-1.14 for every 10",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 decrease in eGFR below 75",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2). The adjusted hazard ratio increased from 1.20 at an eGFR of 60 to 75",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m2 to 2.92 at a eGFR below 45",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      This effect was independent of the left ventricular ejection fraction (LVEF), but all-cause mortality increased continuously with reductions in LVEF below 45 percent (adjusted hazard ratio 1.18, 95% CI 1.13-1.23 per 5 percent decrease in LVEF).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28486497\">",
"    <span class=\"h2\">",
"     Change in GFR during therapy for HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding observations of increased mortality risk in HF patients with reduced GFR were largely based upon baseline estimates of GFR. The relationship between change in GFR and prognosis is more complex. Worsening or improving GFR is associated with increased mortality risk in some patient populations but the cause of worsening GFR influences it prognostic significance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/9,15-24\">",
"     9,15-24",
"    </a>",
"    ]. Most of the data on the relationship between change in GFR and outcomes were obtained from patients hospitalized for worsening HF.",
"   </p>",
"   <p>",
"    The best data on the association between worsening renal function and mortality come from a meta-analysis of eight studies with more than 18,000 patients with HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/18\">",
"     18",
"    </a>",
"    ]. Five studies involved hospitalized patients and three involved outpatients. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Worsening renal function, defined as an elevation in serum creatinine of 0.3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (27",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      or more, occurred in 26 percent of patients.",
"     </li>",
"     <li>",
"      All-cause mortality was significantly higher in the patients with worsening renal function compared to those with a serum creatinine that was unchanged or increased by less than 0.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (18",
"      <span class=\"nowrap\">",
"       micromol/L):",
"      </span>",
"      43 versus 36 percent. The findings were the same in hospitalized and nonhospitalized patients.",
"     </li>",
"     <li>",
"      The mortality risk increased progressively with the degree of worsening renal function. The respective odds ratios were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      1.03 (not significant) when the serum creatinine rose by 0.2 to 0.3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (18 to 27",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      or the estimated GFR (eGFR) declined by less than 5 to 10",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2",
"     </li>",
"     <li>",
"      1.48 when the serum creatinine rose by 0.3 to 0.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (27 to 44",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      or the eGFR declined by 11 to 15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2",
"     </li>",
"     <li>",
"      3.22 when the serum creatinine rose by more than 0.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (44",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      or the eGFR declined by more than 15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, other evidence suggests that patients with improving or worsening renal function may have worse outcomes. Fluctuating renal function may occur in a sicker cohort of patients with significantly worse survival than patients with stable renal function, as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis of data on 401 patients enrolled in the ESCAPE trial found that patients with an improvement or a decline in estimated GFR during treatment of acute decompensated HF had similar outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/22\">",
"       22",
"      </a>",
"      ]. Compared to patients with a stable GFR, those with either an improvement or a decline in GFR were significantly more likely to have a reduced cardiac index and to require intravenous inotrope and vasodilator therapy, and had a significantly higher rate of all-cause mortality.",
"     </li>",
"     <li>",
"      Similarly, an observation study of 903 patients found that those with improved GFR during hospitalization for heart failure had worsened survival compared to patients with stable renal function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/23\">",
"       23",
"      </a>",
"      ]. This finding was largely restricted to patients who developed recurrent renal dysfunction postdischarge.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additionally, the mechanism of worsening renal function in heart failure is important in determining its prognostic significance.&nbsp;An analysis of data on 6337 subjects enrolled in the Studies Of Left Ventricular Dysfunction (SOLVD) showed that early worsening renal function was associated with increased mortality in the overall population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/24\">",
"     24",
"    </a>",
"    ].&nbsp;However, in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    group, early worsening renal function was not associated with increased mortality, while in the placebo group, the association with mortality was strengthened. A significant survival benefit from enalapril therapy was observed in patients who continued enalapril despite early worsening renal function. These findings suggest that worsening renal function is not always a marker of adverse clinical outcome. On the contrary, in the case of ACE inhibitor administration, it is a manifestation of the agent&rsquo;s pharmacologic properties which exert a favorable effect on long-term outcome.",
"   </p>",
"   <p>",
"    In addition, as noted below, treatment of decompensated HF with diuretics may improve survival despite worsening renal function. (See",
"    <a class=\"local\" href=\"#H17931529\">",
"     'Diuretics'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H73447122\">",
"    <span class=\"h2\">",
"     Blood urea nitrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elevation in blood urea nitrogen (BUN) or blood urea is also associated with increased mortality in patients with HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/21,25-27\">",
"     21,25-27",
"    </a>",
"    ], an effect that may be independent of the serum creatinine and GFR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. A probable contributing factor is that a disproportionate increase in BUN is often seen with a reduction in renal perfusion (ie, prerenal azotemia). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H22#H22\">",
"     \"Assessment of kidney function\", section on 'BUN and GFR'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17931522\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the limitations imposed by impaired renal function on the ability to correct volume overload and the frequent association between impaired or worsening renal function and mortality in patients with HF, it is possible that effective treatment of the cardiorenal syndrome (CRS) could improve patient outcomes. On the other hand, the worse prognosis in patients with HF and impaired renal function could primarily reflect a reduced glomerular filtration rate (GFR) being a marker of more severe cardiac disease. In this setting, improving renal function alone would not necessarily improve patient outcomes. (See",
"    <a class=\"local\" href=\"#H28486377\">",
"     'Reduced GFR and prognosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are no medical therapies that have been shown to directly increase the GFR (manifested clinically by a decline in serum creatinine) in patients with HF. On the other hand, improving cardiac function can produce increases in GFR, indicating that types 1 and 2 CRS have substantial reversible components. (See",
"    <a class=\"local\" href=\"#H17930178\">",
"     'Definition and classification'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35223?source=see_link&amp;anchor=H49850194#H49850194\">",
"     \"Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57915129\">",
"    <span class=\"h2\">",
"     Improvement in cardiac function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence suggesting that improvement in cardiac function is associated with improved renal function in patients with types 1 and 2 CRS comes from studies of left ventricular assist devices and cardiac resynchronization therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 220 patients with severe end-stage HF who underwent placement of a left ventricular assist device, 60 had a baseline creatinine clearance below 50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      (mean 37",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/28\">",
"       28",
"      </a>",
"      ]. At one week, the mean creatinine clearance had increased to 60",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"     </li>",
"     <li>",
"      Analysis of data from an observational study and from the MIRACLE trial found that cardiac resynchronization therapy improved the left ventricular ejection fraction and the eGFR in appropriately selected patients with HF and moderately reduced baseline eGFR (eGFR 30 to 59",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/36/10823?source=see_link\">",
"       \"Rationale for and mechanisms of benefit of cardiac resynchronization therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17931529\">",
"    <span class=\"h2\">",
"     Diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diuretics, typically beginning with a loop diuretic, are first-line therapy for managing volume overload in patients with HF as manifested by peripheral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary edema. Issues related to diuretic dosing, the time course of the diuresis, the side effects of diuretic therapy, and the management of refractory edema in these patients are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3962?source=see_link\">",
"     \"Use of diuretics in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of diuretic-induced fluid removal on the glomerular filtration rate (GFR, usually estimated from the serum creatinine) is variable in patients with HF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some patients have an increase in serum creatinine that is presumed to be mediated at least in part by a reduction in renal perfusion due to a decline in cardiac output induced by the fall in cardiac filling pressures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35223?source=see_link&amp;anchor=H2022685#H2022685\">",
"       \"Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology\", section on 'Reduced renal perfusion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some patients have no change in serum creatinine that may reflect maintenance of cardiac output perhaps because they are on the flat part of the Frank-Starling curve where changes in left ventricular end-diastolic pressure have little or no effect on cardiac performance (",
"      <a class=\"graphic graphic_figure graphicRef58693 \" href=\"mobipreview.htm?32/56/33677\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Some patients have a reduction in serum creatinine mediated perhaps in part by one or both of the following mechanisms:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Reductions in intraabdominal and renal venous pressures. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35223?source=see_link&amp;anchor=H2022699#H2022699\">",
"       \"Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology\", section on 'Increased renal venous pressure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reduction in right ventricular dilatation, which may improve left ventricular filling and function via ventricular interdependence (alleviation of the reverse Bernheim phenomenon). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35223?source=see_link&amp;anchor=H124107751#H124107751\">",
"       \"Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology\", section on 'Right ventricular dilatation and dysfunction'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients with decompensated HF, it is possible that the best outcomes occur with aggressive fluid removal even if it is associated with mild to moderate worsening of renal function. This was suggested by a study of the effect of hemoconcentration in 336 patients with decompensated HF in the ESCAPE trial of the efficacy of pulmonary artery catheterization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/32\">",
"     32",
"    </a>",
"    ]. Hemoconcentration was defined as baseline-to-discharge increases in the top one-third of the group in at least two of the following: Hematocrit, serum albumin, and serum total protein. Patients with hemoconcentration had the following significant differences compared with patients without hemoconcentration: They were treated with higher doses of loop diuretics, had more fluid loss (net fluid output -6.1 versus -3.8 L), lost more weight, and had greater reductions in intracardiac filling pressures.",
"   </p>",
"   <p>",
"    In terms of patient outcomes, hemoconcentration was strongly associated with worsening renal function, which was defined as &ge;20 percent decrease in estimated GFR (odds ratio 5.3), but also had a significantly lower 180 day mortality rate (adjusted hazard ratio, 0.16, 95% CI 0.02-0.44). Although the total number of deaths was small (n=29), this study suggests that aggressive decongestion in the face of worsening renal function may favorably affect survival.",
"   </p>",
"   <p>",
"    The findings in this study, which was published in 2010, provide support for the recommendation included in the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association HF guidelines (last updated in 2009) that the goal of diuretic therapy is to eliminate clinical evidence of fluid retention such as an elevated jugular venous pressure and peripheral edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/33\">",
"     33",
"    </a>",
"    ]. The rapidity of diuresis can be slowed if the patient develops hypotension or worsening renal function. However, the goal of diuretic therapy is to eliminate fluid retention even if this leads to asymptomatic mild to moderate reductions in blood pressure or renal function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3962?source=see_link&amp;anchor=H4016559#H4016559\">",
"     \"Use of diuretics in patients with heart failure\", section on 'Goals of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6653820\">",
"    <span class=\"h2\">",
"     Angiotensin inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin inhibition with an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) is a standard part of the therapy of HF with systolic dysfunction, being associated with symptomatic improvement, reduced hospitalization for HF, and enhanced survival. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2680?source=see_link\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the above benefits, ACE inhibitor or ARB therapy for HF is not generally associated with an improvement in renal function. Although a minority of patients have an increase in glomerular filtration rate (GFR) after initiation of ACE inhibitor or ARB therapy, most have a moderate reduction in GFR that can often be ameliorated by reducing the intensity of diuretic therapy. The supportive data and management are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=see_link&amp;anchor=H6654443#H6654443\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\", section on 'Effect on GFR'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17931536\">",
"    <span class=\"h2\">",
"     Vasodilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous vasodilators used in the treatment of acute decompensated HF include nitrates (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    , which is recombinant human brain natriuretic peptide. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34698?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of acute decompensated heart failure: Components of therapy\", section on 'Vasodilator therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35701?source=see_link&amp;anchor=H6#H6\">",
"     \"Nesiritide in the treatment of acute decompensated heart failure\", section on 'Effect on renal function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With respect to effects on the CRS, the Acutely Decompensated Heart Failure National Registry (ADHERE) database of almost 100,000 patients defined worsening renal function as a rise in serum creatinine between admission and discharge of more than 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [44",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    or more than 0.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [27",
"    <span class=\"nowrap\">",
"     micromol/L",
"    </span>",
"    with a serum creatinine more than 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [133",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/34\">",
"     34",
"    </a>",
"    ]. The rate of worsening renal function was significantly higher when intravenous diuretics were given with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    compared with intravenous diuretics alone (relative risk 1.20 and 1.44, respectively). However, a causal effect could not be distinguished from patients requiring combination therapy having more severe HF.",
"   </p>",
"   <p>",
"    Randomized trials have yielded conflicting results on the effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    therapy on renal function in the treatment of acute decompensated HF. The largest trial, ASCEND-HF, found no change in risk of worsening renal function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35701?source=see_link&amp;anchor=H6#H6\">",
"     \"Nesiritide in the treatment of acute decompensated heart failure\", section on 'Effect on renal function'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17931543\">",
"    <span class=\"h2\">",
"     Inotropic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous administration of inotropic drugs, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    , has a role in the treatment of cardiogenic shock and in selected patients with acute decompensated HF. However, both routine use of short-term intravenous therapy in patients with acute decompensated HF and prolonged therapy with oral inotropic drugs other than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    have been associated with an increase in mortality. As a result, the main role of inotropic drugs other than digoxin is in the management of cardiogenic shock or acute decompensated HF. The supporting data and management are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=see_link&amp;anchor=H17#H17\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\", section on 'Vasopressors and inotropes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34698?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of acute decompensated heart failure: Components of therapy\", section on 'Inotropic agents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7769?source=see_link&amp;anchor=H20#H20\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\", section on 'Summary'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33446?source=see_link\">",
"     \"Treatment of acute decompensated heart failure in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been proposed that inotropic agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    may, by increasing renal blood flow and possibly by reducing renal venous pressure, improve renal function in patients with severe HF. Data supporting such a potential benefit are limited as illustrated by the following observations regarding use of dopamine:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A potential role for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"       dopamine",
"      </a>",
"      in improving or preserving renal function in HF was suggested by small series indicating that dopamine can significantly increase the glomerular filtration rate (GFR) in patients with moderate or severe HF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. Dopamine increased renal blood flow at doses of 2 to 10",
"      <span class=\"nowrap\">",
"       mcg/kg/min",
"      </span>",
"      in such patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/35,37\">",
"       35,37",
"      </a>",
"      ]. This effect appears to be due to dilation of both large conductance and small resistance renal blood vessels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/37\">",
"       37",
"      </a>",
"      ]. Dopamine also caused significant increases in cardiac output at doses in the range of 5 to 10",
"      <span class=\"nowrap\">",
"       mcg/kg/min,",
"      </span>",
"      but the proportionate increase in renal blood flow was greater than the increase in cardiac output.",
"     </li>",
"     <li>",
"      The clinical efficacy and safety of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"       dopamine",
"      </a>",
"      for preservation of renal function in patients with HF has not been established. Preliminary studies suggest that the combination of low-dose dopamine (eg, 2 or 5",
"      <span class=\"nowrap\">",
"       mcg/kg/min)",
"      </span>",
"      plus a diuretic may reduce the risk of worsening renal function compared to diuretic therapy alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/36,38\">",
"       36,38",
"      </a>",
"      ]. A report from the DAD-HF trial of 60 patients with acute decompensated heart failure found that the combination of dopamine 5",
"      <span class=\"nowrap\">",
"       mcg/kg/min",
"      </span>",
"      plus low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      <span class=\"nowrap\">",
"       (5mg/h",
"      </span>",
"      continuous infusion) produced similar urine output as high-dose furosemide (20",
"      <span class=\"nowrap\">",
"       mg/h)",
"      </span>",
"      with reduced risk of worsening renal function (defined as rise in serum creatinine of &gt;0.3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      from baseline to 24 hours; 7 versus 30 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, the role of inotropes in patients with CRS is uncertain and trials are underway to better define their role.&nbsp;At present, the routine use of inotropes cannot be recommended given their association with adverse events when used outside of selected patients with cardiogenic shock or acute decompensated HF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17931550\">",
"    <span class=\"h2\">",
"     Ultrafiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrafiltration refers to the removal of isotonic fluid from the venous compartment via filtration of plasma across a semipermeable membrane. In HF patients, ultrafiltration is most often considered in patients with acute decompensated HF and diuretic resistance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impaired renal function. By removing isotonic fluid, ultrafiltration tends to maintain physiologic electrolyte balance, in contrast to diuretic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34698?source=see_link&amp;anchor=H26#H26\">",
"     \"Treatment of acute decompensated heart failure: Components of therapy\", section on 'Ultrafiltration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three randomized trials (UNLOAD, RAPID-CHF, and CARESS-HF) compared ultrafiltration to diuretic therapy in patients with acute decompensated HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. The mean baseline serum creatinine levels were 1.5, 1.7, and 2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133, 150, and 177",
"    <span class=\"nowrap\">",
"     &mu;mol/L),",
"    </span>",
"    respectively. In UNLOAD and RAPID-CHF, ultrafiltration was associated with a significantly greater rate of fluid loss than diuretic therapy but no difference in serum creatinine. In CARESS-HF, ultrafiltration was compared to stepped pharmacologic therapy (including bolus plus high doses of continuous infusion loop diuretics, addition of thiazide diuretic (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/32/1542?source=see_link\">",
"     metolazone",
"    </a>",
"    ), and selected intravenous inotrope",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vasodilator therapy) in patients with worsening renal function and persistent congestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/41\">",
"     41",
"    </a>",
"    ]. Although weight loss was similar in ultrafiltration and stepped pharmacologic therapy groups, ultrafiltration therapy caused an increase in serum creatinine and a higher rate of adverse events. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34698?source=see_link&amp;anchor=H26#H26\">",
"     \"Treatment of acute decompensated heart failure: Components of therapy\", section on 'Ultrafiltration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, although ultrafiltration may be helpful for fluid removal in acute decompensated HF in patients unresponsive to diuretic therapy, the available evidence does not establish ultrafiltration as first line therapy for AHDF or as an effective therapy for CRS. The 2009",
"    <span class=\"nowrap\">",
"     AHA/ACC",
"    </span>",
"    guidelines state that ultrafiltration is reasonable for patients with refractory congestion not responding to medical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17931564\">",
"    <span class=\"h2\">",
"     Investigational therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two other classes of drugs have been evaluated in the treatment of HF, with no proven effect on kidney function: Antagonists of vasopressin receptor 2, which mediates the antidiuretic response, and antagonists of the adenosine A1 receptor.",
"   </p>",
"   <p>",
"    Neurohormonal activation in patients with HF results in the nonosmotic release of antidiuretic hormone (arginine vasopressin), which leads to free water retention and hyponatremia that parallels the severity of the HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33546?source=see_link&amp;anchor=H15#H15\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\", section on 'Neurohumoral activation and heart rate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38742?source=see_link&amp;anchor=H3#H3\">",
"     \"Hyponatremia in patients with heart failure\", section on 'Predictor of adverse prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11654?source=see_link\">",
"     Tolvaptan",
"    </a>",
"    is a selective vasopressin 2 receptor antagonist that produces a water diuresis, not a salt diuresis as induced by conventional diuretics. The effect of tolvaptan on cardiovascular outcomes and decongestion in patients with acute HF was evaluated in the EVEREST Outcome trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/44\">",
"     44",
"    </a>",
"    ]. Tolvaptan had no effect on the coprimary endpoints of all-cause mortality, mortality or HF hospitalization, or seven-day patient global assessment. However, there were significant benefits in a number of secondary endpoints including an increase in urine output, resulting in reduced dyspnea and edema and an increase in serum sodium. There was also a statistically significant, but not clinically significant, greater increase in serum creatinine with tolvaptan (0.08 versus 0.03",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [7.1 versus 2.7",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    with placebo). Tolvaptan is approved only for the treatment of hyponatremia in patients with HF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18809?source=see_link&amp;anchor=H12#H12\">",
"     \"Possibly effective emerging therapies for heart failure\", section on 'Vasopressin receptor antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adenosine, acting on the adenosine-1 receptor, constricts the afferent glomerular arteriole, thereby reducing the glomerular filtration rate (GFR), and increases tubular sodium reabsorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/45\">",
"     45",
"    </a>",
"    ]. Thus, selective adenosine A1 receptor antagonism can increase GFR and promote a diuresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/46\">",
"     46",
"    </a>",
"    ], potentially acting synergistically with loop diuretics.",
"   </p>",
"   <p>",
"    In the PROTECT trial, 2033 patients hospitalized with HF and impaired renal function (mean creatinine clearance 51",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    were randomly assigned to the experimental selective A1 adenosine antagonist rolofylline or to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44456/abstract/47\">",
"     47",
"    </a>",
"    ]. During the study period, there was no difference between the groups in cardiovascular outcomes or in the rate of persistent worsening of renal function, which was defined as an increase in serum creatinine of 0.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (27",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    In addition, rolofylline therapy was associated with a higher rate of neurologic events (seizure and stroke).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4380818\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced glomerular filtration rates (GFR) are common in patients presenting with heart failure (HF) and are associated with increased mortality. A systematic review found that mortality increased by approximately 15 percent for every 10",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      reduction in estimated GFR. (See",
"      <a class=\"local\" href=\"#H28486377\">",
"       'Reduced GFR and prognosis'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      A fall in GFR during treatment of HF has often been associated with increased mortality in clinical studies in which the mortality risk increased progressively with the degree of worsening renal function. However, other evidence suggests that patient outcomes may be improved with aggressive fluid removal even if accompanied by a rise in serum creatinine. (See",
"      <a class=\"local\" href=\"#H28486497\">",
"       'Change in GFR during therapy for HF'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the limitations imposed by impaired renal function on the ability to correct volume overload and the strong association between impaired or worsening renal function and adverse clinical outcomes in patients with HF, it is possible that effective treatment of the cardiorenal syndrome (CRS) would improve patient outcomes. On the other hand, the worse prognosis associated with CRS could primarily reflect a reduced glomerular filtration rate (GFR) being a marker of more severe cardiac disease. In this setting, improving renal function alone would not necessarily improve patient outcomes. (See",
"      <a class=\"local\" href=\"#H17931522\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no medical therapies that have been shown to directly increase GFR in patients with the CRS. On the other hand, improving cardiac function can produce increases in GFR, indicating that types 1 and 2 CRS have substantial reversible components. (See",
"      <a class=\"local\" href=\"#H17931522\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The effect of diuretic-induced fluid removal on the GFR is variable in patients with HF. Although fluid removal may result in increases in serum creatinine and rising serum creatinine is associated with worse prognosis in patients with HF, aggressive decongestion leading to worsening renal function may be associated with improved survival. (See",
"      <a class=\"local\" href=\"#H17931529\">",
"       'Diuretics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     United States Renal Data System: Excerpts from the USRDS 2007 annual data report: atlas of end-stage renal disease in the United States. Minneapolis, MN 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/2\">",
"      Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nhlbi.nih.gov/meetings/workshops/cardiorenal-hf-hd.htm (Accessed on September 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/4\">",
"      Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation 2010; 121:2592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/5\">",
"      Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/6\">",
"      Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006; 47:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/7\">",
"      Heywood JT, Fonarow GC, Costanzo MR, et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007; 13:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/8\">",
"      Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/9\">",
"      Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004; 43:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/10\">",
"      Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/11\">",
"      McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/12\">",
"      Shlipak MG, Smith GL, Rathore SS, et al. Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. J Am Soc Nephrol 2004; 15:2195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/13\">",
"      de Silva R, Nikitin NP, Witte KK, et al. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J 2006; 27:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/14\">",
"      Lassus J, Harjola VP, Sund R, et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 2007; 28:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/15\">",
"      Smith GL, Vaccarino V, Kosiborod M, et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail 2003; 9:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/16\">",
"      Akhter MW, Aronson D, Bitar F, et al. Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. Am J Cardiol 2004; 94:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/17\">",
"      Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004; 147:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/18\">",
"      Damman K, Navis G, Voors AA, et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 2007; 13:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/19\">",
"      Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002; 8:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/20\">",
"      Logeart D, Tabet JY, Hittinger L, et al. Transient worsening of renal function during hospitalization for acute heart failure alters outcome. Int J Cardiol 2008; 127:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/21\">",
"      Klein L, Massie BM, Leimberger JD, et al. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail 2008; 1:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/22\">",
"      Testani JM, McCauley BD, Kimmel SE, Shannon RP. Characteristics of patients with improvement or worsening in renal function during treatment of acute decompensated heart failure. Am J Cardiol 2010; 106:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/23\">",
"      Testani JM, McCauley BD, Chen J, et al. Clinical characteristics and outcomes of patients with improvement in renal function during the treatment of decompensated heart failure. J Card Fail 2011; 17:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/24\">",
"      Testani JM, Kimmel SE, Dries DL, Coca SG. Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail 2011; 4:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/25\">",
"      Aronson D, Mittleman MA, Burger AJ. Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. Am J Med 2004; 116:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/26\">",
"      Filippatos G, Rossi J, Lloyd-Jones DM, et al. Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study. J Card Fail 2007; 13:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/27\">",
"      Fonarow GC, Adams KF Jr, Abraham WT, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005; 293:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/28\">",
"      Butler J, Geisberg C, Howser R, et al. Relationship between renal function and left ventricular assist device use. Ann Thorac Surg 2006; 81:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/29\">",
"      Adelstein EC, Shalaby A, Saba S. Response to cardiac resynchronization therapy in patients with heart failure and renal insufficiency. Pacing Clin Electrophysiol 2010; 33:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/30\">",
"      Boerrigter G, Costello-Boerrigter LC, Abraham WT, et al. Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. J Card Fail 2008; 14:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/31\">",
"      Stampfer M, Epstein SE, Beiser GD, Braunwald E. Hemodynamic effects of diuresis at rest and during intense upright exercise in patients with impaired cardiac function. Circulation 1968; 37:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/32\">",
"      Testani JM, Chen J, McCauley BD, et al. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 2010; 122:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/33\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/34\">",
"      Costanzo MR, Johannes RS, Pine M, et al. The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database. Am Heart J 2007; 154:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/35\">",
"      Ungar A, Fumagalli S, Marini M, et al. Renal, but not systemic, hemodynamic effects of dopamine are influenced by the severity of congestive heart failure. Crit Care Med 2004; 32:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/36\">",
"      Varriale P, Mossavi A. The benefit of low-dose dopamine during vigorous diuresis for congestive heart failure associated with renal insufficiency: does it protect renal function? Clin Cardiol 1997; 20:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/37\">",
"      Elkayam U, Ng TM, Hatamizadeh P, et al. Renal Vasodilatory Action of Dopamine in Patients With Heart Failure: Magnitude of Effect and Site of Action. Circulation 2008; 117:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/38\">",
"      Giamouzis G, Butler J, Starling RC, et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. J Card Fail 2010; 16:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/39\">",
"      Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007; 49:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/40\">",
"      Bart BA, Boyle A, Bank AJ, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol 2005; 46:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/41\">",
"      Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012; 367:2296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/42\">",
"      Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/43\">",
"      Finley JJ 4th, Konstam MA, Udelson JE. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation 2008; 118:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/44\">",
"      Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/45\">",
"      Vallon V, M&uuml;hlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev 2006; 86:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/46\">",
"      Dohadwala MM, Givertz MM. Role of adenosine antagonism in the cardiorenal syndrome. Cardiovasc Ther 2008; 26:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44456/abstract/47\">",
"      Massie BM, O'Connor CM, Metra M, et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010; 363:1419.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15619 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-062E1C4994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_26_44456=[""].join("\n");
var outline_f43_26_44456=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4380818\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17930178\">",
"      DEFINITION AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28486377\">",
"      REDUCED GFR AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H81276792\">",
"      Reduced baseline GFR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28486497\">",
"      Change in GFR during therapy for HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H73447122\">",
"      Blood urea nitrogen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17931522\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57915129\">",
"      Improvement in cardiac function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17931529\">",
"      Diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6653820\">",
"      Angiotensin inhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17931536\">",
"      Vasodilators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17931543\">",
"      Inotropic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17931550\">",
"      Ultrafiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17931564\">",
"      Investigational therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4380818\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/15619\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/15619|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/56/33677\" title=\"figure 1\">",
"      Frank Starling curves in HF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2680?source=related_link\">",
"      Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35223?source=related_link\">",
"      Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38742?source=related_link\">",
"      Hyponatremia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7769?source=related_link\">",
"      Inotropic agents in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35701?source=related_link\">",
"      Nesiritide in the treatment of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18809?source=related_link\">",
"      Possibly effective emerging therapies for heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33546?source=related_link\">",
"      Predictors of survival in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/36/10823?source=related_link\">",
"      Rationale for and mechanisms of benefit of cardiac resynchronization therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33446?source=related_link\">",
"      Treatment of acute decompensated heart failure in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34698?source=related_link\">",
"      Treatment of acute decompensated heart failure: Components of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3962?source=related_link\">",
"      Use of diuretics in patients with heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_26_44457="Management of severe refractory atopic dermatitis (eczema)";
var content_f43_26_44457=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of severe refractory atopic dermatitis (eczema)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/26/44457/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/26/44457/contributors\">",
"     Jonathan M Spergel, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/26/44457/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/26/44457/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/26/44457/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/26/44457/contributors\">",
"     Joseph Fowler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/26/44457/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/26/44457/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/26/44457/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atopic dermatitis is a common, chronic, inflammatory skin disorder characterized by the presence of pruritic eczematous dermatitis. In most patients, the disorder is managed with careful skin care practices, topical therapies for inflammation, and the elimination of exacerbating factors. Patients with severe disease that fails to improve with conventional therapy may benefit from phototherapy or systemic medications.",
"   </p>",
"   <p>",
"    This topic reviews the causes and treatment of severe, refractory atopic dermatitis. The clinical manifestations, diagnosis, and conventional management of the disease and the role of allergy in atopic dermatitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42631?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10842?source=see_link\">",
"     \"Treatment of atopic dermatitis (eczema)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/59/26551?source=see_link\">",
"     \"Role of allergy in atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SEVERE ATOPIC DERMATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with atopic dermatitis have mild to moderate disease. However, a subpopulation of patients develops severe symptoms. Severe atopic dermatitis may be loosely described as the presence of widespread skin lesions or physically",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    emotionally disabling disease that significantly compromises a patient's quality of life (",
"    <a class=\"graphic graphic_picture graphicRef80481 \" href=\"mobipreview.htm?4/59/5046\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Clinical studies have utilized scales for defining the severity of atopic dermatitis, such as the Severity Scoring of Atopic Dermatitis (SCORAD) index and the Eczema Area and Severity Index (EASI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/1\">",
"     1",
"    </a>",
"    ]. Although such scales are useful for standardizing the results of research studies, they are not routinely used in clinical practice. Patients with severe atopic dermatitis who do not respond to conventional therapy may be classified as having severe, refractory disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EXACERBATING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to initiating second-line treatments for atopic dermatitis, clinicians must ensure that severe, refractory disease is not a result of the presence of an avoidable or treatable exacerbating factor. Circumstances that may contribute to severe or refractory atopic dermatitis include non-compliance with conventional therapy, secondary infection, hypersensitivity reactions to topical treatments, and exposure to triggers of disease flares.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Poor compliance",
"    </span>",
"    &nbsp;&mdash;&nbsp;For many patients, a lack of adherence to the treatment regimen and basic skin care techniques contributes to persistent disease. Over 50 percent of patients with atopic dermatitis do not administer treatment as recommended by their clinicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific reasons for inadequate application of treatment are summarized in a table (",
"    <a class=\"graphic graphic_table graphicRef66729 \" href=\"mobipreview.htm?15/28/15819\">",
"     table 1",
"    </a>",
"    ). These include concerns about medication side effects, patient dislike of topical preparations, and insufficient time for clinicians to educate patients about skin care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Environmental triggers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exacerbating factors for atopic dermatitis may include low humidity environments, xerosis (dry skin), overheating of skin, emotional stress, and exposure to irritating substances, such as harsh chemicals or soaps. Avoiding these factors is helpful for avoiding acute flares as well as for long-term management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10842?source=see_link\">",
"     \"Treatment of atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with atopic dermatitis are at an increased risk for secondary cutaneous bacterial, viral, and dermatophyte infections. The possibility of secondary infection should be considered in patients with skin lesions that appear refractory to conventional therapy. In particular, clinicians should be aware of the possibility of Staphylococcus aureus and herpes simplex virus (HSV) infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10842?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Management of infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Colonization with S. aureus occurs more frequently in individuals with atopic dermatitis than in the general population, and S. aureus is a common cause of secondary infection in these patients. The presence of purulence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    honey-colored crusts suggests S. aureus infection. Even in the absence of overt infection, colonization by S. aureus may be an exacerbating factor for atopic dermatitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10842?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Staphylococcus aureus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Secondary HSV infection (eczema herpeticum) may also occur, and rarely may lead to life-threatening dissemination of HSV in patients with atopic dermatitis. Punched out erosions, hemorrhagic crusts, and vesicles are indicators of this infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10842?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Viral infections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hypersensitivity reactions to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed hypersensitivity reactions to contact allergens in topical emollients or medications are another cause of an apparent lack of response to treatment. Allergic contact dermatitis can be caused by vehicles or active ingredients in emollients (eg, lanolin, propylene glycol, ethylenediamine, formaldehyde), topical immunosuppressive medications (eg, corticosteroids, calcineurin inhibitors), and topical antibiotics (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6469?source=see_link\">",
"     bacitracin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/6-12\">",
"     6-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contact allergy to a topical emollient or medication should be considered when patients present with atopic dermatitis that fails to respond to or appears to worsen with these therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The identification and elimination of a contact allergen can lead to clinical improvement in affected individuals. If a contact allergy is suspected, patch testing should be performed to identify the responsible allergen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3721?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of dermatitis\", section on 'Allergic contact dermatitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26104?source=see_link\">",
"     \"Contact dermatitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Food and environmental allergies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, patients (typically children younger than three years) with refractory atopic dermatitis may have undiagnosed food",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    environmental allergies that are worsening their disease. The role of allergy in atopic dermatitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/59/26551?source=see_link\">",
"     \"Role of allergy in atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An incorrect diagnosis may account for a failure to respond to conventional therapy. The possibility of other disorders that may present with clinical features that resemble atopic dermatitis should be considered. These may include conditions such as cutaneous T cell lymphoma, autoimmune disorders, and nutritional or immune system deficiencies (",
"    <a class=\"graphic graphic_table graphicRef50324 \" href=\"mobipreview.htm?16/38/17003\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other therapies are available if severe atopic dermatitis remains refractory to standard therapy after potential exacerbating factors have been addressed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/14-20\">",
"     14-20",
"    </a>",
"    ]. Patients with refractory atopic dermatitis should be seen by a specialist (eg, dermatologist, allergist) familiar with second-line treatments such as phototherapy or immunosuppressive agents.",
"   </p>",
"   <p>",
"    Many of the second-line therapies for atopic dermatitis possess the potential for undesirable adverse effects. Thus, patients should be selected for these treatments only when conventional therapy does not provide sufficient improvement. The standard management of atopic dermatitis, including maintenance of skin hydration, control of pruritus (including wet dressings), topical therapies for inflammation, and management of infection (including dilute bleach baths) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10842?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Bleach baths'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10842?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Controlling pruritus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PHOTOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultraviolet (UV) light therapy is a second-line treatment for severe atopic dermatitis in adolescents and adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/16\">",
"     16",
"    </a>",
"    ]. Options for phototherapy include narrowband UVB, UVA1, psoralens plus UVA (PUVA), broadband UVA, broadband UVB, and combined broadband UVA and UVB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/14,21\">",
"     14,21",
"    </a>",
"    ]. The administration of phototherapy requires the availability of equipment and trained personnel. Potential short-term side effects (itch and acute burns) and long-term risks (premature skin aging and increased risk of skin cancer) may occur with phototherapy.",
"   </p>",
"   <p>",
"    Studies comparing the efficacy of different forms of phototherapy are limited. However, some studies suggest that two newer modalities, narrowband UVB and UVA1, should be favored over other forms of phototherapy for the treatment of atopic dermatitis. Narrowband UVB narrows the range of UVB emission to the more therapeutic wavelengths around the 311 nm range. UVA1 limits emission to the longer wavelengths of UVA (340 to 400 nm), which can penetrate more deeply into the skin than shorter wavelengths of light. While narrowband UVB is the preferred form of phototherapy for the treatment of refractory atopic dermatitis in most patients, the less readily available UVA1 may be more effective for the management of patients with acute exacerbations of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Narrowband UVB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Narrowband UVB is an appropriate initial choice over the other forms of phototherapy for the treatment of atopic dermatitis. In a randomized trial involving 73 patients with moderate to severe atopic dermatitis, mean reductions in disease severity scores (compared to placebo) were greater among patients receiving narrowband UVB than those receiving broadband UVA (9.4 points and 4.4 points, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, narrowband UVB was compared to combined UVA and UVB in a half-side comparison study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/23\">",
"     23",
"    </a>",
"    ]. Narrowband UVB produced a significantly greater reduction in pruritus after six weeks of treatment. Non-significant trends for faster and greater clinical improvement were also observed with narrowband UVB phototherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Ultraviolet A1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the availability of this modality is limited, UVA1 is a favorable treatment option for acute, severe exacerbations of atopic dermatitis. Both medium dose (maximum dose 65",
"    <span class=\"nowrap\">",
"     J/cm2)",
"    </span>",
"    and high dose (maximum dose 130",
"    <span class=\"nowrap\">",
"     J/cm2)",
"    </span>",
"    UVA1 are effective. In an uncontrolled study of 32 patients with acute, severe disease treated with medium dose UVA1, disease severity was significantly reduced at the completion of therapy and one month post-therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/24\">",
"     24",
"    </a>",
"    ]. Medium dose and high dose UVA1 have also been shown to be superior to combined UVA and UVB for the treatment of acute, severe atopic dermatitis in two small randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High dose UVA1, which requires longer treatment times and exposes patients to greater amounts of heat, has not been shown to be more effective than medium dose UVA1 therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/27\">",
"     27",
"    </a>",
"    ]. Excessive heat may be an exacerbating factor for atopic dermatitis in some patients. Thus, medium dose UVA1 is typically used for treatment. Cold light UVA1, which utilizes equipment that minimizes heat exposure during treatment, may be even more effective than traditional UVA1 for inducing clinical improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role that UVA1 should play in treatment of non-acute atopic dermatitis is uncertain. A small randomized trial reported greater efficacy with narrowband UVB than medium dose UVA1 in the treatment of chronic atopic dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/29\">",
"     29",
"    </a>",
"    ]. Two subsequent small randomized trials found that narrowband UVB and medium dose UVA1 were equally efficacious for atopic dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. However, these two studies did not specify whether the treated patients had stable disease or acute exacerbations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Psoralen plus UVA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoralen plus UVA (PUVA) photochemotherapy is also effective for the treatment of atopic dermatitis. In a randomized, investigator-blinded crossover trial that compared oral PUVA versus medium dose UVA1 for severe, generalized atopic dermatitis, PUVA decreased the severity of disease to a greater extent, led to more rapid improvement, and induced a longer remission period post-treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/32\">",
"     32",
"    </a>",
"    ]. Bath PUVA, in which patients soak in a psoralen solution prior to exposure to UVA, was as effective as narrowband UVB in a randomized, half-side comparison trial of 12 patients. No randomized trials have compared narrowband UVB to oral PUVA for the treatment of atopic dermatitis.",
"   </p>",
"   <p>",
"    Despite the efficacy of PUVA, there are some deterrents to its use as a routine choice for phototherapy. Evidence supports an increased risk of melanoma and squamous cell carcinoma among patients who have received long-term PUVA therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. The risk of cutaneous malignancy with other forms of phototherapy appears to be lower [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition, the inconvenience of taking or applying a photosensitizing agent that requires a period of strict photoprotection post-treatment makes PUVA a less favorable choice for some patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/56/25482?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'UVA radiation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/39/14970?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology and clinical features of basal cell carcinoma\", section on 'Therapeutic exposure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/53/24410?source=see_link&amp;anchor=H10#H10\">",
"     \"Risk factors for the development of melanoma\", section on 'PUVA therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Broadband UVA and UVB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Broadband UVA and broadband UVB have been available for many years. In randomized trials, combined broadband UVA and UVB has been shown to be superior to broadband UVB alone. Combined broadband UVA and UVB phototherapy has been suggested as another option for phototherapy in cases in which narrowband UVB and UVA1 are not available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     In children",
"    </span>",
"    &nbsp;&mdash;&nbsp;While phototherapy is also effective in children, information is lacking regarding long-term side effects. Retrospective reviews of the use of phototherapy in children with severe atopic dermatitis suggest that it is at least moderately effective and is overall well tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. However, due to the uncertainty of long-term risks in this population, the use of phototherapy should be restricted to severe cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SYSTEMIC IMMUNOSUPPRESSANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several systemic immunosuppressive agents are effective in treating severe refractory atopic dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/15,39,40\">",
"     15,39,40",
"    </a>",
"    ]. The use of these drugs is limited by the potential for adverse events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    , a calcineurin inhibitor which blocks T cell activation, is effective in inducing remission in adults and children with severe atopic dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/17,41,42\">",
"     17,41,42",
"    </a>",
"    ]. It may be used for short-term or intermittent long-term therapy in patients who have not responded to conventional treatment.",
"   </p>",
"   <p>",
"    A systematic review and meta-analysis of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in the treatment of adult and childhood atopic dermatitis demonstrated that cyclosporine consistently decreased disease severity in both open label studies and small randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/42\">",
"     42",
"    </a>",
"    ]. After two weeks of treatment, the pooled mean disease severity decreased by 22 percent (95% CI 8-36) in the low dose group (2.5 to 3",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    and 40 percent (95% CI 29-51) in the high dose group (4 to 5",
"    <span class=\"nowrap\">",
"     mg/kg).",
"    </span>",
"    In an analysis of low and high dose groups combined, after six to eight weeks of continuous treatment the mean relative decrease in atopic dermatitis severity from baseline was 55 percent (95% CI 48-62).",
"   </p>",
"   <p>",
"    The quality of the studies included in this meta-analysis was judged to range from good to poor. There was also evidence of publication bias, which would increase the magnitude of the benefit seen. There are no double-blind randomized trials in the pediatric population, and studies on long-term use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    for atopic dermatitis are lacking.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is usually started at 5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    divided every 12 hours. Cyclosporine trough levels and renal and hepatic function must be monitored. The drug is tapered by 1",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    every one to three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Alternatively, an initial dose of 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    followed by increasing the dose as needed has been shown to be as safe and effective as an initial dose of 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    followed by tapering [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse effects associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    include increased risk of infection, nephrotoxicity, hepatotoxicity, hypertension, hypertrichosis, seizures, and malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    as a long-term maintenance therapy was evaluated in a randomized trial that compared cyclosporine (3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) and enteric-coated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    sodium (1440",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in 55 adults with severe atopic dermatitis after induction of remission with cyclosporine (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/46\">",
"     46",
"    </a>",
"    ]. After an initial increase in symptoms during the first six weeks of therapy, cyclosporine and mycophenolate sodium were similarly effective in maintaining improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/46\">",
"     46",
"    </a>",
"    ]. Adverse effects were mild and transient in both groups. During the maintenance phase, 62 percent of patients in the cyclosporine group developed hypertrichosis and 15 percent developed hypertension requiring treatment. The main adverse effect of mycophenolate was fatigue, reported in 46 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;T and B lymphocytes rely on de novo purine synthesis for the production DNA and RNA.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil inhibits T and B cell proliferation via the inhibition of inosine monophosphatase dehydrogenase, a key enzyme involved in de novo purine synthesis. Side effects of mycophenolate mofetil include gastrointestinal distress, myelosuppression, and infections.",
"   </p>",
"   <p>",
"    Studies of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil for the treatment of atopic dermatitis are limited. A number of small, uncontrolled studies have reported efficacy in adults with atopic dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. In one retrospective review, 17 out of 20 adults with moderate to severe disease improved within four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/51\">",
"     51",
"    </a>",
"    ]. However, in an uncontrolled study of patients with severe atopic dermatitis who had previously failed treatment with interferon gamma or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , five out of seven adults did not respond to mycophenolate mofetil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/52\">",
"     52",
"    </a>",
"    ]. One retrospective case series evaluated the use of the drug in children. Among 14 children treated, disease improvement occurred in all but one [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a randomized trial, enteric-coated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    sodium (1440",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) were similarly effective as long-term maintenance therapy for 55 adults with severe atopic dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Cyclosporine'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    , an antagonist of purine metabolism that inhibits T cell proliferation, showed some efficacy in treatment of adults with severe atopic dermatitis in one randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/54\">",
"     54",
"    </a>",
"    ]. However, the trial had a 43 percent dropout rate. Subsequent retrospective studies have also suggested that azathioprine is moderately effective for some children and adults with severe atopic dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    were similarly effective in reducing eczema severity in a randomized trial in 42 patients with atopic dermatitis unresponsive or intolerant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/57\">",
"     57",
"    </a>",
"    ]. Patients were treated for 12 weeks and permitted to use topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide ointment (body),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    ointment (face), and oral antihistamines. At the end of 12 weeks, the severity of eczema by SCORAD score decreased by approximately 40 percent in both groups and approximately 70 percent of patients in each group cleared or had minimal or mild disease. No serious adverse events occurred. Fourteen patients in each group experienced upper airway infections, common colds, and mild skin infections. Infections of moderate intensity occurred in five patients in the methotrexate group and in eight patients in the azathioprine group. During the subsequent open-label phase, 84 percent of patients in the azathioprine group and 95 percent in the methotrexate group continued on their treatment. Benefits were maintained in both groups in the subsequent 12 weeks of treatment.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    has a number of adverse effects, including myelosuppression, hepatotoxicity, gastrointestinal disturbances, increased susceptibility to infection, and increased risk of cancer. Hematologic parameters and liver function tests must be monitored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    antagonist that inhibits transmethylation reactions and promotes release of adenosine. The antiinflammatory effects of methotrexate may be due to the inhibition of lymphocyte proliferation and the antiinflammatory activity of adenosine. Methotrexate was reported to be effective in adult patients with severe atopic dermatitis in a few small retrospective studies and one open label trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/58\">",
"     58",
"    </a>",
"    ]. Although some clinicians have used methotrexate for the treatment of pediatric atopic dermatitis, the drug has not been studied in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/39,59\">",
"     39,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    were similarly effective in reducing eczema severity in a randomized trial in 42 patients with atopic dermatitis unresponsive or intolerant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Azathioprine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is generally well-tolerated. Adverse effects include gastrointestinal upset, hepatotoxicity, bone marrow suppression, and, very rarely, acute idiopathic pulmonary fibrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of systemic glucocorticoids is not recommended for the long-term management of a chronic, non-life-threatening disorder such as atopic dermatitis because of a number of common and significant side effects (eg, growth suppression, osteoporosis, cataracts, lymphopenia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/16\">",
"     16",
"    </a>",
"    ]. A short, tapering course of systemic glucocorticoids is sometimes used to abort an acute exacerbation. However, the dramatic clinical improvement often observed is characteristically associated with an equally dramatic rebound flaring of atopic dermatitis following the discontinuation of these agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10842?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Corticosteroids'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Leflunomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical improvement has been reported in three patients during treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    , an oral immunomodulatory agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     BIOLOGICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinant cytokines, monoclonal antibodies, and fusion proteins have been used to create drugs that work via modulation of the immune function. These drugs are often referred to as biologic therapies. Biologic therapy has been successful for multiple immune-mediated disorders, including psoriasis. Studies of biologics for the treatment of atopic dermatitis are limited; however, a few drugs have shown benefit in small numbers of patients. Further studies are necessary before any of these drugs can be routinely recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Omalizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38629?source=see_link\">",
"     Omalizumab",
"    </a>",
"    (anti-IgE) has been studied in case reports and pilot studies for treatment of severe atopic dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. In one open label study, 21 patients with severe atopic dermatitis and asthma were treated for nine months, resulting in significant improvement in atopic dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/64\">",
"     64",
"    </a>",
"    ]. In another study, 6 of 11 patients had a good to very good clinical response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/65\">",
"     65",
"    </a>",
"    ]. Side effects include injection site reactions, anaphylaxis, and possible increased risk of cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    (anti-CD20), which eliminates B cells from the circulation, was given in an open study of six patients with severe atopic dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/66\">",
"     66",
"    </a>",
"    ]. Skin symptoms and the severity and extent of disease improved in all patients within four to eight weeks. Adverse effects of rituximab include fever, infusion reactions, and increased rates of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Infliximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    (anti-TNF-alpha), which downregulates the Th1 inflammatory response, was studied in nine adult patients with moderate to severe atopic dermatitis resistant to conventional therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/67\">",
"     67",
"    </a>",
"    ]. All clinical parameters improved during the induction phase over the first six weeks. However, these improvements were not sustained in most patients during maintenance therapy administered through 38 weeks. Infliximab therapy is associated with risks of infusion reactions, infections, and malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Alefacept",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alefacept, a fusion protein that binds to CD2 and inhibits T-cell activation, and selectively reduces memory T cells, was investigated in two pilot studies of 10 and 9 adult patients with moderate to severe atopic dermatitis for 12 and 16 weeks, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. In the first trial, alefacept led to a 78 percent reduction in atopic dermatitis severity. In contrast, in the second study, two patients had a significant reduction in atopic dermatitis severity (EASI score decreased by at least 50 percent), four had smaller reductions, and one had worsening of EASI. In addition, two patients withdrew due to worsening disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Etanercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    is a fusion protein that functions as a TNF receptor antagonist. Case reports regarding the use of etanercept for atopic dermatitis have yielded conflicting results. Etanercept was not effective for improving atopic dermatitis in two children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/70\">",
"     70",
"    </a>",
"    ]. However, improvement has been reported in two adult patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/71\">",
"     71",
"    </a>",
"    ]. Adverse effects of etanercept include risks for infection and malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Interferon-gamma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon-gamma (IFN-gamma), which suppresses Th2 activity and has other immunomodulatory effects, has shown mixed results in the treatment of severe atopic dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/17\">",
"     17",
"    </a>",
"    ]. Several studies (including two randomized trials, albeit with methodologic flaws) demonstrated a reduction in symptoms and body surface involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/72-75\">",
"     72-75",
"    </a>",
"    ]. Response rates were low in an open-label study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/76\">",
"     76",
"    </a>",
"    ]. Potential side effects include granulocytopenia,",
"    <span class=\"nowrap\">",
"     fever/chills,",
"    </span>",
"    myalgias, headache, and pain at the injection site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. The data suggest that interferon-gamma may have only a limited role in the treatment of severe atopic dermatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Mepolizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mepolizumab (anti-IL-5) was used in a randomized trial in adults with moderate to severe atopic dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/77\">",
"     77",
"    </a>",
"    ]. No significant clinical improvement was noted in the treatment group compared with the placebo group, despite a significant decrease in peripheral blood eosinophils.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     OTHER THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Extracorporeal photopheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with extracorporeal photopheresis (ECP) involves the irradiation of a patient's peripheral blood mononuclear cells after they have been exposed to 8-methoxypsoralen. The cells are subsequently returned to the patient via infusion. Extracorporeal photopheresis has improved severe, refractory atopic dermatitis in a few, small, uncontrolled studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/78-82\">",
"     78-82",
"    </a>",
"    ]. In one study of 35 patients with severe, refractory atopic dermatitis, extracorporeal photopheresis led to a significant decrease in the disease severity score (mean SCORAD 74.4 pre-treatment versus 36.8 post-treatment) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immune globulin (IVIG), which has immunomodulatory effects at high doses (2",
"    <span class=\"nowrap\">",
"     g/kg),",
"    </span>",
"    led to no significant clinical improvement in severe atopic dermatitis in a small, randomized, evaluator-blinded trial. However, a few case reports and small uncontrolled studies have reported improvement with IVIG therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/15,17,83\">",
"     15,17,83",
"    </a>",
"    ]. Overall, there may be a better response in young children than adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergen immunotherapy with dust mite extract in sensitized patients with atopic dermatitis has been studied using both subcutaneous (SCIT) and sublingual (SLIT) administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/62\">",
"     62",
"    </a>",
"    ]. Dust mite SCIT in adults with chronic moderate atopic dermatitis significantly improved disease severity in a small randomized trial and an open label study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. However, dust mite SLIT was effective only in patients with mild to moderate atopic dermatitis, and symptoms worsened in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Probiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Probiotics appear to be of limited benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. In a meta-analysis of randomized trials, statistically significant improvement in atopic dermatitis severity score with probiotic treatment, compared with placebo, was more pronounced in patients with moderate-to-severe disease versus mild disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/88\">",
"     88",
"    </a>",
"    ]. However, this difference is unlikely to be clinically significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Traditional Chinese medicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of traditional Chinese medicine, or Chinese herbal therapy, for atopic dermatitis has not been adequately evaluated in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/26/44457/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/30/6626?source=see_link\">",
"       \"Patient information: Eczema (atopic dermatitis) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/23/15730?source=see_link\">",
"       \"Patient information: Atopic dermatitis (eczema) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe atopic dermatitis remains a difficult condition to treat. Before initiating second-line treatments for atopic dermatitis, several factors should be addressed:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Assure that the prescribed treatment regimen is being followed and maximize the use of conventional therapies.",
"     </li>",
"     <li>",
"      Intensify efforts to remove exposure to any suspected exacerbating factors.",
"     </li>",
"     <li>",
"      Treat secondary infections.",
"     </li>",
"     <li>",
"      Confirm that the diagnosis of atopic dermatitis is correct (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Exacerbating factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Differential diagnosis'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with severe, refractory atopic dermatitis can benefit from phototherapy or systemic immunomodulatory drugs. The use of phototherapy and systemic immunosuppressive agents should be reserved for severe disease that has been refractory to conventional therapy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Phototherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Systemic immunosuppressants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most adult patients with severe atopic dermatitis that has been refractory to topical therapy, we suggest treating with phototherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For patients with chronic disease, we suggest treatment with narrow band UVB. For patients with acute exacerbations, we suggest treatment with UVA1 (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For adult patients in whom phototherapy is not an option or is ineffective, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These agents have been shown to be safe and efficacious, but have different side effect profiles that may influence decisions for individual patients (eg, those with hypertension). Patients should be monitored carefully for adverse effects. Alternative systemic immunosuppressive therapies include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Systemic immunosuppressants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with severe refractory atopic dermatitis, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Alternative treatments for these children include phototherapy,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'In children'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Systemic immunosuppressants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic glucocorticoids should not be used for the chronic management of atopic dermatitis. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10842?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment of atopic dermatitis (eczema)\", section on 'Corticosteroids'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The use of biologic therapies may be considered on an individual basis after other therapies have been tried and failed. The most promising of the biologic therapies are",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      . Further studies are necessary before any of these agents can be routinely recommended. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Systemic immunosuppressants'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Biologics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/1\">",
"      Schmitt J, Langan S, Williams HC, European Dermato-Epidemiology Network. What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol 2007; 120:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/2\">",
"      Beattie PE, Lewis-Jones MS. Parental knowledge of topical therapies in the treatment of childhood atopic dermatitis. Clin Exp Dermatol 2003; 28:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/3\">",
"      Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006; 118:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/4\">",
"      Krejci-Manwaring J, Tusa MG, Carroll C, et al. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol 2007; 56:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/5\">",
"      Ohya Y, Williams H, Steptoe A, et al. Psychosocial factors and adherence to treatment advice in childhood atopic dermatitis. J Invest Dermatol 2001; 117:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/6\">",
"      Karlberg AT, Bergstr&ouml;m MA, B&ouml;rje A, et al. Allergic contact dermatitis--formation, structural requirements, and reactivity of skin sensitizers. Chem Res Toxicol 2008; 21:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/7\">",
"      Coloe J, Zirwas MJ. Allergens in corticosteroid vehicles. Dermatitis 2008; 19:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/8\">",
"      Iliev D, W&uuml;thrich B. Occupational protein contact dermatitis with type I allergy to different kinds of meat and vegetables. Int Arch Occup Environ Health 1998; 71:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/9\">",
"      Lod&eacute;n M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J Clin Dermatol 2003; 4:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/10\">",
"      Pirker C, M&ouml;slinger T, Wantke F, et al. Ethylmercuric chloride: the responsible agent in thimerosal hypersensitivity. Contact Dermatitis 1993; 29:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/11\">",
"      VanArsdel PP Jr, Larson EB. Diagnostic tests for patients with suspected allergic disease. Utility and limitations. Ann Intern Med 1989; 110:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/12\">",
"      Corazza M, Mantovani L, Maranini C, et al. Contact sensitization to corticosteroids: increased risk in long term dermatoses. Eur J Dermatol 2000; 10:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/13\">",
"      Mailhol C, Lauwers-Cances V, Ranc&eacute; F, et al. Prevalence and risk factors for allergic contact dermatitis to topical treatment in atopic dermatitis: a study in 641 children. Allergy 2009; 64:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/14\">",
"      Gambichler T. Management of atopic dermatitis using photo(chemo)therapy. Arch Dermatol Res 2009; 301:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/15\">",
"      BuBmann C, Bieber T, Novak N. Systemic therapeutic options for severe atopic dermatitis. J Dtsch Dermatol Ges 2009; 7:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/16\">",
"      Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 2006; 61:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/17\">",
"      Schmitt J, Sch&auml;kel K, Schmitt N, Meurer M. Systemic treatment of severe atopic eczema: a systematic review. Acta Derm Venereol 2007; 87:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/18\">",
"      Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol 2007; 56:e55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/19\">",
"      Jung T, Stingl G. Atopic dermatitis: therapeutic concepts evolving from new pathophysiologic insights. J Allergy Clin Immunol 2008; 122:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/20\">",
"      Krakowski AC, Eichenfield LF, Dohil MA. Management of atopic dermatitis in the pediatric population. Pediatrics 2008; 122:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/21\">",
"      Meduri NB, Vandergriff T, Rasmussen H, Jacobe H. Phototherapy in the management of atopic dermatitis: a systematic review. Photodermatol Photoimmunol Photomed 2007; 23:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/22\">",
"      Reynolds NJ, Franklin V, Gray JC, et al. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet 2001; 357:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/23\">",
"      Hjerppe M, Hasan T, Saksala I, Reunala T. Narrow-band UVB treatment in atopic dermatitis. Acta Derm Venereol 2001; 81:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/24\">",
"      Abeck D, Schmidt T, Fesq H, et al. Long-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitis. J Am Acad Dermatol 2000; 42:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/25\">",
"      Krutmann J, Czech W, Diepgen T, et al. High-dose UVA1 therapy in the treatment of patients with atopic dermatitis. J Am Acad Dermatol 1992; 26:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/26\">",
"      Krutmann J, Diepgen TL, Luger TA, et al. High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial. J Am Acad Dermatol 1998; 38:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/27\">",
"      Tzaneva S, Seeber A, Schwaiger M, et al. High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. J Am Acad Dermatol 2001; 45:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/28\">",
"      von Kobyletzki G, Pieck C, Hoffmann K, et al. Medium-dose UVA1 cold-light phototherapy in the treatment of severe atopic dermatitis. J Am Acad Dermatol 1999; 41:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/29\">",
"      Legat FJ, Hofer A, Brabek E, et al. Narrowband UV-B vs medium-dose UV-A1 phototherapy in chronic atopic dermatitis. Arch Dermatol 2003; 139:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/30\">",
"      Majoie IM, Oldhoff JM, van Weelden H, et al. Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2009; 60:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/31\">",
"      Gambichler T, Othlinghaus N, Tomi NS, et al. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. Br J Dermatol 2009; 160:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/32\">",
"      Tzaneva S, Kittler H, Holzer G, et al. 5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial. Br J Dermatol 2010; 162:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/33\">",
"      Stern RS, PUVA Follow up Study. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/34\">",
"      Nijsten TE, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. J Invest Dermatol 2003; 121:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/35\">",
"      Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009; 60:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/36\">",
"      Tay YK, Morelli JG, Weston WL. Experience with UVB phototherapy in children. Pediatr Dermatol 1996; 13:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/37\">",
"      Jury CS, McHenry P, Burden AD, et al. Narrowband ultraviolet B (UVB) phototherapy in children. Clin Exp Dermatol 2006; 31:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/38\">",
"      Clayton TH, Clark SM, Turner D, Goulden V. The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. Clin Exp Dermatol 2007; 32:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/39\">",
"      Shaw MG, Burkhart CN, Morrell DS. Systemic therapies for pediatric atopic dermatitis: a review for the primary care physician. Pediatr Ann 2009; 38:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/40\">",
"      Akhavan A, Rudikoff D. Atopic dermatitis: systemic immunosuppressive therapy. Semin Cutan Med Surg 2008; 27:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/41\">",
"      Sowden JM, Berth-Jones J, Ross JS, et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991; 338:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/42\">",
"      Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007; 21:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/43\">",
"      Brazzelli V, Prestinari F, Chiesa MG, et al. Sequential treatment of severe atopic dermatitis with cyclosporin A and low-dose narrow-band UVB phototherapy. Dermatology 2002; 204:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/44\">",
"      Mrowietz U. Macrolide immunosuppressants. Eur J Dermatol 1999; 9:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/45\">",
"      Zonneveld IM, De Rie MA, Beljaards RC, et al. The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens. Br J Dermatol 1996; 135 Suppl 48:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/46\">",
"      Haeck IM, Knol MJ, Ten Berge O, et al. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol 2011; 64:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/47\">",
"      Grundmann-Kollmann M, Podda M, Ochsendorf F, et al. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol 2001; 137:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/48\">",
"      Benez A, Fierlbeck G. Successful long-term treatment of severe atopic dermatitis with mycophenolate mofetil. Br J Dermatol 2001; 144:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/49\">",
"      Hansen ER, Buus S, Deleuran M, Andersen KE. Treatment of atopic dermatitis with mycophenolate mofetil. Br J Dermatol 2000; 143:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/50\">",
"      Grundmann-Kollmann M, Korting HC, Behrens S, et al. Successful treatment of severe refractory atopic dermatitis with mycophenolate mofetil. Br J Dermatol 1999; 141:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/51\">",
"      Murray ML, Cohen JB. Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. Clin Exp Dermatol 2007; 32:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/52\">",
"      Neuber K, Schwartz I, Itschert G, Dieck AT. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol 2000; 143:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/53\">",
"      Heller M, Shin HT, Orlow SJ, Schaffer JV. Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients. Br J Dermatol 2007; 157:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/54\">",
"      Berth-Jones J, Takwale A, Tan E, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 2002; 147:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/55\">",
"      Hon KL, Ching GK, Leung TF, et al. Efficacy and tolerability at 3 and 6 months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults. J Dermatolog Treat 2009; 20:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/56\">",
"      Hughes R, Collins P, Rogers S. Further experience of using azathioprine in the treatment of severe atopic dermatitis. Clin Exp Dermatol 2008; 33:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/57\">",
"      Schram ME, Roekevisch E, Leeflang MM, et al. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol 2011; 128:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/58\">",
"      Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol 2007; 156:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/59\">",
"      Borchard KL, Orchard D. Systemic therapy of paediatric atopic dermatitis: an update. Australas J Dermatol 2008; 49:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/60\">",
"      Wozel G, Vit&eacute;z L, Pfeiffer C. Severe atopic dermatitis and leflunomide: first clinical experience and highlights of pertinent experimental data. Dermatol Online J 2006; 12:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/61\">",
"      Schmitt J, Wozel G, Pfeiffer C. Leflunomide as a novel treatment option in severe atopic dermatitis. Br J Dermatol 2004; 150:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/62\">",
"      Belloni B, Andres C, Ollert M, et al. Novel immunological approaches in the treatment of atopic eczema. Curr Opin Allergy Clin Immunol 2008; 8:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/63\">",
"      Sanchez J, Ramirez R, Diez S, et al. Omalizumab beyond asthma. Allergol Immunopathol (Madr) 2012; 40:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/64\">",
"      Sheinkopf LE, Rafi AW, Do LT, et al. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 2008; 29:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/65\">",
"      Belloni B, Ziai M, Lim A, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007; 120:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/66\">",
"      Simon D, H&ouml;sli S, Kostylina G, et al. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008; 121:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/67\">",
"      Jacobi A, Antoni C, Manger B, et al. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005; 52:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/68\">",
"      Simon D, Wittwer J, Kostylina G, et al. Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema. J Allergy Clin Immunol 2008; 122:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/69\">",
"      Moul DK, Routhouska SB, Robinson MR, Korman NJ. Alefacept for moderate to severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2008; 58:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/70\">",
"      Buka RL, Resh B, Roberts B, et al. Etanercept is minimally effective in 2 children with atopic dermatitis. J Am Acad Dermatol 2005; 53:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/71\">",
"      Rullan P, Murase J. Two cases of chronic atopic dermatitis treated with soluble tumor necrosis factor receptor therapy. J Drugs Dermatol 2009; 8:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/72\">",
"      Hanifin JM, Schneider LC, Leung DY, et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993; 28:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/73\">",
"      Schneider LC, Baz Z, Zarcone C, Zurakowski D. Long-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis. Ann Allergy Asthma Immunol 1998; 80:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/74\">",
"      Reinhold U, Kukel S, Brzoska J, Kreysel HW. Systemic interferon gamma treatment in severe atopic dermatitis. J Am Acad Dermatol 1993; 29:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/75\">",
"      Jang IG, Yang JK, Lee HJ, et al. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J Am Acad Dermatol 2000; 42:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/76\">",
"      Noh GW, Lee KY. Blood eosinophils and serum IgE as predictors for prognosis of interferon-gamma therapy in atopic dermatitis. Allergy 1998; 53:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/77\">",
"      Oldhoff JM, Darsow U, Werfel T, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005; 60:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/78\">",
"      Prinz B, Nachbar F, Plewig G. Treatment of severe atopic dermatitis with extracorporeal photopheresis. Arch Dermatol Res 1994; 287:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/79\">",
"      Richter HI, Billmann-Eberwein C, Grewe M, et al. Successful monotherapy of severe and intractable atopic dermatitis by photopheresis. J Am Acad Dermatol 1998; 38:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/80\">",
"      Prinz B, Michelsen S, Pfeiffer C, Plewig G. Long-term application of extracorporeal photochemotherapy in severe atopic dermatitis. J Am Acad Dermatol 1999; 40:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/81\">",
"      Radenhausen M, Michelsen S, Plewig G, et al. Bicentre experience in the treatment of severe generalised atopic dermatitis with extracorporeal photochemotherapy. J Dermatol 2004; 31:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/82\">",
"      Sand M, Bechara FG, Sand D, et al. Extracorporeal photopheresis as a treatment for patients with severe, refractory atopic dermatitis. Dermatology 2007; 215:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/83\">",
"      Jolles S. A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis. Clin Exp Dermatol 2002; 27:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/84\">",
"      Werfel T, Breuer K, Ru&eacute;ff F, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 2006; 61:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/85\">",
"      Bussmann C, Maintz L, Hart J, et al. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Clin Exp Allergy 2007; 37:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/86\">",
"      Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2007; 120:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/87\">",
"      Lee J, Seto D, Bielory L. Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis. J Allergy Clin Immunol 2008; 121:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/88\">",
"      Michail SK, Stolfi A, Johnson T, Onady GM. Efficacy of probiotics in the treatment of pediatric atopic dermatitis: a meta-analysis of randomized controlled trials. Ann Allergy Asthma Immunol 2008; 101:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/26/44457/abstract/89\">",
"      Zhang W, Leonard T, Bath-Hextall F, et al. Chinese herbal medicine for atopic eczema. Cochrane Database Syst Rev 2004; :CD002291.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1726 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-4EAA1F1B94-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_26_44457=[""].join("\n");
var outline_f43_26_44457=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SEVERE ATOPIC DERMATITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EXACERBATING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Poor compliance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Environmental triggers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hypersensitivity reactions to treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Food and environmental allergies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GENERAL APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PHOTOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Narrowband UVB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ultraviolet A1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Psoralen plus UVA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Broadband UVA and UVB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      In children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SYSTEMIC IMMUNOSUPPRESSANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Leflunomide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      BIOLOGICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Omalizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Infliximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Alefacept",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Etanercept",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Interferon-gamma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Mepolizumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      OTHER THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Extracorporeal photopheresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Probiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Traditional Chinese medicine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/1726\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/1726|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/59/5046\" title=\"picture 1\">",
"      Severe atopic dermatitis 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/1726|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/28/15819\" title=\"table 1\">",
"      Causes severe AD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/38/17003\" title=\"table 2\">",
"      AD DDx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26104?source=related_link\">",
"      Contact dermatitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/39/14970?source=related_link\">",
"      Epidemiology and clinical features of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42631?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/23/15730?source=related_link\">",
"      Patient information: Atopic dermatitis (eczema) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/30/6626?source=related_link\">",
"      Patient information: Eczema (atopic dermatitis) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/53/24410?source=related_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/59/26551?source=related_link\">",
"      Role of allergy in atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_26_44458="Palpable purpura";
var content_f43_26_44458=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F77522%7EDERM%2F56272%7EDERM%2F70300%7EDERM%2F65932%7EDERM%2F58626%7EDERM%2F57440%7EDERM%2F77723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F77522%7EDERM%2F56272%7EDERM%2F70300%7EDERM%2F65932%7EDERM%2F58626%7EDERM%2F57440%7EDERM%2F77723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Palpable purpura in cutaneous small vessel vasculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Palpable purpura are present in this patient with cutaneous small vessel vasculitis secondary to Henoch-Sch&ouml;nlein purpura (IgA vasculitis).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palpable purpura",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Palpable purpura are present in this patient with cutaneous small vessel vasculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:",
"     <a href=\"file://www.visualdx.com\" target=\"_blank\">",
"      www.visualdx.com",
"     </a>",
"     . Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Leukocytoclastic vasculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCa3m81hHMwhWJctEOpzyoY9z/KpJLhjGyxxrhnwzDOG6ED+vFVSA9xjy2ZZerSdWPqcfyrSSB28gFxHGuceuP8K8+Vrn0ZMEhSN1uJ3EcfRD95275Hb/CqvkJdzSjyh5sse5Y0HAGOmafIsZjwmxoFIG7adzn29hT5ZhHut4FkBkUAqPvlSc4z6mhaMNyKRWkCxQlBFbpt8xOnI5Gfrx+FPGyztVmRvOlQ7NzcoD7DvUcSmYTXUhKQJw/bk8BVHrircphivHV4gIooyVhH3UJ6ZPfA59zQxpjYxNbwvIfvl1jQN97PUkCpJHKbIgVEh5Yn5mDt3I9QKLFzLfHGcKhcu/RABnn3/qaW05lLLuQsSN7feYkZP0+tRcZV8j7HBcSEusbfu4lOArc8n39ak02HzpNpKRrIQvztgccnPrgDn3NSXzTSJa+dh2J+SEgYA7Y/zziiQvbT7VEbKP3eCcgADnP070XHr1Jr2aELJ5TlyWCwRkADHUyYH6CobMqIBFFChu5BiMHoi9y3vwaZAbe4Xd5wWMtlDjDMCe3pj/CpbiREtDDb5M8oAlKjlVz0Huf/AK9PZ3EyhaWitH5qsywhSQ7uSWUZy2P5CrzRNGzssW9FQLHg52gjJZvrRH5UitAitFbRrukkc9TnJPvzwKjSed4WggDLlgZSF+9k/Kv9TSlK+gbErRlbVo4WBMzKJS3Qk87fXA71WW2kkklESFkVwrSA9AO+e5JrUH2b5dihoIshST80rnqxPoKrXUS7CMsyyMxzjaBH6j6mhOwGVN5940krKoj34jUnJbPU/TjrW3LIsllZQ22fK3fvQMjzmPXAHUVl6gfOkhmDEM+0eWo/JV9B0yasyXElvcFZWRJQPKaSFvlCfxbf0HvTbvqDRXJnMkshjzG7cME+8RwAP89qtwQxqsk83HlAoWY8s2Ow9BnFMheWMwJIsiRQ4YqPvdOM+5yBmpQ8ZtlW+cY34IB6HqTjuc8CkmOxALt5ZInziXIRVK/cxyMf40skAiSQ+b5twu5yRyMZ7H8fzqdogLhSPvqoAB58sscH8eaiv2gSWbylKRo2xFY5YgDlv8+1CdgsZzSzTO0kUisAVwGPVhy2CeSB61ZuQz3alGZ5ZV8yTB5YkfdPp/hUkqpZwRxCEoJWDMSdzJn0+tT2aeZDJMqrmU7ASPvDPPH04oauwvYmtLKSGFbnyUf5/LhGcZc8Bvp6VVOze4jYmNMks4wcj+LHfngfSrmvXu6GySE+XcdR0Gztn2J7VVsLeOe5MCt+6GF3twAijnr6t+dEtNgj3IoFYSpJGNoPO9sEKeo/ICpoVWcszlWEahpNo++7twvtUIny3lsoFr5n3jxkdWIH5CrNwjyTskSeSJkLlMZ2DHH5D+dTsxken+ZLqrSRgADALA429eh/Woby1e8lEKxkC4XcoZs/Jnpn3Pf0q1FHHEiMsu1C3QdQirjJp91dSMkbo5Es2VBCjCKAAB/Pn2q4OwjDvwZdREYJOCYjtX7qDG4j3J+UewpTuR8uVjkLPJ5YwMFcKo4/QVo2DRW9yJMKquGc8fe2jAz9SSTVAKtzK8zKyxbt5lzkgDkAfqfxq5TDctaes8SPlSjzfuWlPHux+vtQsWbxfL3bZn/dhRgsAdqkexwTSTRSx2amTzM72VgTgIGHf/aI/nWrpUiNdxXLgvDCFQ5GNu1SFUf8CyajrYOlynqSQtfMrr++Lgb2OVjUEcY75NWdLiF5q5EICwoCfnJCgAYBz37mqPzXmo3OXcBcjJHAPOQD9eK2/D6xbppp/L2JHiFAcLuX+97dcD1pX1sJ6RM+5ULJNcqdyKxSEY+9nPX6Dk/WlszG96kdvsCiYGL5eSwGAT6Dgk1DqN1izJnUGYYAXup+8R+Jxk0adazwz2caqXnlBEYzyOMlvYetJbj2Wo7VD9kae3WYyiaYRSTleoz8zfh81UbyF7/Vz5DgQPL5nTG2McByPc9BV6SDz7l7ROYYgqyOG4PdiPQkmm6lJAzTT2rYS8GAg6JGp2jn6DP41on3JSIpBtSa6g3xQMxiQ7ge2N35A/nU2lKIJp4lKh5tqq5ONqHqc9uKieLdc7LfP2W2g5Q/w5Gce/amyr50kTxoqhXUAE9CAMn6Z/lUbFX0sWLuQXVzd2lvCYoPMEjnPJVQAox+f60yaDzWE0iBTMxKIR0XqfwwKavnKu6JYkMyDysnIbkgt7nrVm3aLzUYYEQQoGwRu29h9TgUMFpsQXcbxyxwSJtnEjNIT6sMLx7DnNZs5lml2qAIlXyI+549PrV++V1vpBMXmlDCIleiHqSPp0pAY45ZxNEzyqMQDp5ZPG736frS1DzKtxO0kr5RgrAKjKDkDONv8zVqQI8dy/kM1xJJGIs9VUDOM9OgFM06M3EpmkBOx9zLngKOOKliuVmuLiSEhDgCFE+bknGfwAz+NUtRSI2mljZbOCVXd1Z5MDkO69AfpWXNsvbsGYhLOMbHI4KhQQB+ea1nK2a3o5K7clyuWMwGVP1LHFYVlCZfNgmBEsmG2jkbuSxP0ANXYSJNHtBqFxHDLIkIjBMhxxtVcgD6njNULjypV3OC0roVOeiDt9eBitNDjQL55jjzmUQbedxPBBPXgdqzJiE0ubKv9qSXy1DDJKspyD9ODTauhNkE/lTvLJatiIgLGp654G4/kabAwjSR2CiYiMIMep6frVawLusSiPaSWWIHgkY6mr2pR+TBaxRHz5GRsoF4D52rz6jB59qEiTfsSZZbhpcxLFzKcj5Seg/xqwFhe4DMzSRKpAUHluOB7CqiNB9q+z7fOWRgNyDAZv8ACrVtIsEgPkedOTsg28Lu9SO+Kl2uUOkuxDLidEWQKNqbchAenHsO1T2sYuJZLhZjHsU5djz056d/5VkbcTXEl1IzorBXkzkk9yPU1bmuFAjEYOyY7kicZOB0Z8e3NS4t6lbFyVY5Zd6IMo3EPJy2PvN68VGz43oQskrybpD2wo6Y+tNguvs8u21Uos4IjdjhiPUen1/CkuLeS2u/KHLqoRVXgrnn/wCufrQJEl1cxwWUkEBZ5GfMjdgP7o9STzTo4mghRLgq0khLfI2Xc4wufQdTUMtpEYtux3dNzs2eFbPJyPTpUMTSkC4UlGcH5nOTjsB9B+ppaDsXdsf9qLFC5nMajcwGdzZyeewAoO6dWV2CoQVZyMgKTk/jUltEunwspws0yCMKeGOTzgfTrVW+vH8iGCDlRlix4VmHAx/eAz19aLCILJcTCWNVcRj92uOI/wC6PcnjirdpbbptxkZC27ygBku3fGPxokLR2MMYjKqx2hgMs5XjP59KIZWmlE7QsDt2KAeBj39KNyizZi2e5kRwFtoY/wCM7izenvk1AL1pxsjVI4Vzs28c/wATn144AqbT3VC1rJ94bpJinGBzhSe1VpfNkVmCoqTMqkActx6dgPSpt2A09K8j7CXWOR3RSVYevQZ7BQM8etUgrXUU15JIq2/EccmD19FHsKdE0z2cenW4XEjBJ3AO3ruwfUgc1K4j8xFLSXFvG58sgcySemBTEVrtlkuI/KgKsE/cxhcFRxlj7n+VRTiMStLMq7dyhdncLxhR2yf5VbmDSAwjiZsqz/xNIRk8+wwKpahsluoreDeEhxlzj/WY5xj0pWGaDxNFEszPlx++kGeA2OA3qenFVtkNu8k7Bf3AGwvnlsZ4Hrk1oM8QWG02soKhmUL0UHqfUmq95NGZYpJlG5X+0iKPJ2qPu/iTimkBDGRC8gkLG6kKySR9Mnk4I+uPyqWzS2aa3W93NCR502Ry2Pupj0J9fSqUMTrNNLMxMzuo4+6CTn8uKmunKSTXEw2TD5hu6lj0H0xz+NEdGO10Mvd93cSXm11iAKxuFwCoGMAd+SRVo28VrcRwP5sksEY3ov8AfPYegXNR3yLa2dvvkMly2ZTj7iqp4A/HnFJLJNFYxSTSIstwDIZMYZueM+3Sqb5tidB17AG8oW6b7guXcjGWcnCj6AZP5VYktWFtcIgG4yCIuDysfTA9zzUel+cWW4hhR8KUZ5cgknlm9z0/SpZfMt44LdFK3ErhmdjztyAoPpyetTcdgtZrYzATKzeXuZlwCAqj5QT/AJ6Us9y9yS0bESythtvB24GRn0PApkltBYaZODIJHDGNTnBYk/MfpjgVLbx28kLqwC3Vy3yADCqo7/oKTTHdFO4cXTKunRCJk/ck9QeSWJ9gP1qpHc/YZpLhAsjOGigB6gjgNjoM85NXJHKsCAY3nJ2hT/AOCB9eKbbwx3Fy0RZR5cgUHg9OT9eAB+NNOwNdSq0DTSwwouHEYjeMcbiT2+ueauLBayTw20C5jR8SjGSx/i/AdKZKJS8t0/BdyAwOMDnn2q5pW6K4L72WBAyfKME8ZP4HFNuwdNChrSfaJBOC2x5CY416Bh3Pv0rTs1W209PswD3DySLHvHH3cbiD2HJqtqDyK/mSBYo1j8xU/hUk8D68Cq5kaOyRjMxLrtDd1X+Ln/PWlzN6hbQs2k1xY2SRW8KhEXz5HK5ODxuJ+naq1xc3NjpnmWyqXuwuQw455B/Lmpru7eSK58wbZZoxhkOBtPC59hioLiKS2ihVgwZiilQN2EA6/qDiqVupLJdIjOAf9aZsIhboSc5c/jn8qGu7e01VpGklIgDKhX5jIeBj6En9Knjn+yPMiwFhArCFsdWwADj2/rUN1pSX9+8a/K1lCJZSg5Zs5Iz9T19qEuwm9dSZIpW05mMcgnuZQjuBwqf/AFufyqpPErzuY0H2YMIYsN94Dqfw5NSXt00t2bS2DRQopYt7EHH44zVWIy3DxQQh2htos5HbjJ/T+dEwjc17REGmXDqAGk8ydiVyyKRhQT7ALWIkc26FUTzUb92pznc2Rkj2JOPwrUvJ1jtktIv9bKu2Q45IJz+HAFJNHtvIvLl228EmMHquANzfnUt3GlYz9VWRpYViUs0YMUYHY5wMfiTU99NAv2W2tVISxbJ3HO5jgAH8iak0+dY3G6F1Ee51ZjkuWORj9B+dOaJY/stqwbc/76VRzkgcFvYZJprRDuS+bJBa2xmc/bJZTNJkdByAT+JPH0qG3izaXTSAtsJlZ267E9PcsabdTzTlERk8xmXnHIA4BH4mnardtbQxx7/laNMgfxYyef0+ualdw22INVePS9OtrQqjTtEqSENlxn5mPHscVLp1msctrAknl3D/AL2ZufkAOQB6Z/pWfYFZ77c8Tys0mVVjzuA4yfT1q/NMtlZX7SO0s8paKKUjvnBI+nb6VqtTNporW8VvLLLNOX8uCUSSJn7+5j0z6AVlxOltayatIjOZbkwKo42Fk4A/MZq68sgtxawgZeeNQz9VGAdvuRwTVbU9m6ZYISLNdyxK3zZkbgMffAJ/GhDGr5T6asfmGONEUKMZ82Ruv5L/ADrOvZHubmMxHyLdQBgtknrlvy4Aqa6jSCC3jgkzKI1BBHc45/LP51Zvhu026jiSNN0hDMvOHI4Qd8DrmhsGjGmLzSxmBVEEZfy2B53dcg+wUfnT9QvCdSknSJVSDaqxrzk47np1Oc1JIjFYY7JSrQCRUROecAbj+PWq1oyoJ4ZfniVcuw/iwcEj9aZJ0lrN9nVHlUCWf5Y1Awdv+z6D3pttMojkzmGRUJ3E/dH+J7CqjSLc34uGcLJnb5znIQd+P5UHyGeTaJZY0JKgEZZiPvE9j3xRylFy3lU2LrCfuHmUjhj2VR3PuarR2srXIDbmlZynXIB9KdLKI7ONnWQYBjt4kO1Vbu3ue9SQ3ItEjeSXdclCECnlV/8Aiu2fek0wLEDYykXzOXZVLDhVXox9AMdKktULBwjHznl+aQnr2z/jmq9gxeQZyTGoKRg8ADnLt6Z/UYqxHc7oY7cHfK5Ms5VdoOecZ/T2qWNosgEJdR2bFLCNQkjZ5kHoPq1MtmS1SJxGpuQxJ38hOw/WqplCTmAsIREckou7ygBwB2x/jVgneI7rblAZJFVjwFAwCR9SSKmxSHzwNeN5St5k2AHfOc542j/PNF+otRLDHiV4kCSHA6DGQv44qSW6kFvbw2S7J5lJcKOeSNqj3P6ZqnfQGERQGQOykIcdAc5Yk+g6Z9qYCxRGWWCNSysE3szdie4+nath0iGQ2I4FjAy3BCjk8dsmqCzh5Z3DloSAQsfG7n5QT2AAzVy1nd7WRXCv5x86VzgcA/KPoMdO9FrCJFtdkk1orBZLxfPkP3hFGO35YNVoW2yCIsvKlfOfnbn37tjFNv7yRtz4PnT48zHHBHyp+QBIqYOikIpEnk/JhRwxx1z7n+VS73GVDPLbwSRRbki2Mu4r8zMx5x74wKu6futLaQFVW5iykXGDHx8xI98gUy5uFhmEZKtLHFuA3f6x25JP0HFRaMzs0jS+Y0Al24B2+Y3/ANajUB8cMMOnG5uZiZCcFV+8Tnrntk/kBVO2jZ7lUWMl8FeOcdMn8T/KtF5ba3gQMiMq7p1iz1Y8KD+Z4pLZlsnkBOL+eMJufgAHqw/GmgKapLJLcSyuzIreWn06dup5OKWVo4bm7mTeiqAu8jcR0xx3IAojkaJYo4QFaLLS+Z68gH245pI0zaSLCCQgMr55LEn5R9e9IewumFhI6IfuqAzgH5d3JOPXFJ5Yk8uN5vMXHmSyEfMwydo/KryWr2kEdnH8txcr+8b0x1J9gO3eqnkRtLMttHJuP7uE/eLnov06E1Wwk7iy7LvDkRBCUijVSQxCnLfQ9PwFM12X+07ppooEiRIxAg7vyCM88cCi3t3EUvmPhImbaCeGx95qt6pseCK0jCebsG1E5/eEdSe5xSvYdkP0uyIjs/mEqbWkkVD8wyRz7cUS3C3t7cOj4hSULvHVQMgY9e5rPIkTTpD5mAxWMkkgKOBj3OM8VfsbRZTZQxyhUaVmMrDgqBx/LpS3DbUS+MUGnqZgxm3b1yM7Y88sfUngfjUU2+C0WV96O8ZKKOMKen6kfWpJ7mOe4liKkGZkjDt/Cg749+v4028kLqPKRmMkgjjB6lVH9TS3BJ21ILl3VkXcpWCNRuP8O44AH+eaSZZLNANhWVztUKPmXIAyfoOfrWvawi1hsUuVjJMouHB6EAfLn6cVmQO818Zsbtzkgu2N+W5Of5CmLfQ0tcNrpmnRQS7CTtcr1ZgOf1OBVO1BeS1ti6pJMu5v7oz1P5A1Lq1s0upxRTMWRAZZCAevYfSkjtmkvWnMbIwUv8pBG3IAx7cGtJWFHREVxqqPfQ/aFDmQhmU85C8Lx9QTUF8ryXMEERRvOG9o2GMjknn0zio2gMNxE88TyTlPMAUZJyPlB9BzVua2KayqRyFJUgAeQn7oxkgfgQKnRbjItJidn2XWFiJ3SFxk/KAQPzq00kl19pvBIN8SriMZyzMe/wBBis69kmjvzGU3StEDsU/dz7fQUscxSfCZVUfO3P8AEB/icVPoBdti8HmK2fMWTb8wzuC/Mx/PFVbeOZJZt7urMoeXPBLE8A+3t7VLKkkxkhdlRYUAZlPViw+X86tSGOSxnngPmPM6BO+0c469+CaoCnYxm2S5muQgmuSUVs5wpxuz9AMfU1Zto5rbT2vQEjkusqFL8kE8EjsO1ZtuEmkaKV2aOCFnIxzjPP5n+VXp7jzba0T5wUUyeYxzk9v5cUrg0KswImLuHuHkYOwHIRccD6nH51QuJD5VzuwWjQIijoZG5Y/qKkidbG1mvTseR2CIpPB55Ge2WI/KpY7BorsPM4kdQkrxtwTyf1OKewETWl1DbRpN+7mWIOM/Mdv3QPbPJ5q6SXgvLhVCxuVt1VRyRkLj270y2UyeWchZr2MozdSMvwfyGKfqc8dtbixSQLJG7SfPwTx8o+pJ4+lG4NmZcRzXl9K0CBAm6LKnCqAMdfXJNN1GVZboxrBuj2oi7+S8gUDt2GRj6VLbR7NPdMMPKi+fB5ZiQOffOPyqWG2Nq6NdoQYI/tAAPCs33enfFC0ExsVgthIsayM0oLDeDyq55Zsdz0H1pbxJLi0tLeP5TaQvfSMo/hPQc/XGKbbRSyERklZGf96w6cKWJ+gzS6e0+pXExVlMflDzFVtu+NOw9jtH61otBPczdENw9zLduAkaK05JJO3jk1JpkETXDS3RysNq0rqcgFz0UerHI596XVCqw2tpKCkEq+bOyDBC49PTPFJptpK5hgQ5nvG3oZAcDD/MT7dB+FGwjIZZzbSttSMiYAccluAV47DpUkDSxWaLH/rrsmUqRywUnGPqatTW8Saa1w821PPK28YGScZLuT6DAqOyd8peSMI/KjMUOPZflH17/jUvUCCHFvGzRq0ZmgZQcfdDMOSfz/Sq80gFlLCYPKkAIkB4xGcN+vFLOZ5/MERUpF+7V/7xJAzjuM8fU0+6snuLe8nndjJv8t07bkAAH5kVQmU/KeWaUz5FnaopcKcAs3IHPXircTixgimdy00xOyBU5P0HqfX2qS8vN9vFp1vAskcUvmTSD5TO/UnP90ccnjjiqUG6a68wyO7yMdzry2AOi+grS3Qdy1FezPO7MyQukZKqBuEQz29Ce5qW2CxRxzuzOGY7QOWYD+JvTk1kyQyzxzNCqxxSMFLZ/hzgH35q093HLfRQ27rDDKBCGxgsoOWK+n1pWA1IpZ2ie2UgmTb5hHBYdlHtmtOaL7Mr2sIImdRGzY4jz2PvkVnaRMzxG4jMcHmEkNjlQOmPUn+dNkMqrLHsfcP3hLt8wY9Af1JNZPQpa7k6W+6J4oshWZfMYnPJOFz6+taFyBLuS0Xy4lhxnHLDPUegJ6VT+0xwqlrC24xxiWWYrwHIwF/DOatRsrW5kDMkL7Y0wMkqO/v61GqAS4t2t5UjicAoQhIH8WPmx64HepZIwLAqqCOAECM93JIGT35HSqUYnnu2jhVyiJzuP3s88e3rV7W7j7PMIbMZnUGTIyeSMD8QM0+mo3oEhMsC2wVIUEp3zE459PwA/OnTSCMO0aEswCkue3r7cfzqsEUvFbMpycKwzzu789OpxS6tcR3M5ijznODgZx/s+54JouFggYTSNLKrGZ33Kzfw4GSce/H5Vd/eR2ttCchIcFAgBLMeecd85z6CooUaF2DAsTExUg527jj86hkklIjlt3EUO6RUI688EnHc9BQkAtohmjmQEtKXOZWIwoHJGe/OPwFaN1IjWi29qpeGxVpN5OPMY9vpk/jWbFC8UMNtEyAswHlA5wpGeT64rRuQBuht42lhJEaKpxuwOD9M5OaTbTFoVbW3iaeB5JA5b94dq7V+XhR785/KprW5jWxur26CSzzMdoK52kcIAT04yakmVIIjapJmTywJS3IXvgegwetN86C7eCNVZ4LaPhAmN2ercdB0GaUZWYblX7NPbWBLSGW7uDkpjJKnv+dWLNDb6ZNKcFWlTdg5LqMknPpkfpRcxOifaFkCzRoEI3kEu/QfQLUl5cJZ30MUqqI4IVIhC9GHTPr1yfegZcvPslsbb52e+lRml74YjgfQVkMZobffbNlxLjcw4zjAx+HP1p0lzC0l1cxf65JPJQlupK8nHoMnP0qpHKDZKOFyxIOMnjCj88mgEi3fbLXSkCAszoY03nGCTgOfX1p2nXBtFuLqYb53jKRHOcZ4B+p5/CkluIpNQaSGDzFiibaWPyj1z9BxVNQsaSSTxhyRypbbh2GQ30AI4p7jRalYyabZW0ezYxabMh+6PU0unMskSSTMFtIV4Utg/Me/sAM1Wlc3EUkMaKkjqPmA9eFQfjnmqUscgsv3fKyuygHqiKAC35cfWnGNxM0IrqOfz7tZMzyS7Ygq9AO5P0qw7/Z7+Z5HUiC2xlW+6zDpn/PWpI4rXTlskmlErqjTMETAPGAg/EjJqrdRqtxbwuoeR2EsiqCSTkHHHoBR1BakmtJcWgitN4kcqq887cgZO72GKmzKhVpIlWGAJHuH9/OelReQ8+qRzFQY4+Gt85AzzyfTpV9TDb2diJxhJC87DrkjuaU2hrQS2Mga5klLSMybArenp7Y/rQ94bgNEE2JKyqdpBPlJnj8TVazMjgvFzLKzLFGTg5P8XHpTI5orTRpbxELzKxTG7bnbgEY96UVcHuTveLHdSbFzKrxRhMgfKDk/Tmq8Lxz604DmVSWVmHd+Sf1x+VFlE1zqKGXALp57egzk8flVezhKWkjISJHcLHjqx5JI/E07MC5JNH5Quxhp5VOznGFHyqD+RNQTRSGaKIMoLqrfuxwB2z9fSpBbQ20DXJUsmx40wM/dwMj9ap6SJYp0ZwwjAMgyeeMgUO7BIv3OEQRKil/OMh564G0ZPfmpRDJBfLbxvmSGIk9wDjnn0AqJA8KtLIgkcmNdp4G8ndgVZjuH2XvmMFmd0i56ncctj2/wp6k9TMsgIYo7dUxNchRI2M4UnP5YH605me71Bp45FC+a/wC7PAKIpH+frSSXhk1m4vIlxt3qFx0AAAOPxqvDK8tpcSxOqpCPKBPHXG76njFO1ihLyErbWUSIW8pCxO3jc3PX0Gc/iKtySbob64PHmqAmW5Uk4GPyNRCUSQwKCXEgO9T15OT+gFJLDuEMEIOQgyAO4BJb6AE80XBE8JP+sKkW9pGmWY4GMdPryaz9rX17K87bASZWYqchQOFH0H61buHNwJII3xDJcDI7sMDAH060l3FI8rpBINkrsgPQqM//AFqL6B1LNi4MSNJEA7zD5R91EX5gG9enSrNlcQ3kj3cisx3+bICMKij7ob3OOlUdRuBaw+TbDaoLAHqWY/L/AFNMs5IvsssETMLR2Dy7gQBtHTPvQJhf20vm2q25b7VeLz6De3IH/AR1p409rCyyRhroGFAORsBwx46DgnJqolxcS3bXLjaUjQRkf8skzgY9zzVq4nmjiso7XDhLZ1AbuWPH4AU09RMreI9tzdzTBW2gpAh3ZwAcfiSc/lTrNJItLmvd7uZg0EI3bQmD0H4k/iKqRJmCZsKIrS3DOx7sc/zJFJJL9nsbRd7GG2TzR6M5GOn+8TVb7Ele5jjlxEq4hs4WZy565HPH5D8apROxmtYHQp8gkZjwFLHrj2xU1pcRzKYJz+7kl/etjBHzZz7DqafZxpPsjkR2neQSB/SNRwuDT2Q2EsTXFwjrKUghl3EOcMsYOVJX8M/Wq3lyRWscb7ishe7ZmJG5D90n6sOBV+CCa/1Gd42SOBInklkY8GMDAH481VDNNCJpATAhECBuuFAP8s/nQIggjcxzo/7pYwGlCr97j7pPZRTvtUMGmCNITFcOrtLKDyE7qPr0/GnSO76c7ttihGH8sN8zAHHzD0PpVW9+QTkp++mlESqOdyD0/StIu2g2h0xjgtIRJnzZU3YLZSEZByB3wP1qqGtpNTlmjkDWlvGrjco3OW4AUepqlqMt08zGPMl1KwjjXGcADsB2zxTo7MrLBDPn7RK22QjpCg5Yj3xnmiwzoLR9kMMDKqIq+bk9zjg/TJ4rSmlhi0snAlncBd2cc9W/L9c1z1tdCRprqV8xNJsjQjACjv8AXgCtUzIsEOIyZTG21jwATzk/QD9awluFizcxqtv5fmkSuRJIAcAf7P16Zq0imKKN52BaNVXyuiqW5AHtxk/Wsu2eVXkeRWVN+U3HJJ6/qetX7jzTqkFs5LSh90xRehbk/hilYZozqqRu0WfkjwXUkGR+pHsDwKz7e2uDqiyScyNlWKHqxAJX8BU1xcNIv7kBSGaV5M8IMYAHvii0tZmRzJJI2Mbiv8KkgnB9e1D1BIbMhUqYnUzP+8ZsEiIkk7R796nisU+3TREMnkDfvxuCnrj24yansk85rdociedmmw3O0A4DH8KLuWK3j81XEjPMRJnGNoxyB6npSiBH5ySwSXLRFY4iERSMBm68/XOce9Q2dq1t5PnI0txN91BwcZ4B9B1zU6xfvkidGfbOZnVeQDyQAfbufaliIv5ZnVioYb5MMcIgPIHvTAiiiaK9nmi+ZkDEDado4xgE9cE/kKs6ROYEnvAjmSO3QovpnJwBTp5JItKPyL5Qc4Zjzluw9sY/KoGMcMMSyOQzKsjqDgOoJwPx4qdgtcdHJtvIY0ZHkuIgJ2OcAE5K+/SrUT263G2d3SJ91w7xjbuTjauP7o4qjaxO1ym5iWkXCqB8qljgcewrQLWz6hfPdSFreGNULgA7znOAPTpSSu7CehRZ/tDSuNoJwc9OpyTn1AGKfq48y4jYjMzIkgZhg8cBcdcE8+9QoxeeS5KSZMhit41HUgZ59AOppLWJptSUzszux8wtn+Fen054osPzFtghke2k2gyj5pP7iDlsDuWP6VJa2q3VuZvux2qGXKjlmJO1fbApbZgs11bMI/NuT5YI6oc/Mc+gHFQafeYsr6wQhVml+Zuu1FGAfxOauKuJ+Q65eK3tJIGyPNk8tto5IHLGowvmSQfaBGxldZduMA9f0GBVbV2k82Z5J0Fvjyg+MHJIDHH5D8KZqOxDAtoZNkat+8c4wOAGPoOTxT5Rpl572OVJbkxyAhgsZxjcBxn2/wDr0jXEUwl8qNf3gSIE8jb90c+5JP4VBexjzraKNibbHfIJTPLY9M9PWnQQILy2iZseY3mkYxhVyQM/lStZj0LWpuhmeTczKriBMHhsDn8yKXTZbmO5e6KkybHjyRgL8uMflUN1m61CGO2fFvbqzuAoUbscdf8AZz9adJck6Q8xdlu7kgAnk/McAY9cd6dtdRJ3RZghk+xWfkBy87FyzDBbjkZ7j3ps0ctvo/mFkUz4C7vmyoY5x6dKuafd+QrJOysbO3aOMnnb3498AVFcxo9vJB994rbzA27jJHQfh/Op0DVjdOQrGskRUzfdUDuSMsSfzqpcRyS6UZWlUK0hAXGdzHJ49h0qQyNbyWsJUApCAxXszA/rWmsAlv8ATrbG2KBC7R45YgcdOOcULQdyjMBBJOI2GRCIA/XgAZ/rUOmBLiW0Xc4kHmS+4GOntUrrHK7ozb/MZUXA6EnLY/CqT2zWyTMVP7xG8o+gyeT7URaYDodQkns/KlOfLUhMcDAJOMe5x+VW7uWPEkU8hRMxrjHO7A4/maqaXFHDaruQbGYKxByeuefyPFL9o+1TwySJny98gVenP3c+vFPQLBNdvLdSXKr5mZ8QxZ4OB1x2HQfnSW8jNfiOY7vLlMsjH6Af1NU9Jika5JneTZF8pI+9yCelLbiUOjEbmkOzaw685/mRSegJGtFFGy3EkCg7YWY477n4A9OlZ9tbYMUayebHNK0Qwvbu3tzx+NW71nt7oWowgVUMijnoTx+fNFrMYtQjfGEVWygGcZycn07U+YLEUe+Kee4GAkSyd+F5x1/OrIhMEdmWkYSvbfO2OVGeT+NRrbo2mLGf+WjhAg6E8ls/ianumFxcR7CvASJlznjG4nNJu6F1M22OdWjEYAkDAjce7Hn8MCrQKP4jS2dw6wN5rlRweSelJp0CPL5448xt6segGef0FVlEtw893ASWuHaCMscM2cAEfhQtFcqxLcwvMyeQcm4bzsuduFyeP6/hUbhmsFtLdm3ytjcf4gW6gfQVKsS3OpyW0DqVyI4zjG0AEEZ+uafboN9zcsy+TED8xPPHAx+VUnbYm3crMy28YEjDkMxC9CQNq5P1yaSIBdOlLS7TcMdvODsTr+Z4qheHbaRBg28qWLZ4x/8AWqG5k3RW0ixSSearjgALGijaD+JNUo3ZLehZkhmewji+Ri6CeY5xnP3AaTUHaO/uJYyZLdI18vK7Q2wHBA9N38qddRvs+9ueVwpOQSdqj8ucY9qvaksCah5V4zssEMayOOM8ZK57ZJH4VS0EYcEBVoFkZcTKZWQHJXcDjj1wD1qWOSRLi3lK+WyLtC/xKNhxz9eantc7LhVAjYQnMwHzMT0UH0xTleC9GpXIcrGoCIjdcA7Rk9ujGhg3rqSWk0klrdIrJHE8cdsq5xvA5HH4Ek+9UxcFrGzsVRNi+bO2f4t+T/SnTJPHbuHAX5ftKjHGwKdo9s8cVDGwtbW6jbDyxsixuh9RtIz371KWo2ktirKISII0489g0wH3sLzSyXIluJR5QEjKYwFODGvpntVa8uXhYG3i2EqLeAkc4B+ZvrnipdO3STy2sYXKgCPKnlh1Jx6n+VaCuQWkRttRC2wRLopzI5wsMff6mmRwyN5s4yPtLeVACfnZAeW+hqydk6SxmQCMYErqODt/hXvyavWiZuY3RAJRHujU4G0Y6n0GKluxSKstmWuAkcakwnAA4UD0/qa0LVY55PMuAzzuQqAH5ATySfw7VNGRIggGJCzKJFHO5icn8P51cURfaSIuI4WwPl++3Qn8/wCVYtjIo2EUatEVkY/cVsHyxn0+gBq1Zxbf3q5lubgORzgjJ4LenGeKrrbiNXRSu8NtJPJHy/8A66uCcopkijC4G1VfuOBkkfWpuwsZTP5E7xq/mKN29gP7pzhf05rR1HUo44vs0OI3cruAXGAoyfrk4posYALd93/Hv5jM54LEkEAe+ari22Okt26zSSDzmCc7ctwh98irdrB1Lig28ZXyzGzKqMS2cDGSP/rVWUpON2zZET8m3kDsFpbwySPLFMf37ndsU/LvPXH4cVoWducFJPLeKLOwAfLu4C/qc1Nhi6aAkHlgEvNHtCoOeTk59gM1BZshjdISyrMxLJ3KA4ABrUgc2V/dyHIlt08qLYc5Yj+ZJ/Ks2eJ7aDAKnyVERMY6yHnGe4FO5O5G979su/IhjTyImdsv0B24/Qd/WnRW89wm+42o8kqKgbjICnHPt1psMQstPihifEs8Lea45wN3T/PrS3MpMbRR5LqhBYnqSOT+HQYouiloPglZpzfAE+WQqKF4wFIyf504wjar3G3dkTnavX/PApGjdLaHywfNnVRjrgNgD9AakuAwvYgG3RrgKRwrY4/I81IEkDSWEFuQxE7Qu4VjlUUnJGPXv9cUlrHHavcfu0mMESfe+4hxk5/E/nVeRke8D3JLQl+SeBtUdB7ZFXI4vPsrSBmTy5JDcTL2K8nn1Occe1CbBmDGZBHcyA8ovknju3qfXLGpbmY2MrxWqx/aoFWNGAypPdsd8DHWrCNGbC4mjkUgFZJB2UjLAD9Kz47l01JZLhSjCRZJj68bj+HStYi6iX0cbXYt41aTyvLdjKc853Et9T2pryvczSecTIJpF2ZGMIozk/iaVLxPsjvcRRxLPuuSzA5Zi2FXPoBTNPubZFa9vlMduyNIqIcs4zhVHp0qrMm5rQ7V8QNPFMPKgIUeZ8xO3r9ecmg27T3O+fKRwRDaBwHJbJ57/SsmfzIbSLc4NxdMdw7hTyce5zWjJqKpai7DJ9qkmMEUQ4EaDGDg+/61PLYZD+7uLq+kBJtUZ5nyeWXhVH6Vfs26+ZtcQfvHfdxvYcD8BWRcytHdzhVIjgiTzAO7Z7+vJzVu5jlSG3ijP7rO52Hy5OCcn16UctynoiR54zZyszfvHQ4bnO4v2/AVPp7eakwdyqOpyo67ic8fhWDYpI8MUcn7wSAShQfv5OB/Ot2LEVjfpEcyGUQowOcHABNQlZ6huVorsM9qz7jJJKzOQP4VG1a07C+WNri5kl2hsomegAGMVQtII2ubONm/dLDukJ6gAk8flT54E+wW9vzhy0rorA8NyAfT/wCtTdhDdLbfJBHJ8uxfP49Tn8uBVq6bzLcAEEsyRIVPGB8zfrxVvRhCNQE7rggmILnsq9f1rLtr1heKu1eZfLXI45OSfyFZorcmmU2ypbQspZc+air/ABYxyfq36VM9ujSbQB5YJVsHBIAAz9KZcsoubmQISkk+CQeMLgnH4kU6yy8r5H7x45JGXoAAeBmmIW0kEgM+0fPMzEKNo+VTxn8qoRyRwSxuclCN6MB94jnH51autttp8UAIZzbyPgH5VLcc1XuoEaaNHfEqxIq7eRjd3poEM1p/3qq0o+1yFPMIPUHJb+lW/Kj23silVIiSNQTn5z3P51nzwrLq8sihCiqRvbvtHP502KV5LSZjhHLCVm6AADIH4nFVoCWho6XPbRi43lBFbMzbsHLHGNx/I1Rl8yGzhZPkQhpAx/hDfL/U021jkg3xSkSlgHIHIJ2cD8zUF/5l3F+5KkNJsRR0AQf1OTTaW4X1NkXENvp0kCSeY/2dQAegJJ/pULtDHZW0hQj5ZJBzyrcY/piozCzGV2fBXZEABzwMnn9Kbrc3myWkUeBLHEvPpuP+FTYPIghudmqBIpCVijA653E8k/maS23S21woDFpZDEM/hk/kDTEijt3vpnyUgJ4HrgBfrzU4kNpcGBQShi3D1DFOv8600SEPghiu5VSLawWFo8EcAAc/jk1XuAtzaviMoZXWGPjACp3+hNWbe6t4IWit40WUW4QuOMM7c/pUFyFk+zm1YpBE/ko7Nku2CWJ/wpKVhNXKtptZERpVfZyhA+8x7/8Ajv4VYWSSSOe5nOAdzbGIO4ngcflUBYwXjXFuoyqELxkZxtBqF5t1ysDM0jKFMj44ODuIH0ApX6jY67RYLdoIiym2TfI45MjnoB7DimJBNYLYW/lo0sscbSIfmDHdkA/XJq4sEl0hncksYy8qnjnqB+QqGG4DX8lxIzgQqoiwcZwO3v6VXMTYsy3PmaZqZmXfJcSgM5OBGoPIA+mKzrm1aDTLaZh5YdmdFYjJX1x6UXkm2AxSNvl2ly2ON20Bfrya0DsuNcit3/494Y1V+M/Kg3N+GRQncLGRGEZjbWQ3EbUWXG7eQO3tV2GFvsLOzqs75h2oM7iOpz/WnwQxwgbyy3AQNkdD3JqwwUxeWjKg2F3l7BW6gfkaUpAlYotECIgI49u0gbemB1I/xqVbeWeZ2gZkd1Cu2Pur/d/GrlkQDJPMgDtFiKM8bR6n6jrTIgbW3K7yzM3RRzJxj8h61m3cont7WO1hLQyIrxqArY6uQQcH681UtIpbd55VUmBUz8xx5mOmPfPNXFgZ0iQlTnG1P7vcn681e1NViKW6bMeYGG45+UAf17UgRRsSzoUkXbK7mQuR0A5yR+Jrb0izt3uJmlRjaRx9QfnYHnoO+TWYspjWRY/4ziRjwwHUj69z9alN4YI5JEZC08TIgJyVBPXj2/KgGSyr80twFURvIUjPBCE8Hr1IqnHaS3dxsI8qOMoqkHouep9as+UrWsBkQhU3MIy33VHPX3JHNTrN5eDCgLvGdvYZYgAChsb2My+YXV4hKYt2x5bIMYwccenX9amutQay1dI4l3ra7TIgwQZMYUe+P51JqbGJ4gHVwSQpXoo4GAB79+9QRWZSS2UBQwLPMeucHP41XM7aCLVjEUaSa8lZYwHlkAP3/nwR/Sm3cZ2QtMkaqGEmN33d3HbuKfuU6ZHGzKWlYs6oPuoOf54qO6LXV5AdyqkLKW3HO89gfYdam4dSO+V0hKRokbKhZ2bqUHb8Tj61FpNs8mmXt5IFLRKULt/AMZP51A882+ZJFbzJsBkJ4J/+sP509I5t4EhURxyBmUnpxwnuAOSaqLsOxFE0jpbRPIy3H3yQuSuRtA+talrmCKYTBsl1+Y9AiA5AP1/WqFk7RSTXeW37SSDxjdwuPfPb3pdXBC2lvbyFikLCTII2AkDk+pNJagSzmO+IdT5e0BdjnoSQSPc4p2tme6+1CIuEVgsQz/GeCfwB6e9Oto5bO3gVwBczynaH6gDoT7d/pVdZSkVlBavvmMryu45BOSAfxPP4U46biY2+eCLQ00z5jcs5lLKOAnfPrwMVmoXmtJJZ932ZGwzY+8Ty2M/RV+gqW8dIjIbh95iiyEU4Yuemfw7e9T3e2z0iKxZT5l2UVi3RAvLf5961WoFLU7lJdOa2XcYwEXcfcenbArPWNREyEBIlYYY9lVc8flj8alu1MtsXVQqiNyRkjliACfwzVtUM98kcoLqhAIXphVBYfyFUFi3DbpcTW7NG6mCMOEAxl5Ov5AfrWffbPtknzgkyLGoB6bRuOfQZxV1ruWSeSdSpM7v8gHyqq8Akeg5rGbz9Ruy6srTNG83pnB/+tRJAkac8ywiWNjjzzErMF4PBZj+gonumkWGFpeUDyuzHIXjgf0qlqLeU1vguZ2VpWBHyrgbQB6jJqa/BCTfMGLl2Yj2XgfTmmMZpzmO9svJkbckSBs9V6nj1/wDr1uxXEdvaxTmIvCHkfg85OQAa51X+wXuYV3hNikjoDsJH+NaNyd0elxSAFiN7nP3gFzz+dZyjfUVxJjNLKMHa5xEvOBtA5+vWtmIB9QkBlVYhjaGHPGB+lY9szFIpIxiZI8nngFm4A96uo0lp5qO+blklLsOdrEjismhmrLcLaieWP5182Tblf9YcY/DqKzrWOaJQxUGWKYDDDoD3H61KZF8h0ucMFcliD344zUkhHmTopO7ZwR03bck59hSj5jK8HzQhmLCScnYiN90FsA/iat/ZCszoz5G4W2zvjHJz+tVrPMd1Yog+RNibh83QZ/rUtlKz7WbLuZZjn1PQY/Cm1d6BdrQq+IG+zaoYkPEcSr93jHOP51O1p5Vx5fzZkWNMn+EE9frxVOZHury7m3kiBkj4GdxHUGte9kkgn8wsFRZVTaf9lMn9TRbUL6Iyb4NJaajtDZjdlUDkbcYpioBNBDM29Zpscc4RV7/jT7iby7JlxueTyy2OODljn9KS9SM3OEZY3VlRD3Ixkn600Is290HuJ5VIWOEFsYABwQMVUSWNrKWYDYY1OSo4LtwKgRGhtwk77fPhwSBk8v8ApwDT9MuEFrc7FIQHzGyMggZ2j+VUlYTNDSlQ3eDJiOJQSf7zEYzVOGGO5uWKyqc7iGPICr0pkiiC1u43dQ7usS5zxkDkfmeaW2SK2geNVPlbyiOT25HH445oDqF80akWeW8yS5LNxgYAA/nU+pws9/IYOD5YVc8Y+UD+tUbcfatVSGRSBAu52Y8k8n/Cp4MXXnvEznYqEq33gDk8ewwKbWmoixIBZSrlRMVdfMxgjcASVB79uaiskhe7S3QqyITMy9fm4zn8zSRpHdS6fHJKy+YpkOPyx9Tiq4m8mylngGwy/ug46klu/wCFSlcbZJayLG6NdECMHeqqcmQgkgfnVed8XdwY1BaT5S3U8gH+uKuTPFAskRiImCCMMewPUDHeq1y5LyRrGsUvm7yw5LA4AUUbaDRo6Uiy2F3vJhwjuxHIJxgVlGIRWFtEW8uSUlhledvQfzrU1GS1jnuY42x5gWNCOAAeWyO5wKyrvZJIs7tz5TSKoHCqpAAH5VSJ6jdUwrlVbKGQIW68qoxUt1F9kS5dQRtiESYPOH7n3x/OqaTkTWuIgxLZJxlVYgDp696vx3yS3Fy0sO6F3LsSSM44FGwMRpFmWWYMJA7hGwOSAei+3+FSBfOlKIuyOIDzixwAB0UHvzUslq6bIoIPJEuMLnngZJ9s1E8TEvCBuRWbLL/ezwB7Z6mkMtTQh7MyRtK0s+V3cDkHPPtUZke2jt2lx9okyAXOWXoM4HYfrVmbcCsULkJDnzGDDBLdcVVhdnnmnMe94wpXjAHoPoBUATWPnOc24ZQFMQZfvNlucZ6Zx17CtKSMm5Vv3bC3UIiZ48w5z9QO9VbUCC1EhUk+YoUk8MeDjHrU9jGy+a+0GbCsW/55rnr9SeaGPYh8phJKrhmZ5CqsB1J6/oKhdEe6SMAAQjy8gfeLAlsfhWnkC4SS3IaU75AzemcA/oeKgt0WOBCvzyFpGPqD0z+dISHTyPcXMAX90kkSgA9I0z39emTUk6eV508YOExDCg6k46+3c1VgnklviA4MQILbAASg7ewqO2mlvFubhg6xoSw9Ac4z78DFDQ7DpIjGu99ypGcgg4LZ6f04p0N5IBiFwMQMAdo4U9se9T6ncjzoIZk+VAZXyvLEgheP1pFtZGQoUDf6OucdVAzjcexNFhXIGRo7ckDAkABVv4lA5x7VdkRrL7OpUTCECV0Y8GR+OSPQYNZ13P5kksssh+aEiM+g6flnNTMrW2nS+axMsoIck8biAAPyxQlcDKjYQyymSbLB8bh0Gckn68UxD8yx4Y4Vckn+J+/5Yq1AkMZkM3AjikdW243H7qnnv1qjcp9niJwTKHWLGf4scY+nWqSsO5rQmKKSCMMHcRmb5erdlz+p/Cs+O9huJSh3IJZ/MlLDAKIhxz9eaXzFitgkjfPsDlu4AO0fhyTWXGrCRvO+by4h93uMcAe5rSMbCWpfnvwkEO2VXEUG7k9yDgDvk5H4CpYmWC9hCkkMqEqBghVH3vzzWPHbKdPngCu92WQqwGQC3OPoB39qtWyObTULqe4Abb5akfwgcYHtzVWuBLBH9pjWeeRUdpizKT95cgj8gKm1C5M+pSzQPtWKMoO5YnqT79BWckv2eNd+1hHhQeynrn8qmgWExiKIGR5W8ySQn+LrjinZitcXVrtLeVoFUrueJGjA4AH9TjNU7+4kspoHDsBcFztY8KSAeT+FLrFytzq9pcRjYhni+THOMHH15p+ryRyQ2CTPhWkfB6j7vT8zVKPUL2dil9umjtLUNDMdylVdRnGeSSfxosJY7e/sLmVy8RO0qOC/ynjI9TioZbl1mgtZNrB0PGenv+YpP+Pe/wBKigZGZYzIT2BPFaNaDuWJrhfK1KaR8NHGqID2ySf8Pyq3dhDdWUMLnY0QJJOfvOO/4VUgm825uI2TCvccjHUKpOKZBdsizXAU5jMS/MvGQM8H15rN7CLl9I9+8kiYQCRyTjqoGAf50PK9zJ+6J3rCEByR0Xn69aht7hvsN05hX5ojGhVsE45JI+ppbCR/7Qjm8oAEvvPbaF/+tSSGn3NixIa5nyciNFRSB1YKP15zT7KIT6lI8E++NTu3Y2seeRj8KiS5+zaDFKhYSSz+YqY5ORgc/Srmlw5Nz5ETZ2KBx1yBznseayloNBb7ZYre2YedNNcF32dQoz/n8Ks6ltl1KdYZAkSkp1wCTx19eKu6dYRLeLyFKyFGA56IT1rKgtSshuGA2idcgc9VJHH51lca3NGJhaxWsvllflkfI9CMD+lR2pt7YlWeQ+UHf0wcDI/PNRXxlivFSSQCGIIDgZ/iB/pTbpklvpVZCWkYsP8AvoE/Tim1qSndXJtPhktlWRiB503mEHnGP/14qtfPNNHbdDvlkf3645rQtGKanuyj7onkPcA5yD+QqlaQvLcRs7/6i2Mg3Hnklv5U0gZloXuNVcIA5JSNF3cYzzn8jWkJFi1gPKiyGOd3X8tv49P0qosYsrhZWIUlUfeeTkqTWW8pW0nmuHKtGCODk9Dk4+rVVtbATq4eHzQ4eRsIqZ5HUCpplMAktIWBZ2VWOckqq5/nWbHMkNxIqJlINo3deqjv61LbTPEss9xGBM+XAHJTPHPpxV8nclM0NU+aOJIwzhiJsE4yeFA/PNJYuGs3jIzKHBx7ZbOKzrxpDqMNvNKQC+FXqcKM/hU9s0ltZy+aCUe1UouMnLse9HINmhosQAmurgNJ5tu8pXHCkP0/ICqek3KW9hqDs24yQKq8YyScY/AVc+0MmnyxryscEnzKMDGR1H1p1tbI2h3KSMrgSxhMDnJIDY/Kiwh0MqxyTyxqjQqhgTPOGx6+2aLyJPPntx89vAilGHBLHAI/nUE6Ilja4I2vLLLuGQRzjp+VXpY/3ccYA3meJVAPD9WP+NDVgHKFmuisSKqmUbEJ7qOeaqyXKBHupERpHkLKxzwFb/EVFbTMvlyMxBiEhQDjsTn86m1GOEaTptvvLMzozr/dU8n/AMeH60oq4yvaIi6nLNdlsorkBeVwo5z6ZojhVLPUUMJdVt9u8DlCTuqe5VobrUVgPyEtEBnOMkdT34purzxQWN7HGWDuEjdVGAQFGST2PH60CuN0dvLha4jikkcKViBX70nfGO/T8qalrF5oigNz55twzxyIAUbkkY/A9av2skV1pFrDb3kVo8Nt5ZikLDaxbhwR1znnvxVfWHJvb25hmZ/s8Edq0rcGV1XG7H4mqtpcnmbZYe7NojkZaQqxO7txyee9QRSRxhYIwoBYEnJ9OP581Znjj867JXDrE3yAcDI4NZ0sXl2yCKfdesQ0zfwRjHCj3/rWLRoTXsoMiWcYIIfLAdNwH+T+NXJlSGwtgjDfNgPu/U8e38qqRwotvl2ZSeryDk4/rz0rRmtg9q0pjyR8iZzyQO3pnNJAVLq7SSxj3hgI2ZwuPvYHzMakhulc27IsiRTIPMPtnd/KmOvm2cyknzDwPUj1+ntTkIWOcgPlWCKg7epNAyazYm3WHJjkuOcKBkDnk/h/OrFhI005wvllEwu3osYHUe59ap2boiSzBt3HlZIzyR/PJFWNOKi2MCuVUq26TqCQPur+RpkhLIkOiErGVZ1EeV+/Ifb0UCqyx+RpYmZnZTLhUHGcEjj3qVSpuxtVTFbEbYyQRt4DAn3qR33xRq6iPEjSNg5AJOFA9fWlzFFiFRJaeZdn9+1ztLdSBtwcH2qSSB5Dd20DfJJKkCuGOcA81nSsSlsZWk3LvURD24z7sSan1QNZR6ZBGdtwBl3fqT3J9+ae4vIS88mfUZbYlSpCwx+g2nn+tLNFHf3NtN5RW1QuQpzu3BCcn8qTyhMI4o0ZZGTuMNgk5x74zUN1PIxeDaAV3KD0yTgAfkam/QEQW0Ud01soLKrYDAnOApzzVGedZoYDht/nGbaeDuY8D8AP1qe/kgWBgmV2g25wPv8Azc4/Copn869REUBwzFwOqAkAflzVJahci1F96zMMjzwkAGOgzk/jVVJRI1wG2qss3koI+MEcZz6AVJezmTLEFY4csRt6yE8fpVJVkt7W8uXUCaNSdmf4m7j8xVpATWjx3NxNKiBUacKHDEdflH4YBP41Dqkkceny2yyI9q1wzgoDlk3YH5miW5FlGkMkcfkxAyk+rBccn0qrCPMt7OU/M7HzGyMgbecfTnNaWESQXSySpHs3GaQPI2clhkgLj2wKq2S3Ok6uSN+3fuIYZxn+lV70iHVr9EJxbiNlYe7Z/rW9f6PNeu13HdyJauoUg4Jz1wK1UboFKxT1glGtEt3HmLK75GOFUZ4/Ok8QqZL2zgQBSkDOAexJBrKWUzasPJZyiReRED3LHaSfyq9qbte3V9P5uXSNY8txjAzim1qJM3LOwjliLStHDJEzLvfBHOfx61zM8Mx165DjyjCyQbWHPygsf5VuFp5buRp4jtSLz1UDAY8KK52RmDrcSuZU+0MeSck7QB/WhivZmnp1xb3Fs6W+5nbcrMehLdCPQ4BqMBTYtHGrIbi9RRuOcIDjr+dS2zC2ktpFwFkzOE29gMDP51KbiF4YLeRFieKRmdx0IUbh/OokOw6ACWyuFA3tHkKuPvFnxx+VWjG62NsIlPmzQMZBtwFJJA+v3uaNCCSyeapIEcaDgY+bBbn86s2Kh20xZnxvjVmJ5wGcnj8hUXYuo27ES3VhakuWhlIlKjgAEAAGti1u4I7nUIoPO/ezpHGM9AHJwfyrORg935yIXkHmOuec4br+NWtCCS3M0rxgjzt23ODwT0qJO+hVy49xIbm6hIChGfAHYtgU2LEaB1x5IkfJzknaMgVn6c4knFxcK+yRmlwTjeqhjx+lSXXmwsqqpZRGJQvThhnn35rJxGmaF/DHGZI5X/e+Zu3Z6nZu59s1FmO51K2cOF83LMyj14A/SoWj81r9km3GEuoY9WYgCrWliK3nMkmBtCqBjOcEjH6U2uoeQtvaTRzalIo/dhBGue4XIOPxqCWZbaKRnX5Ps0kIAOSSuFB/pUk97Pa6NGkpx50QRSRneC+c/wA6h0lYZ720tmQ7PLkuJQze+fwHSqtfUW24zXLczzWeFfZLDGS2O+AM/maw9XRFtgI8mQt86noWMnA/IVtGaa8W0kRSyEJED2VlG4/pWPHGbqDT2yT510g68Md5PH4VcFdibsZMO+91G6RCVPnAOinAYc5/pWxrEUtpalnXZ5yEhSOQMYGf51N4S0+Vr/VpYQFMV4pLcZGQeOfpU3iu1cK818/2h1Yj96fmHOeo9M/hXRayI5vesYe1pb+0cuGLQMc55VgpBB9+KsWbZtVlkDEQW8ciqOhALEE/pWcpZJLO4BLTYkfaf4cKev5U17wqLiPe4eS0jRhjjcxGP0NQ4jbudDqFzC9oGiQhVs41YDuzOOv6062by7KPcrw78Oo7YX5uafqXkrazC3Zdkk8cWAO0aZ/nj8al1He7WCtKxmFuowFyMllG32qAvpYNQX57OKA4MMQLj/aLZP6VE10yfJEreZbCSV2x93Jwufz4rREm+91q+CZEJMPPQMQF6/XNU9TZrbVb0SwjbNN5eQeCsa7yPzI5osgTsF1D5WlJIGO1nc5YcsAAM/SqMswe4tliK43xopA6kEElvxNWJJGvI9PtS4QSKCQ5wFC/e/AkCqVv5hntk8s5DMMD++X7DvxUpDTNW3b7TK8L8M7szkDP8Rzn2AqK5gikhSY3GRPMx4H8Kr8oq4hVrXVrqKRV2HyEyOWV2PI/AVThKo0KC2W68u3REjk+6zuwz+lGiBs6PR/tQsdNnt5rZLfy8SQh0ViVPLknrxisDU7i4ku7t7wLNcLsw0bAodxwuccZANaH223js7p/7JsUeN/IVQrYJYcnr0wKyLu5UvGEhhto5tkpSAYBAGc8+9PRkwTu20aaqcy7/MjDH/V8bpJCQMH2pl3Ht2xMYxMHxkcKu3qPwz1pZJAksjkZkhPzYOd7ZzgVA91JbbppcJdTOdxUZ2D0x+NZJJs1NJjBK1nCcsFBcjHyg56/lUlpIZY0ed4hApO1ieAM5Offisya7SG4mELhgsaqHII2k8Eflmp4YzPaxxxwsVk5Zm/ug4wPr0qWugFe9vXvLv8AdKQqKPKZRzjOBwPz/Grc3zTTESZfZ8wj9QpyPrk84qjsMbsw2lYBtUDj5j/MYq9chvKjjjCCQbzgr2YjrigCsImECQgBMLJM5A5BC4U1Ze4eLTpmEXmSS7EiT1Kjkj0GM5NPtMQWhnjRT5wdHDDgD1HtgVDbNLO012UIaGIlSThgCMD8OaLgP0ogzRiZT5AiJUL6nJGPUDPFW7pI1vGRSCgbndzgKoLH8aTS4UjRZicxLyADztHU/h/WoJAXjnIXMhId8+h7e5P9KncZatog4S6uDKojiMkZcgEsT1qnex3Et1FKpGyfy8D0Utnb+Q5rQluAwlfejMu2BQ5++2MZx65P6U1pwNQKxx+aiMMM3AA27Dn8f1qkSRXlwsN7N5aurxkuj9NgPUH6np9awLqW4iBlJJO9mAY/MrsQOa3r+WWSd4kYNvmADkcttwAv580y5WGTW7WJUO57lnz0BIxgH6c0W1GnYyspa2Dm7VC7Fo0GM7TnqfqcfnULxNEku2Qtdska4BxmQsT+QAzWrdwxyNLbkLIbOXDY43Oz4GPYDis+6kIvrq4k2u8cixR7PukjggevBNaoSMu5WT7NDA8mWaUsOx4Gcn2JIp+p3rSXLQSK3lmcyhNuThQBj+XFOuv9QjxyFnjeO32nqSWzz+QqS8Esd/FNHGRNCjvx1OSOfzFaRiS5WObuo5IoJ1lz588nkgHsQec5q9pqfZ5YUl6RzeUQe2V5/lUuhwvdanoIDmSW4eS4csctuDHk07VoQl3PAZM3AvZSdrZ4AH/6hWqiPm6FWAW7XevNKBcSzKAvl/dKhD1z25H5VZuHlaxjsw4aW5dY5CDwCwyxB7EAVhm4ePVp2Rikk6l2yMAEpyP1q3ps0Q1y489iFghfYx6ebjPX3qmZsgjh8iSW+XDwG+S3hweGVBjj8TWgu2HwvqsynDO0imR+B/dAHvxWKszf2DbIjAFGFw2OuN/I9utbU8m+3hsDHmGbLAMMEYLN+PQUaXBt2HTX90dNso4mYvBYujYbBYBtw/mKyraVLq3MZjBUKfLdurMWALH8asyy2/l6s0chMEcD+SwXknC8H05rWg0hYLq1s4FRWNhbmZpONrF9345pWbHoitp1zs1ae1W3+WKPYsmfUA/nxVO/eWK1up2ACCWWIEDliSFp+nOU1gs8gCRyTK0h6KNwX/GopHkutMjjtgzRfbyEVh9/5ix/lUtXHzWNnTJI7e0vwhdQwPlnHUqAuB+Bp2mbgsb+YrtFZCVieT/FgD6VJoslvLo0E06gqr3IdScDkZGPfP8AKqunyFbHUItwDPZRIgzgY3E/rmosDepq23l2lmzMwfbbRxAjrlyGI/z61cVzb2UjJHGs04khUqMOpLDjnpjNQ2kcc+nXhbZlLhEYHnJwAAPyq3aqL28giUKAFknGOGyoU/zrJrUrRLUzbq58mO5s3+ZbNJRGD1DMwXGfpV3VZXnkdiphC2qApnJXKcfngVDqYhMFzM5zLJLuPHBXd0/Wnx4eyvVciUtDCwOerkjj8B/Kple9mC2uiS3jeLSLlZMjfcbenBGRuFIbmSCeFiqEiIIMDg/K2OP1q3BH5VteHOYMyRR553M3IP14FJdxJ/bU8cKqqxkbATj7sY4/MmqeqDqUb0udPS3cs7wo6oSegUc/hk1HaoluGeORzO1nJG7A9FGMAD86ntElm0/Up3VXmISMkHhS7gnH0HFQzSpZxSvASVMMrMM89U4/M0krIbaL6D7BJp9s6j93aSTsuMZbbjJ9q5jw4ZLa70MXKpJawB7qRf7pJKjP45Nb7yy3utiaSMgNiEAnoFTcxI+uBimWlssXg24dT+/nmt7ff6DPQfiTWsG0zKY2yvLaHUfFZtkmZTPGY3Uh1JKDjJxzz+tS6vp7LpgnCTxQyMQysFOQMfiPxrFGUlfT4FJe71EuSvUxoQB/LP4VvatbX1hBdieRpIh90PkfLjgmulNNGTTTOLvITPLcIoEhhtPm5ycu6qMe+DT/ALJjUbt4w0lnFqEUTHpxkADPr1qXSoVlu7+9iYi1SaG3Yt6AGQ/+ggVrRy7PhxYSPEyTXerpc8L8pBbA574A6Vm1cq9iEusl15GHyrMBtH8UkwUfoK2NQtil/PJDIDFDcwWbNnhjuYtj/vmsyWU2PiLU3AYWkerRgqwxuCKzBc/WpdRuZbK2MHlD7Sl7JIec7iUJAz3wWqGrFpk+lRStZFpQUheEXUu7Iz+8baT+dLfyPFeh5yFDJLJ1zhZGwAPqFqZpfKs72za5yrva2C5HJAZi2Pw/mKZrKGPXb4SJsaOaI7WXPlhI8hcfUgVDBO7GQaelxqVssnmBYomAZOqkZYnA69qp29qyOl2wUyNcOxSNiSq7flxnp2rStrm4i3yQxlZGjmTOMbTM6rk+2KqW6+UihDILiS5lV3PK7FUDOfxNJPQYJG1x9jtYdqx3RQnK9gSFOe2fmJqxYm3lhe4YrtsoBtHOS5yAf5Ukdyrz27naJHlijiZjgLHGpB4+rdahmaOGOMQruhmkLbuuIlO1Sw9ScGhq49iXU4ZBo6IkTTXElwdgVSzPhBgDHpmq11bDZaQ2sU6XKKYXWQjO7vxj/Irc1HUo4NDgiheZbuzga1YRxkhGZ8GTPQfL+NLdMkOp2V5Zb3igLwCafq5SMDcQe+T3osSpvqYvnMjJDCo81mVs5yAegHP4mpD5s0yTYAUyFVZn4JHy9fSqcySR2UgON4lAeQcnAXIX68VbjWWKOxb7yyJkIoyqkkbQfUk5NZGxJPColhgCgFXYsWOQWGcE+1aNuGtYYNvKl3kZD/FgZyT6e1UbhWazjDICm9i8nTLH+oFTPN5tlPcxNmHzBGAOWxjt9TzU7MCvao7X0exmaNAWlzx8rZPP6VLJcJO11LDlnkBwx5+XgbceppWtG+xRSsrKZHMXJ5JGCc9yOtLZeRDE0vlSFgxKcjBXHBx7tVC2LlraySPJFvBlAIKDoqhdxPt2FEspW0HlK3kzFVZyOTjkgf7I45pYFNqVllJffGdxzyduRg+xqCV22R7QQsCBQrdmbsf8+lSwuyzIHt7EO5+dmEZU8ZXr09M0tncqkFwWBILogXucHP8AM4qG9aQ3FjbwwqFMxkXc+QDgcnvjPaoJGaGC3KyKy+Y0ZwvLAZYt+uKEtBp3H2+1ZAWiLiKR3VRydzZ6Hvj1qRIgscUtw5YytgNnjg5OT+dQWs5TSY7tD+8kDJKGPTd90j8OKv2kMUkenKzFUSMyKh5LZYcfrRYEZsTH+1vPKFYxK0nl54Ve386k1R7ePVpJIBJiKBZQxGMOSD+GcVYBTzHLyKVSYqzdcKxJb27D8ao3aCW3muphKv2j51QtjBzj8tuAKpCvqVrG6uPIlXZgzOrNkZ3nlv0xUbTRSvbLEH/dYmmJ4LAZwfrk1f08ESZEIBUqNpbITI28fh/OoEgW81O0eT91uTYoBxnnC8fUVSBsy72JoYxJMWEouVY7SM55P51Pq0j6tfTR6dKsUyhFjMa56DPJ78kUlyu68drksC13JO20cbUXjj606xWDTZ7ad2OGshPOCMFZA+R+HIrWHUl9GZOj3Rsdd0y5ZI5Wii+zuhB5di2R7HjNWLBZtVl1OWNVEs/nbDxzzlgPf/CqgQzSyukRDw24kkBOCWyTn8mH61n6NO8NncHmRhBIiEHHzO2S31xwPrW0SGuqHfZJbmSC4CNvSKSWVsZJ3FVQY9zVjSbFBqVzDOoaK2SQykHoxXqff/CrHg+6Q6tPHIwaFofszL/cKBTn3Oagnmhsn8Srbxko6iRGI+owfwIqmSr3INIgibRLzzsBksRIpBwQSx49+1bEywyana3JlZVGneeV2ZO88MAOwG3vUel2f/IwR2ihFt9NhQKwyclcnGe/U1i3S3KX1w7M4EdvHEwXqAzYwfrmp6jerLNvE01hp1tCvN/I0ZyM5VnXOfXpXWJKjeJr6CE5ZbSKPcOSAgOTz3qfXDpyeKvDQsIVW3gjmYLnljwP51iLe+T4n124jzGptHBDc5G0/wD1qHoG6MjTojObC3iG77U0hfnqqMWwPqeavJDFZaH4bDFUR5pZJMH5g2Gy35YNVdIl/s+LQnRf30VlcSyOOSuSeT7dKZdSzQ6Vpr6jCM/YJZYVJI+XG1c++TnHvS6XKerKyTPFo6QhSY4oZ5wTxncQAT+daEEiTaolmP3e9bSNsdcAEnFOtLAPb3FvcyKsjacskaspOcyAnHp8ozzUNhE8GsySMp85biNxx0zGxVf5UpLqI0tMzLdXlvACYFlUu5P3mCMc/oK6LwjKE1TSTPGJBLbSckfNzz0/KuUj2pZ6ncvIww7sFj6BguCT781u6few2OoW86yFVtrWzVQ45+bhzUtdSviVivqTSXGlQwNiMjbI6Y+Y7kY5H6V0Oh2EJNmJpNreXOT8mTuUBQD9OTmueiUzs0Vw+x1iQI57LhuM+uK6bSLeV9QtEUtEVgmdmIyT94n8CKz3YpbaEN2ZbHw9aK21vMmjmy3qVIHH5VALAx65PCGUt5QJP+0Uyw59ADUGpo99Z2MQZ2lxDlQODjlf5VPql4I57g2ztMsgKtL1LP8AZ8t+pqZR6gmVdJmEsDxMpCSBJxGDncF659OlNulXMaIANsCsCRj7zR5FPureYTwtanE0qLbmP+6zp/8Arp2uMy3kSwjO6FDIce4wPbhRQkNu7GwTQprNqwPmRfapZyM/eDOFGPwFQamZbbQdIi3bTJciUEdfl3nkducVBdPmazkhiKRIu7A6bVUE89uWzVm7Qw3WmW0wDpGYpWRT3kbZjP0GatIlrUi8ExpD4u0dr5w8cFo0+092dzgfU10nxg8SWtzplzFbiNJAIokYDcxY7twJ7BQKwYFj/wCElvRKsaYS2trZmziMeYct74waW9+z3nxJj057SJ7e2V52jAwHkC4XPfqc4rojsYTV5c3YwvDEJHgrWYpIHz9oM7t08tFiBYn3JKr+NWb1ppfCvgrTv3ccd1dQ4K5AwAclvfJqxq+sSWPh/wAaWECRssjDfIvJIcjP4cD8qy5oJbweDbSSYEPatLGhPCYXqT7kUw3eo7XNUWeAW1mrSTXV7d3hXHYKUU+54NbjY1aTRZ40jjS305bmVWbG9twBcg9Twf51yEFlM1xq9wcGDToDbRsp4LlCW2+uMmrmirNdai1sm0M2mwW6FugDHJP1qX2KLtrdveSvIxcXH2+IhQOOFLY/MYrQkR21uaImRzLI8srk/eKlSc+wOfyrKtJ4YL1LpCrlp2lIX+HDhB7dic1LfTzm1keN2Ev2eZdxPUyuCxHr1ArFmiNWxuEvdImlndl+0XUSJsHKxLuZsfhUWmXEzTRSQYUpbTDLDO0M5OcdzhQKvWlqLWbTrSBUe2s7eVpJR0lbu3sBjb+dV44fOAtzvjuGgHmHGCS4yAPbAY1NrFJpjG0q4gtYxtja5Nq0pIOCoYDB/magvJgcytFujXbBCoHJUDGFHqW5zWprlwWtrqaCNIlk8i1iBPKJtyTn0qk2+KW1dixZAoVMDPIGD+OWNJuwJ33NnTrUtYJG13bHNtKs0bybV85SCWP94Z4z2xVfXr5ZJp7bzfMTyFiMkYBLSNjLD2JABPpzWpJaNCLCC1sILlDAWkmMQk25JYg474A+uaq6oqSW99ci0to/IRDujABEjAbov9rAxz2zT1ZldXMW2iZBCLjmM5kZenJwOT64q3MqLHbMMKrMduB3HA/n1piNLM8cJjCbEBckYOASfzNSXMjiKy8tGaRQgVgM8scZx71i2dBZnIjtooiASgJ2MflBJI/H6+9VbZCrpCcMkT5IXhcscbRTYD5d9EsiNJKV+ZWHA+bG4++ecVIyJZqZnBZo5WbZnLPgZz+f86UVcYjD7Sz3Kth97JCuOrEnHHbAFWdivBZZcb9vmkt1Y5HH4VXhVo7e3lknBkmm2RqT93CBhwPc1WvZhDJcWySBsA8g5J/iIHp71bVhbmgHlnMDuFJuCFIU9E3cAd6kicTTTxygRxyAykjnJBGP5VVMp8nzAyreSlAqgcKgXk/TnAqRli/tC3jt9xyqRvj+JjzgetJLqVbQjlkk+0Xt1P8AJOoykeOVOcDAHcf1pn2ZYb2NJX3JvWMlTnrz+velLyIsjSIRJJMWEmcn5QR+WQKsP8lvbSrBjcDKVUdQRgZJ98/lUyfYRX1G38iweGEOPLkQM23KyNn5Qvpxyas6KJoJWaQBzb2xWPPZgN2PyIp9uiJa+ZcoXYTpnfn5uCzY9KJmJsYSCCZpGdkxjBI6D1+UVW4mSxC0t76ztWiEkS7riTjkllyAfYHJqGS3uJTuZ+VSGIcjAZiCF9sA1DHdv5t1fPEyM0e2PcezcA/gOtSWb3MjlIA0iRzR3BO3gAY+Zj2FC3E9CrautvYQyS8SoJWkOcB/nPH4YrHsLnddNMIwWR0jiUZxkAng+vNa6wTX9ulnEqHzZWmlcckIrknjsCwApukQmwfRb9k6MjyDvvfJz+QrRAjFkd7KGcOu2cW7szHn5i5yf1xUevvELGznE20y2PkncfmIDKAT7Ve1qMTrfTMQVIMWMf8ALQyFsfiKrX0ol1FYpI/3Yt5IlZeQqKVz7EdTWkNyXe1yGO4gunvJbcq0AMccUeeWBOWGevY9aZpVopi1a8jliFnptujbGP3zuJwPwHUVP4csorOxtLu1Q3gj1ASMHHBhChDkfV6yrYGHQfEBdgqSQzqpHP3ZFAx6VpsJ6lDwsQdX0qXUGfbdgzv5YwcFzgfTgVZZY10y63K+b25ljR+QNvbPrggVPYRxJFaStHumt1YKx4ygjBA/PJ/GtLTYre/8R23h+5VEtnjEhnhfmM4DncOnIxyKpCbszV8P4TX9YaP54pIYOoyCNhHP5Guct7h7jQLh4/mN7dMrDqSv8P5AVMt7daffeILeFkENpClxvXGD8rCMD6l+lSeCNNmt1sdP8s/bJJLhXDHO1tg5x65Bp9SVpqV9VeeTXtOt1f57e0chkHqQMj86dqUn2q41cWyBBcvDZxZ6kZAJ/HBq94lQaZq0ElswSSKy2nyxnLFwB9M0uuWp0qx0+WWFgIXOyX+F2VMj65bdSe44vYzpLuJE1gRxLxpkih1GQuJdox6Co9dC3FtaIly0sIIjRGTZxtBZR64wKfb2btdW+nouWurK2jnI7F5C5qS187Vo7RXUG10+zuLn92ORksq5/ImkmHKXrZxc+K9RMBDxQWtrAqScdQMgiqVvcKdVu2QGQHUJHVvXYmB/I0zwa7R/21qG/LCHccqCAi8AnPbNT+G4Bb+A7fU58+fJqEkmNvJjMbLn6ZFN6oNmT6JALj4aX8zOsV092sKyAZJ3yD9OaTVrCKy1O+sEn3DyrZFmbgBt+CfpxWd4bhnvfCNvZwzMFkmti6jklmdyPp2qe+kGoz2xeX5tkcc2OzecQP6VD1Q+Zp6GpI7SxyzyuARJDahU45OB/LJronu1tfGU0LTDy4ImiJPQkQnIJ9M1y1zKVvLg5GIr1rk5O7IijGBn61f1YbLWQsFe5lit3Zx1zLuJH15BrN76Ar7ssysI9Kj+zSthYrQK47scjH1waktYivhJJmXa73TQox6knAIx/ujrVe4kEd1JbFEMGz7SpVs7BDEwHHueanspYL57WziDmIy+YpZsDiFRn6g5pNMpbC6heM0FjJbxtGUuXnZup3KCMflinxm3try0lmHmh5I2YKeSCrnB/MVUuYFnhvLi2YMjQeckecklpCgGe3v9asW91aLq0g81A0M7CNm+6SiKoAHc5zUK49Ohkams0cLQkhDDDJG6g8Asx4/ALUutS/a/EEM4k8qNJbW3GOMKseefzFVpbr7ZG5LHEk8zStx6MFA/HcaqTTPPbu7yfNuWVcAYOGC8n6CtFoTa52GiwQXdz4kdt8hinWC2iUZI2KDu+gJPHvUOmw2UHis6tPJ5jHRku3cvyH3nOfU8VyFrqs+m31xJDcNH513LG+w/wlaxtX1OSMajFuBM0MdqCD0DMCR+Vbx2MnDc0b6ee50bxNqMxRJdRWObYcbtrHKgfQAVauJoLW70D9+BPbabMZ9wwsalcqfx54rK8RtPdKyRSLEbxm+SMA4jjQD8M4FZEMlzrWqaoTuNqjoHb/YTtntnpVE2bZctriezttUUq3/HtJIYyf4nOPw4Arq/CNwbUX94UXZFZQJuJGdwjJ6+vNcAt/LcabqDIpJdQpJ55JP+NbWpSzWGl29rD9+5JlKHk7dgUfnUsoktJGh0UySxkiSOIsR1OXLYx9K3hF9paSF1w8sSKpAOQzODhR644/CseSXOkaJalV2yupkYcsSrcn8hgVKdWlIMlqGLmV3Ddxj5Vx+Jz+FYyNN0b1yZXXU0t3KLDAlq2eck8YH4tj8DUWi3F1B57QkS3lwWtgzfN5UartL5PQBQfzrKt7ow2mI22otxxk/fEa5/nk1as/NgsCGCJJPFsiDE5UFucj3J/Sl1BLQtWzXEskSuGCKCxB+6HboSfoKu2s5l11L243COJnuGBbG9UUBV/PtUUjQxRwEvm3towZOTmYs2PwyAcVFJOk0d1LJzNsCJEvKgu2SCe2OM/hUNFHT6C1j9iaeWGdXvLRpziZl+QElkAHcKAPxrK8QC2glsrezQwW88KzlWzljJ03Z6bQM++Ks3LW1itgk13diQIWj+zFRHGRwVGe/AzXO+Lbn7bqMWwyeY0EcYE2N+WHJOOOnftmqbM4x1udHBdFhJJJh2lVv3i/xsRgD2FNguIY7oISxAwUTHUgdQewB705NkUcUQjXz7ddzuw4DBjwPXjFUInaNrgyxASTLtCqM/KT29qwsdBpZRRJMS28lgWA+82f5dKZBH9quBbFtoC9x0PHU+pxinoSksjNJEoiQuoOTkgAA/XnGKroTAY2Em+RmLMC2d3OAOOnHNLVDJJlZraNYhiKV22AnkHHIXHfAAzVa5tYUt2hhzHvXEncqS2Bz16fzqSykzc24YkeQ7Fhjnf/TGBVqN4XjeR0G9juJUcLhiST9eKLiSsIbPNpcRyMGmXY3+0wUn8gBis+WaU3z43B0b93g4yysoXH61oRxG7tbkxbj5gKrzg+pOewx2pslmyTJEqK6o6qNx4LHLHn2xmtYyVh36EOry+TqNva26lpGjZiGGcbiMj25zVxnlvrR3iUi3hVUB6cA4yffmoL2FVZ7suvn3RaNSB0jUdQPTINWYnMdsySSbYZGRWCDOwZzn+VQ1qLoQ6nJI0ccpJJYMHUE5Xoo/Slu086xsp9rRrbLIrO3fA4A9+aWW2M0NxFETvM5hQjuM7ic/SlgWA29005DRpH5iKGyBIwCqMetJaCburlCEnUzAhZfs8aZKZwWVcE/mT+lbEUr2us6vAoAjdSpX+FkCg9fwrPWIRae11IiKUPlsqcg7uNvsPlqRla2trprnJklgKl85yd3b88VSYSK/h272PIAu55LcqFPfuT+pNWr6U3WjaaiKS0SJC4Axlt2FPHXgjmq+nZsXM0geOD7Hht5+ZSd2OnTPFWJ4/J06y8yNgJZY9hI4yrc/mO1V5EvRmPeyJCfJ3/MNRkuZFbkELgLn8ap6tZTQJNM4WOaS3ecKT1VgwIHp0rR8lJ4b8TR7WNqVBP8AE7PuY/gHH4Uy/doLedXdpWl057dUccgFsAfnz+NWroLlvRoA/g6O3sWMd2lgxky2AWJ3kY7ngVxNzDN/wj9y/SKe0adQOMgzDOfxrttJuI4NK1h5ynmG3CLv6jERDbff5a57TLWXV2soGKxiOGOErK2zcqHeQPUkkVtfQldSnbQOE1ZZGy1rGFUsOjNGMD65wK3TFbN4isItNZft8oNusucJ/qgjHHfByee4qg9vcrdaosalo5tQHJPXyY9xH0zitawWPT/EOjajIyOY7B72Uk9zwFH4VSZMveOWjhnbU9RWYfvn1CKFgnRwvzc+wVR+ddXoNqo8VQNLLJOjxyPCUHLygnIHrncay9JAmv31G4yLaHzbxkYffeV8Kp+qqoP1qwpmt9R0yJ5czQkTiOPOVLkgoPxwaBNdDM1+Vv8AhIL4OuHtri2SVZABtw5+Ueo45rq/iDNbXfg5oYfnkmuoEhbpsBbHP681y99MNS1vWJ5Bvmnurbdu4JKlmJ/ICrWsSMPEVnbSsPIGpQzqEHSPgjA74Jx9aXNuTytJeRc8Vy22mzeIIUyb5oLS3snVeUZU+ZgfUUuhaStp4T8Q3E0nlPb6f5i/7TMuCM/TH5movEVgyeKPEImLSSW9sEgUNnDykYJ99rUa45j0fUbVGbyrl47TaByRvUEN+OcVSdx9FYxLO2Fl4X1KHzgJ2sowxU5zvC/L+bD8RXQ+IbX7J4VltIIykMEttZxy5+8TIASR+J/OstbaK6vPsUTth75YWGeAocFB+QrX+IWpQ/8ACB6fcy8XUl3CzxDsI3yc/lTtpcJXvYm8PaZ9h1bXmYBY7SFDHGp5DAPgj6DNcWs6HT7CZY0y1ujnaehVjlj68mu+0u/VNL1y6ukZrq5jLjaOAohJP/oVcBpsMdhBp0lw4kt5LL5o1P3SSTj8TzU2CG5rafaQwWXiCWSTc1sscC7j8pd3II98jBH0rSuzcQ2FxI8ayRTahAiyE8kxqOAPSuegYz6EZJMCS71VWPXooAAx6YzXYWd5bXmh29o+4THUQ+9Vzt3Hn9MVjLRlK5larZSWl1YhZ/M82IOcZ58x/uH8B0rWtSdMtbSVQvmJDMSFPzKcqoz75NVbOR59V0/f+8RJDsb+6I14GPwJp1yXudUsrS2cpHdRRu0h44+8SfxXNK/UpaWRmSefYFYZWHngAv8AMRtYHcQfbpRFYiSO4YTIsVu6SmTd824pyB+OadeyrNcu5xJNcSGPGc4LKvP86IbNJJWWYcyzELg9SAcj+VZpl20MuzLG2tXZMKZucZ5/dt1+pNTfuxpkKxKPP+zoCCTwd+Wqd4/K0uJYW3t564zwc7Oaq2MkYv1jZ96KhXceAzbup9Bmr0EZN4UkiSUEmX7R5hwOxOMVRv7dLiZHdcO7IxAHcsTn8hWnCEe1ufnRgkqgOvRgp/8Ar1FLbymdppZBuW5XKnqBjAH9atSZLSY2cSS65hWwlrAykf7T/wD1qo6bcTWnh/UVjbJuJH57g9M1bVvsuo3vnEgzqsoz1CgHBxWTHKDoWFVAWG7cT94k1pFmdjRmtoNP05LccvKyK5LcMcjn/wCtVbULpptRgEUn7mxjZ8A5A5z1784FR6kqSyRQwt8inaWzkK5HOPUgfzqraIv2xoYSAjOEZmPVUGSfxNDYrG2JHjt3EuS0KrEnbL4LH9SKv2kY8uxhUKZmlwe2xV6k/jWJpySySWxlYshL3Uh/vc8A1qwXQhnvLzCukSMoUepOTz69KzauaJBKgk1JIoZAtoGfGByATgk/Xb+ta813Hdazc3EyHbEY0aJf4FwOfyz+dYcMqxmRLeVlkcKhcfwoBliPz61FG4RIo9pMkmZmw3JHRRRHzBnUy6siwWTOqo13dCcwlc7YB90Y78CqEl6RhhgTSXBlk2DuvIXPoCRxXPfaZLrVZLlmy4XyYIs/LHJ0GPQCtQyCI+ZJ5V5Ba7bfY2Qkrkgv05xz1705R0BbHamW9h0+2W21GwsmiTdNFOyhy+Tl2yDgtkfSsTUNRlj1k3N/NDeXEMXmb4iGTAHyjgAVmf8ACR27STAaBYtHLKIky7/vCDz36ACqWsXcd1dPKIo7dbiRQyQElcLy559azauTHR6o7+TzRFHIo8szEkI2Tkk5z+tU73askrLIcRRKFdj8wIOAMdM8/lU08kksVvPIzGPLrnHCADAAH0qK/iU2qwzIoUqGYBuchsnPucVg3qdI37QGnjjmjMpaRGOTgBVH3R2wSKsadHDJcbHlQB3YBSfuDsSR3GOKrXgE9xATEsTqCx2g5xwBkegGaZbiGF9gQBoyWLgdV/h+nXmhu4GhKrQXawyxETBVLgHPJbr/AN88/jVu6jVfOCSxvCsvlhVxznlfy9KrXaqZnjcncTt80tnccZJ/QcVNc4WbTECbYU/ezMgwTt+X/wBm70RVxMkt5ljmljVidsaFMDks/wAuR/npUsMS288kUjh389grB/vMV7+pGayWYvfTS23McZG3DYBUZx+tSSoU1GSFAuWlwZGHTn9Kb7DRZmULDszGxSTyUkJx8qjJP86dHK0h81IHZduxYyPvhyfm/lTpJYpdMeMIJDE8qiQ4wQxAU+/eh7d3WJbaYtG0XyuQQRgc8e3NC3E2C3D6dPc+eS+0FVUMMu5xn8OOtJpdtIL1YJB5bLIZCuzof4Rz9SfwqrCkkqBio8hZdkchGCzkfqAAavT+amnm7Uqs0bNcM5GW+XgZ+pNSxdCHb51i4UN804COD95TuHI/Wr2oxRz24VEXybSSOHA/iLNkn16DFVLGPDwf8tGVgdpHLqFzx+OeamtblprSJZRunmuZGJBHB6r+WeTVCIdRJbTbwfK/mzxxMBwVVTuBI+nFVvEF/JHZNsGQt0WQDkKFDY49yauXCy3EN9fscKZRGWQdz1zj6VDqdtma0X5BGwL57ZG0nPt2q4yC2pmLHIthpNjlWidHG8PgksmST+I/MU6WSXUpII4pQzyi1TdjlSSzHn2KipFsoY59Ilkcsj3EbFlyVG7Jb/8AVVNpJbW5H2QhRPfyxwiMfwA7Rj/vo1o/IGtdAghW9kiILJHK6IQ/GQxbd+BINatlbRWuoa5cToDbWpldUU8qSqkAe3QVkWr/AGmeSFHX7PbLuRT/ABlZCB+HLGrfnGe1v1D7BeXDeapU4Cr/AA7u+en4URkQ0TeEIAEvmuY3d7e2fh22/PIu52AHUnpk9qxbGV76G5kkjEkdvpyM7K2CFCn5Rnjqf0rZnnu5tPn1SadVjubbayoOWUKQM+hyAMDtWTpPkvaaq7REItgi7WXHPl5yD9a0jq0LubukyC70htCnsI4Umt1unu4ycgjAKsew4zj16VkC1eHXbcWjEziVEhAJcHBOWyfXHSksdYuorYwF0ltvJVVQ4yzMOG98dKbb667/AGeM7Ip1tZ5nnztAkYhSx9NqjH1NaLVE8ri2+4zZYzeNtR8uZvI+2wRsqjl1dCGIPbn+dN1qeOXxDrl7uz9lniii2dBHGybjWZpksUHieR7jcUlit7hZScFFBLb2+qj9anaORbQTFAWvYJ7okHllYhhms5aDSLUuWk1o+cUa6jin/eEkgvMMD67cHPpWr4x0ufTPDQMtyHd7uJh7kZIC/wCyOTnvkelUNd2yyeIWlRY5I7GFIkHQMoU0eI9XbW7bTLAO6xW0BupHHzEgAKqgeucmmgtqrGH9on0XxVe3Qf5rO4gugR1OcYx+dTfFdLn7bp1lLGqvdA3jwochfMcsB+Aqjq0n23V9RYsys8dsQDjLKMf4UeIdUfWPECX04K+RZnn+8cEL9OtW9EDWqZr+NdSVPD+ltbMu+4RHZkOMKVCsMe/r7VRnjjl1C9hgBYxOmMdFATJP061y98sxi0+HcGtxbgAdWJ3HA+lbc8slsPEZj+aW4iiVCDjBfFLm6jS5dybSrn7RZaPE4CqgLnJxk7WO4/oK6yydZYL1gDHGkETpkgMzgopx+tYMrRWjoscePLsVjBUZ3DBUn863LWSOazsLdEVwCLaUnqHLhuB68GsXqO5GsiQOrRB3jhUsfYlm3fpimaRdxvNdTXhZmS2SKP8A2WYYB/AGq5IeznVHJRd8p5x1k2r+gp1tAWuZPJYbGkjL5GQAOOfYcVF9SraEEsoMqb02us46cnhMfzqfe0GoFQzFrUSEBl5yQOP1pfJto7uCdWKyJcSMWwfmGdoIHsc1djzPeySbV8uWR0KgfNgbTnH1wKdtRGRcPKTBbykfuZycIPmLYAGT9BVaMMk0HlDeRuRgO3JIH6VakcG/nmi+XEgI7jdxn+dU0ugDNJk4ibAI7kkilfUopQq8ds7xxYXepI7kE5J/Sqss7ymAHKq907MoPQ461avd5lKE7SCkRIPUgAnFVYpI3khmZXA85t2B8xHJOPTNUnYhlPU3eSS+lmJZhHs3eue1MeN00qNxErK7KB7Y6D9KXUWkmlCMgUSgMQD6t0/LFLOrfZLTcz4IAAHQAdW/pV3FohsDJA8RdcyRZZyem9ucfyprQrFHK8XPlxFQcZ+ZjzTHCQ2U8pVnLO21M8/Un0qwrj+zthZQzOu75epzk/TFJ6CGWWIppDvQqE2hTz93H9atXRjEJtg3VRuwfvN/hk4qJEiZnchVjgQhF253n3/nTI2KW7u4BwynHTt0qeZjQs8L72COB5riIdj6tURlMlxcvEzBziOLHTA7/SrD/ugYhsZ0Qs7Z6s3+FU24vraNMBI03jHrVRYrGpa28VksBOWitx52W5Lnt9cnNJNqMMTW3n2qG2XAMSsV3jOSSeoPTn2qjf3PmRYzhVGQMYIOKo7n2mSRNzkYRDyB71pcL6HeaRYW2pW8F9beGH+zqWMRfUCikDjIB9T1NZ2r2ccWsyw3MIsYbeNFMSS+cQSMkZ7sf0o0+/hmtdMt5obsRvbSabKyR7lfPKsh7sCeVpmslLvUNttFcBoUjt3aZCjyyKMEkdqiZEW7nURXnmWxijEjSBnZtvpuyfb0FToNxmLkh8oSH5BHXJP04qj9rS3iEEuV3kop7IwJ7/qfepLd5CsaeYu+QPGzHsOME+n4VyyjY6zdmeL+1XmOIonDDAHIKrgADtnpUNrHHJZs0Cb53UlsEYHoPrn+dVJvMNyjsPMXc3fBJHAx6g5zmpNOmMN7bQRiPayAsWbGCGJH05pJEsjv5pY0tWC+rrt78YJJ9c1d8jzZpZZELW8QDlFJ5UDA57881Vt5PP1E20HlgRtIgZmyJc5OffsBVizlmYPFKF8sCOIbs4x6foaBojgQww4jjUHajt83J6/lzUkZfbP5zoJDwn0J5OPc4FSxx28c0xbMaRyqmQp+YHJ7+uelMdPJS6iAw6lJOeDs6/jyRzR1HcsmPEwsbcFnaQSyybeERBnr6D+VT21zHIixxTN5cLzMXIxwVwOPTnGazLWSWa5mnkCMQQGHVSBwBj2IzSESy3jpFIimZm8yRucALyuB3JPFVpYnqXVnzZiQ7nkRVCrwR8x+Yj04GPzq5K0seiFJwqLPsiwDnAz0P49qybUbdPEKPtMz4eMnkKqcYH16mrNzcSR2drdHypCJWcJ1wFTHI+tKyBlqP9zpsuFzczb4txPPTp7AAGltIRc3kaRxhRcjcrsMBT6j/vkCoyGcTGNkMhVEjUn5mlkAUn6Yp0F40ptLWEFmEJDkcmMKzZNCjpclvWxQuxNYaf8AZ2ON1w6uM4OE3YOPbNM1sBIbVVLyR+WbeDjbvLbfmPt6VDNLDqWtSySFv9eE246jGW6c8kAfnVnVABHYwyOHv43kOC3KKF+U+wGeB7U1EoTVnxbwYYy3ETMyg/dESx8Eds5rKsI3EGnyJ+7a3yd5Py75TkH8APzp2r+cdtqWWPEHlOByW3MASPc4zUxkeBN4QKgSGRWB34w3Q/z/ABrS3YLGVBDcW8pw5WKEStIqAc43AfrTxeNpvh/7Uu6WWSTiMHkqykHj1561ae5ZreOWaNZGZJWkVuhUvj+Zz+FVXtPKgit5QXVFWRHI6Yx1px0E0TaBeNqHw91GC/SQLH5jxMBj5wOgHbtWTd3b2IvImnl8mazQsVHDkLx/LFad6i2ul6vIiuqsiNEHfGAxA6dicHrWFqY3743DC4DNbvg5VVZlIx+BNbLuSt2ba6YdK8L2Op3CGO5aSMqGUEKAw4IP16Vl6iq6oL2XnzI4lhVCNu7JySP+BECt/wAdMt/o11ZQTO1nFEz7Qefl5yT2zjHHrXPw3LFbq4SJmt4JoYo3IwQRhzn605aCT5tWXfGcCx3OrshRZVs7ewZB1J2AtgeuBSy3Mk9tp0BljjIsni4TgJtXv69qqSk6n4iM8jnbcyPtOf4tmO/fiodPhlm1GzEgO1IyhTPXnGP0rOTGkacCtdafe3Lg7J4ncN6n5l4+mAKz5ENvLcKDua3sxBlSGBY+h/GrHmS/2ZciMMNlssGOwJc549zmpbi3jfS7oogEoukiwOuDj/8AX+NJT7BaxzxlxPqTMokl+zoikjGGyBx+dWWB+x3Ts+5riXyyqqNuxQAuD9Sa030pIjdQMQ0kkBcqOoJJ4qtIhGlWUigAeZHuOMbcMCcfkKrmvoO1ylploh1fRIZVZo2bc+Bzt61oz20AutWQMzp5yKNp52RqSDj67RVixjcXsG2MbmjdQemAXC1RszI2uTW9si77m4cFv4URRgnH4GnewnvqbEtmlxAyQwMW+wIB8w6n5jn9Kt6vZS2EdtaoMyxn7Q0qnI3lRgfhuPNNs3lkivZosSKMEZHAU4XIH0FW9WlFzdXU1rNkSyJEqAfcUJuJx+ArJyBasy9LEErXHmqUJdlAByWCc49gSRV63udthfSrAVjGUDY43F8/yxWfpUbXmpxlUKxMrq0hOBljnFJ5ki6S1ork7pXmZCfugcDj1qBtkVuWkmRcEAgyEjJG04z9OtSRXMltqWpCJmRS/wB7uFBFGn7Le3dlBWadIliZsg7c4JA+v8qqG5YSFX2723Fi3PG7n9Ka0EQ2kzKJsZIN0re468Y/Kq6OPsjSIvyhlfd/eORjj860Ve1dGyjRo9wrF1yTtxwPasiG5X7NOCRkrsCjoTn+fNGgXIp3Vrlpgw3gyyNhe+cY/KqsjtvhgkLtEZwW28b8LnFSvIWfyZR8wkdG9skY/Wqkjl2EKEtumZgcY7Y/pViE1aQz3UTxgQsqyfdPC+n5Uloz3M0SvIREy7QB6L6/WnrCqx3BKhljTYqbuee5qrPKbfTo0jXLs4xjntiquSStAUUD/WAp5nJ4I3Z/WiOOSScbSuYhuw33Qcc1BGxkumMpxEEXIXjgDpU9g7yRXM4BXeMR89ycUmIsC2EWmbfMWV5yCeCSmT1/Got7MsisBgOWGeoA/wDr08ybHdlbKKcADucYpDMDbrEPmZ3wePy/xqWNMiDhZWL7iWUjIOc8c1DayFjJMVUlkwo74H/16s3JGCqAAKNvJxj+9SGJRBHEDvkfGNvHApp2Aie3d0kkcARluwzuPpUsdssKOH5dV3FATuJPerL27zkLGuBHgluig/Wmwyy21zFLYMRcIMiQcnPY/hTTuJmsYbTUtI06F786fLZxbJI3idkI3E7kK/xHPPfjrU2sztd6jG0PmyxRW6w+dMpUylRguf8APNaVvfrpej6cbjXb+0aWLeIIoBIEXJ+bOenU0niKyeW0kuodWuNReNImzMm0mN/uuuDyPWh6kxtcteVE9qiyrhYt5ZuxJ9B3zTUHmRqiJIfLTbsJGCw5IPr0p0rwrM6sxZAuCykjAA+YgHp1FU2mmhUl2jlA3ny1b6YJ9B/hUtXOpal1tn2czqSXLAt8vK9xj8McVNJDCl27HfIx/eIrAZwc9f14qhYSma6LOAItoY4PXK9QPTirlnIXltl25Gwlm6MMDGP16eprOSsMjizaSxpIGku+u5v4QR2FbarFHcSmCVhcRHIJ4KKoHT8azGkle4BKqXLF5SMfPgkZPsBjirSyNFqdxbyIEnmij2MRksc8AehIqL6iLG+S81qFRIYIZtrynZ91VyBkduBz9arzzzS317J+7jhEP7sMTl+cD298U63trsW9wBcMWL+SqbsFjn5sn0qS+WCSxtoRl32szkcMeR8pPtincXUYMQaYrli0pmGF+8g5Gau/LbWU08g2KswJYYDy85yvsBUH2dyloLdGZJAUVN2do5/Ud6V3a4ia3kYFreImRXGfnLDIz9AKNUOxSjMcwmuERlWIomAeoZiTk9+DVuBGvtWTyz5sDOEXdwhGMcevI/SqrMY7GFjgI7YIj5wM8HPrSWLGFIfldIwgdWJ6Ec5P8vxos3qDL8ztFDHIVERwJODuJZM/MT2BJAxUUUc8V3FOFk/fyOiR527x1Ib0FRQ3CvoMU1yQsl1J8rAfdjGTkDsMmp5UaSASQThGeZgiEksgx82Ce5xQ7iRUszthu59rCctvBU4CtyR+nFWZrZLtrmS8fa32YOOwBx0yOvQD8a1rKISLFIyhRJL5QVwNpBXAbPrxWFrUsbzvFAS7pGsIMf8Ay1Ck849TTj5he7IJCzXLSnam54WeM87Vzjj24FUZLwtpwtolaaSWfaqg8rErcL+JJq5qFut1qpS2cyLGke9hgADrj6571Hott++tHz5hwXZUx8oDnv68itVoiiBnD3r2zhsshj453jOQMe3FavlS3w07fHGMyQwhUGFbgg5P1FUTa3Euu+errBI9zFFu3cqdo5z2GKuahHLYKLXzF8yxuZGHzckDnGP+BUIzbKrIkutXVncvvhedAzAcLtBb8RXM6hulu5miTbHMqlCR23cfTpWrfiePShfOSt5NKzttxgL0H9R9DTbS0M9pcu4dUhMYbaM7Tt/+vWmrBPqR391nTpoIiAZ1VJMc7QG5AHrk/pVhLLfpupxWpJhEyGJZBhmOBioWnW9bTfKtViHmEEAfeVWLfN71d05JoJoGlw0T3WxSejFR0/lVbhtsY1pEftUdu6MWiuydoPBGMmrNjJ9mubaYr5hEMjOcjBYscHHtmm3U0h1e4mkCgbmkJB/2anm8tba2IiCo4aIk9ZCMEY/lWTvsOy3FtormzggeVj++ugAR1cKc/wD16v6zbrbfamglEii8T5l4BHBpJpFLyCWYm5tYm3DaAu7GBj1PB/KqkF21xEYpcBGkaaQqfSMYH19qWvUkclxJbF77yGbBEJl7ZOeD6mqzzoPDltE6NlSp3BeGbdnFaskKw/Z4zGwXaHKOepYHDEfSq2iWqXVj/ehtB586k5MhzhQAe/FNStsBN4eszfanNLcyG3jiSWTzAeuOQtZdpb7ZZZkkRvLAjQ55y+SSamZkiupY5JmBkG9wGxiPBODj1O0YqXQ4oZIV2lVdplyzcDhOcVLY3uSx3D2mkyXMLqJl8pBGO7Yzx/OooLhzq7yTRksJAhSM43MUHPtxSBInk3xrLHbSzMFUjcwx93p3OKYiiLWWI3DyyS5Y5LHAU/rmlcY7RtSFtp13hxjz0CKfrz+OKiaaKO7mltnd1jjYyZABDHsT6VStYmimMMieaGfOM7Vzn1pm0yNdqZM3VzOItsfCsoHTP4U0uomXbRcX8TxLvlDFV/2cAY4/Oqlpb+Y4YumVEke7BILZJ5ptpceXJO3By+IwOn3sYqW82ie4QOUMKbuDgAYx+dDEQJ5ke2ORtrKQ64bgkLWbFm6mVJGjG58k/U5/pVyV4fszHy2BE20uMk7cc4qtLsjSSTbsBmDHJzgdqFtYDPZwpuAwAk3M5y3YN0+uaQCSGULKgBKhwB3XBovofLjdC5Duqnj35qN9scjO7O5ZAQMe+Bn+dUSx4ULbXHOTJtAC8AccmpiIXhjViEVhlWPOAoz+Rpl3D/pNyuVSNIgoU8EtjkisxRultoXYEKoznp6n8qESy9bNEbd2IZmOEUDHDYovAqtHGo27U3FB0z2B9+9VlKRxR8ufvNn0GcVGX2vvRgQQw3dSfSnYm5Mm4PCituEYLM3vTopl8tvMDqgyRg85NVy7q8bk8EHgdyO351YZ0b5n27zj5B/EfXHpRYYo2EBgxYud0gHJHt+NWrF3AlYgMw4DN/AvfFQXEkYdUBYq2WZh60+SSTAPluIgvAzycHikNMsSXBSMxqrMDyBnoP8AE1AHkQjaxSV/lU9No/pTpsKcghsLkk8/N1pfLuZn2wx/OVB2soOR3NCQzqNNlh/suybW30trfafsn2uJ3k2Z5+4eEznGabrt9fxvcW129qxnMbl7YYEkYHyKnomO1UU1Gwawht9V0+4lktV8tZbeYIWTOQrAg9CTyKn1qWWfUYRcRwWubeNoIomztj2/KM/Tr702RFa6l7VJ4SjRJI5zzvxjdjjj296oODPe4EjB8k5Izhehz9KuTND8oDDySjb3POW/u1VKqqCFk/iy0pHzbe39Ka2OtWLNgyiR47VSHJMbZPBUDnHtmt2ONcGRfMURsrkr3zjOfxzWNYhXtZH8sxYXywGH3iTnj09foK14vMEWyEszM8YDZG0AAnI9KynZivcroGaKXzVIQEldpwAoboPzq48qJepcI3mSrOSjMM5TGAcelZskl7P5MUCIo+d3J6k85J+lFoY47xFu55SI0HmbB0ABwR+NZNdgeptWkiw3TM8hdEmdvLB4PGQT65PNCypI9wFaQtjIJGAcctj15PApl5CYpj8iRK8StsHJ5wOvrioY5AtpaqIiuZshw+dxI/SgC/byIrhmLpLtGxGU5ZicDHoAOabDD5lzODwwkbLSdM98n6U2aaGG8gkR98SkIMDJDdWz+NNuwvm+dOTIJSX2o2NuWx/KkwC7iFwlvCDtVWkbBB7dOaikiiitYhH5L3TjcWJyFBGNp9en51bluPs5imKEMsi/KD25yB602OBEiQykFXDlo0xlCQdoz+Rpq6Bq5SaVn02CDBaKBC5HcliBg1q6paRRSxQWokNzJIGiXIbnbjt9azbqUIbgJj96FjZQONiqCT9c1uSXSwXVtLeAiOEMoZGHDbQ2cjqO1MViDVXuYNGit4QVNrLvY9OhwP5kVk6apbVHM0Mck8rkEMdoxtxkemPXtWtdpueGKScqbpgQ+c8khsH2561nvGGW+CnzHI+zooACiPAyc9TnBGKLtD6D45IFi1CaOMqq4C7m4Y7cDt/niq+mRCzs7AnrI+8RgckdP/r1aSU+ezodkIwwjxuGQoCj9aqT7EniKSNJGjJlm4ALDGPwqua4uWwiHM080kRANwwd+vJ+UfkapatP5rSSMfMm+yu8rkY+YsAR79OtKjSDSDHGS0lx5jhcZLYJOax7mVbiWZJdyJIuPzG5j/KtYMEi9cxKPDkxmzHIDthT/npHu6j6c1Z054U+3RQzKtvJtl8kPyeg2n16Vlag813DbeZtVZcCMZySidyO3OaktFZI7eeID95ujBGeNxyuP1qmyWrmtqkkVhPBDBA0brNuOeeCDwB7frWdCNt4ba4kLRS3QmYKfkVSuCT6HtVjVLK4hlicb44sSr++OSXA5/n+tVrG5W5igM7hImkjiwOTwPvfTPFFxWEv44JNWnit2aZpmSMBR0XgnGfYUk7eZ9llZGVIXeNFc/Uj+VSRqYdTa6fbmKYoQo9Fyp/SmOBJhHQtIZGlYKe7LnP0qG9Rpl8QxK9680QfMRYDHPI6g1V0mNllPlyARrbu4fZnYcAcH1NaLIC8kXmtJHLAMqgwMjj8cZqjpQWIbJQZFdAquCRgY5/Pik5dBlmxyYbi7Y/vbdI9hduc44qPTSYJN0JbyJoysnmdGIOSTj3NV9OumJjU4CrkfMA27CkA05WVbWz253tu3c8BT2/HFStGOwlta202oROzlmkUCV9oAB5OMdT2/OnXVp5enWMVvKCwWQkgYIc5wKs2KCC9tXOFTyy/97JJyOPyFICrWUwYlDCZJN45y2cKv86HdsGrCW8ZthJhsRxOjc9j0NZ1rumlut24K8gTI5wdxbGPwFXJLh54ofLVlMs/zA/xEHiq85khuxIiNGJJmKhe2CRikhDblTbTzm7kkfbCpQpxknGAf5VSl8sIyqATGFkOO/ck1av7eVbiFsFftEfPzfMvPHHuaoqZZzdgjDMrFyB05H/6qvlQrjOBewPApDFA7bjkbsngVVuopMysWYtJIPunjA6VOCxZUKPE8MZXbn+LrmpZZI33DcAFiKDA4BHP86BDPsUvlCSQhcSsMDucVSvklVbgLGZFYja2Pu8jkVPHM6m3hUku0rOSQT+gqtaTzTai6EFQrEEHsO4Pagm5Ag2b5JwHwWyBweSAM02eeJ9RcGHEbneVByF44/CnSTxTKQq48s8tnhxmoJAu6ZoEHlhgA/t3NUIYZztc+WC5QL857nqRVWWRRbqoJwHJUgfMOPWrd1EI4JJPlkjVmVHHRj6j6VSS48po9gjaSQ7RuGcAjAI/WqRm2RxXp+zsQqGRvkUFc4HTmmoFjgjTGZPMw/HG0f1qZY4YgJCAiksyHrnHHb3ohRtiuhUSMTkY5x1JNXexK1FaSOVjiL5cbeOCufSpIIQzNJErFUARSD0z15pFtR5D5faxfkfzNPVWjuooVLbSodsHAz24qG7l2LAtWEEMrZLSHC7cDAHXj1pLhTh3EZaXP3F42+5q1ZpJDM4wrMx+9xwuMkfWm2pE8wUkJvBYN3x/+qpaKRUfLWquu4jIBwOorRsUhkuIri6F19n+43k4DKPx71Yks1htEjWN5Hdw+CeNg7kdqgsUme/UWohXzm2pvfYhboOTxigdjUsP7AuG8qJdalVWJC7YieKfrl3YXt+biEuqwwR26xyLhsKOpxx+VKnh7U7Xfl7GG6R8sRexqVb354rNurW4tZViuzAXA80tHKJN569Rx+FAK3c6J1t1tI5PIXLHHLbhu9SB0pARcSTtNdKhxuVAmR8v8IH41Ru2FvJI0kokXzN5J7Nx6dRTYTIrSrdOoMn3ePuY9x35pO5qbccsgshOiBQSUMrDJGT82Kgt7mOeW5ghyZMjAX7qAdamsjG32UCJ5FQbB5vKs3dvoKk0uBWmnBt1kfO59x2qADj/ACKxfmC0Ft2S4lWLYTvIGR0xjJz+NLu330myNsSbUZFXcRgdAffFVh5MMR8yUDlmLY5BPRce2Kvhib1ntgzB9u0kdQDgkUkWJGVvikKBUdGy+44wp469OuTTLq3SG9ggWXcQ4bb95SeeauadEPNuo1jILPlmfkbeoH5mobvA1FhBKHlh43YBDEc4GOvWhiT1sSX9q1vaW4DjLq8pXOApJ4xUyiO6aJbgtEgg27Qudzk8D6GoZbmWaZd7sckb5CMAcfdx60ljMUbbtCxyN5ZbGdvfAFAbis5l+zRgmJguxwue5wSKWQCK5SKQMGkk2sSemB6+hFRWrRXMMxQsjI23eucoSTzn8BTNRgmgj02IymScncysMgnGM57VWgkTTiOKWcRyCSNm2hlGOeMDPpwfyqHzJ5I54dqtGFDcckcc4qxK0S3IjkDosrKu8DgsPvH+lOlgginvsqqzEDysk9MdsdDS2LF1NpLaTT/KZSwXDHIBjzjHTv60tuoSW4RnUtHJ8rg8AA9B65/pUF9aec6IpeQkrgdC7Dr+NTbEm0xriQrFK7Ale2cnjjvxRe5PQqwOV1BiiLiMhVUtgEZOefyqqbzzElIRSjXWdq89DjOKmeBpUkncnyMFQFPIz0wPSs+BB9lhSHdIJQ/A65BBP4mrS0G0aLoHYFxiWSE+WvdQTtUD0yP0rMtLY5WBNu6OPBLDcxOPmxVhZXtriFLiM5Fxluctnb8v5elV49QaK5Ajfb5cjBl2jDHHHHfrQhEdqkUtwHcNIR5aJx0yOen1FaTK8FnCYmkdI5CqO3Cg4POPpnk1mW3mnSZykjKjclBkfMSCfwrRvppE0ryZZAkLbUOeoGe9axVyWyGwlhDF7nYzrDmMMSxJJGAPc8VHbRxJZIrllkWQMSoyQegXHQc0yMCfVLeaLECOiyEdQdp4C/iatQyqsVxEw2JMGUZ69zn68VPKG424jSKySeYBmmlMjIpI5A4Gfbj61HPDHBDPIolEpKNHx1yec0kt5FPBbROihV3tkZLZ29Se4qOV4n05d8jyTl45AM42jOAKloLEt/fXVtZwyIQUkikhyOxOASPcU+HbDBbyQ4HlboeeeOuSPeqskDlEd95A8wLkg5br07VK5zotxK0QyJFUKT8xwcfzNOyEi7o9jbmNHE5F38pjUD5dpXuce/SmGEDTIhbxbQr+Uzlur89B268U2xjaO+RcDcikHJ9uTmnaZPJeaeloEGA+UKjB3A5znvSbDqXZYiXsGDFWVWAPAAZfX8Aarxogtp7lkWTbLvUOPlJyOcVFb3n2q3hSMZX5w575OelOBaLRZzOREjTqrAHnAPOB+FTfUbehKztBb2sskK/uJWIUn+NgTj8OKozTzXc+nxSEbBIQobjHqR6c0yW6aWRGYswZ8oM8kkcDH41TvJ3cZt1DOkzdM4U9CPwNHKxXJbpCs08y7mRH8nf6ZycfrVVvKkkRpHbZJNjKjOBjOB+IqRZplhuQY1JErOz9MfTtTAkcKRxlt5jfJMfpjse+elVsIgnuml1tCgOxwAUzk45zn9KpxzboLlk2+XEhUgepPepLhXXUVkLMjOoZRgdDxyfWmGPYtzbw7kDnOQf4fT86rcluxXUqsdvLK5R2UsQoJJOaRhFaRTmUtjeAyjrg8/nVWTfLBGUBC7gpOPuDPUntS3sjTKxQ/uS5+ZhjoOMfzpokftH2iGCOMBnyuSemec+1QZleMW1u5NzMdnljuM9c/hULMoeOSNicD95n0PXHrSyTqJWeFfKQMETn5gPrTsJsivZl+xJDtMciZYuz/KOaozsrRCReCicADHPr+tWp4Y/KcspkYrkE8Ac9cVFsfzlRZlZ2ALjGMccZ+laJGbZHaqBtMaFyVwN3HOcmtGG3eWZkkVt+0thec57VTKeVOywHdkhOB1PrWmRMXRWLqmMtJwCefmx/KlIqJPZqy2q+egMkq7Y1A7d3PvT4xILsTXSF3yBlTtK4GAf/AK1IWSa8iA+SMKVUBs7BUUkuY2iWT90jH58feJqGXYDeNJC6LDndk7z1wT/Ord5M0loFWOPeOMqMNjHSm2Tq/lyja4iGFjbgA+/rUE6vEksshbAfbhcck/0pasNi5YyyQb5pMgyxlSSfu5GKjS3nubSBY4jc+Y4jjjAzu9sClNxbm2kKtuYnbyOuB0qxpDQu9m0Szo6v8iKe/t3zmiwFi60TWNR1ATXGlXIcRqjP5ZGQo47c8dzzVDUImsrx4Z4DBMFB2lSp+boSPpXTaxZeINRLzyKsVw+PMgS6COSO5Xdwx9K5UveRXLC/SaG5UkP5qlnJ989sUNWCDujXedZtPMqhS+4yEEcbs9P/AK1QzvcS32ZArptJ2j5dxPBNT2+In8uGEOnIbnGAD1pVsxNNKGkefYwIwcdeTg004nSmXlvQWhjkkMoZlAIOB0PAHYegrWjJ+0qrOkYMYDseoA46etc/Bp7C42MFDO25VLY2jtWjIbYNE4YiR42DHqA2fSsZpXJHTCMBolVmLyNscn7o55qSO1fzUijYsFjUZdtnPU1XuV+0TiOBRtjToWxuOeuPf0rRgO6FJfs5jd3IEhbAC4449sVIJi2kwM+8ylQg/hXAzjkAHtThNH5FvtTYWc72XlsE+nbnFMtQ/kynzCm5CMMMl+f4ffFRwT7IpJ/l+d+vBcAHA/CkHUvIHmtGAYqfvfPyT1/w61Vug5S3n2iNpBuYkHCnp1ojmmaOZjsCrEQCOAOcfnTdPhJ3b5MoAQEwW7cY9OaCieNZbe3ASNSC28uoIGSfl59OKt6lDHILlkkMiqFBkxjLZyRVNJXO2UnHlyBSMY+6MdOnvU9xcXLwMZokXzfuDgF+clj/AI0LQQl9cg2kEb/K6khsn0HHFI+PtMrtINhjDSEHqzdPy4rOupklSWeGKRslcGQ5YgfT15qzvVbhHwrwSICE6AkdGpjL9rPG0cAlZ91uG3ED7pPQVKLixjt2jjO10Ytl1BLcdvSsi2uN0F0zS7RJ+82hAcN/SmtLFOZ33FAAB93qTx/OlsJq5G7yCznEPzeW64PGeefyx/KmWn7uYOuGEaAIcYAJBGT681Lq5jkWJI1CgbSxzgkg4AqteSOZ08sHYSkcgB54GcfhkVpzK2g23Ynkt8XEKQ7jH5i72C89D0P0qrchYkllVYxLOXjiJGSqd/ox4quNRubcJF5pJ38kHjAyMUsDGRreKeRhiZzgjkHGefWhaEFyARIl1DIGjVlGwO2ccVWURyxWbXMxkhDMBHjGQo6+h5pl4y3F2JAV3yrny1B4GcDNQhHM0zvLGgGQozjH4fhitUFkXJWZ7smRwXWNUCjoCDng/lVKa4d5WhkkJky+DxgZ6EVX84vOQwcF8E4Hf2phjMl6sjhQGQny15YY9aY07FuICMRI1xEd8HzMOdpHb8f6U293eQgBCnOGKjpnnk1nSM0GmhihbcACw6g57fhVu3uoAYA8jHexMit0GDyfyqJE3uWZ53+wp8h8pdsj46l//wBRqwLrESMpaPLqcKORg81XaQNCq/P5MeQ6sORluv8AKnxwmaGNQUO1h8h4Jzz19Kl7jLkN4XvLl8sw8vcVByD8vPJ+tGmg21plVlMI5B6nBHA4plsDGkKBTITE+91HHPb9KhWYrp2PNKblHXsRyMUgL1paPbTpbiEIUG4yHt6VDqiAl4D92U+flk5OM55qO/mJmWTc7DylJJOSc1Bq93DHLGEkcEwlOmdpPXHv2pW1uFxsULB7aR0KqV+WRmxtK9eB19KSZwJpUUEhHLbOgx36e9OjEkywsxKpIu9evzdAf5VWEkhv7shSr42gYxz3zTvckkvUk2tM7l1kVSFXO3n/AOsKW5SNrVGRjxEAUXnnrz+FVppjHdKS4KiE7jycDPb+VQSNttiyv8zybQM9OOlACXsizQzMNxbAA2+oGazxOGtvMDNGV2o3HXPPX2qwSwPkW8QUSS4dn6kYHA9BVeWNYIWjjO8GfI9wP6VrcgljuBbL5T24EDLsKliN5PRm/oKpXc0xt4cFFCI2FA9T2qadPtLs88+0g7VUHqcZ/Sn2tuZLV5Ui3ZZYxuPfOePemSU4zERCQmSw2uT2x6VFKVZAsZKqzBxuOQT6fWp7uBQI5Q5EsTMJEHRhnoKqwModZIFAcNuO7kD8KBDpYZpbeHc5YvucRqcbO2TUFvmOfe+GMgMe49PSrSISNyNuCthmHGQTUklujTrGrkqihgAOmTTuKxPDFBJMyRSOqMokDbcYbpg1JJdNLbLE4yw+TcR0A6H8TU00WJLdcBYUAyw75NRxNH5q7d0hyQeMAHPFTIpCpCITt8wCRhkfLwB6UsxjhDW7JtRX4wOxHWp7qZkkjDgPEyruKjBBJ7VHtRtRZJc7ZNo+c9BUlIbBH5Q2JgyStwM84A6mqhhkRVmuH+VmywB5IzV5o4AXaGRpLxpTsJ6BBUMl8IrdzFBGyMuxpHGSv0H9aaAjhg2xItoxHzk7m44rT0a8TSdUtbi5jdxFJuCZ2np69jWTFPL5cKFD5MJyOcbjWvo93ANU065vseXFMDKCu7aOxA744P4UXE9iZNL0e0mnlfUb0b13BZ7ImQZ54OcMfem6zqdtc38TTW80VtBAkUaSn95IAuAzH3rSn1JTNLp/iG8F9bO5YXSv5jQsRw6H09VrM8Zx79Tg+yzwTr9lgjLxncDtX+H/AAqtyVe+pptLG13E6oUtpgSh3hi2O9Odf9EVrchNnOS33/XiqsES7QGXG8KV3HG0VZaUNLGsSxo6nOw8qox2H9awZsMm+eRDACVX5vNbqSeOKlAgIfKtiMjIDdf7xB9TSqSEUDEahd2xiBlvb8+lSaYgtLxdyABf+Wb9D3/yaQ/Mlju0d3jjDoT04yPlPHP0qzNKHk+yW/l7OZW3Z9OBnv61RcebfMIZDHG2MqwztXkkLRbz7b5igMkYA2diB2yadrIV7mlIjRBLmScsCoQgNyR3BHTrUIZZopPLwroR5RYbQOfbqeaW7kfIjlSTy/4cMMLz/nmmTzERsqhk2nkA9j0yfrzUjTLbXBgs7mI3JyqlVDDhgT/nrUiXFy0URKEeWmATgAL3+tU2X7QLe3bYY3G5pASASvck9qW0Mq7lmXJB+UjsCKC0y0gAjuHKq4dshQCWUZz9ORTZLmNmSeVBIcFQNxyeP6cVWgum+0vbjGHQBucH0wPwq2v2QSXCGKQxvjy3BA2jHQD1pJPqJsz/ACBHMxMoWHyiAjHr7YqWIFbd4TGPMWNVjIPI79OmKgntjcXkTDyowRj5FyFx7dc+tPjkEjzyrIF8ojLY+/ngACql5D6BcxiNngBYtOFJ2p374pMxmCaTcsMaDP7wfeYdsevela5H2lwJDuVcbgeRj/61MuIoZJWjLY3EFc8DkUJLqIrGReAJw4IRlb+FuecUkRkEkrqocFjNuPXA7UXar9shij8vys4IHrnrUCkfbLqNXZw5woIwSM1XKguJbTAXRmXELqSU2jKgNjsaW3Z3ubu4mnQJE5BLHJJPT659azxcNE21iDhTvIP3tp4zUELl7aRxnZJJ5g9TjpWkYks0LW98xZEkISVSFb1bnI59MVUuhEtwroPvfNgnJFRboHkEjsF8xeAOpI5BNZL2tx9u+0rNhA2A3+0R0NapXE2ads1wY4ZDIB5ny7c5xg1chjV7iZbZSZI3BIHLEY7frVG0BiVFl+byfvJ/GCD6d/rU5uBHPcPDmPKbc556ZocQjqhl46LFLAl3vEZBbnjc3XA9ulPeRAzPMFGCO3OemB+NYNuUkjIciN8FSAOW7jNaqy+ZBKyqrFyjDPO3pxWckPY14mWSacoo6/LuOd3b+lWJYYfInkV3Dvkqqj7oI9e9RWxM1+ACigRgjnrxzVnVmR7ZFVVUIQoAPQGsdmO46xk8iKCOMgbvlb2bpSlNtuY5GGBlycdCDwKimjcpOEwojZSvPpUbpLiRlwA+CIx6A9T9aAuWY7IFIiC26UNtyOo7VHd+VPDkxbIkIVcD0PIPvmi6nUW9rjJJfAwen/1qiBZpzCoIVX3AejdaCRkbhlhg3uSoIRm+vFE/mhriUMo3qFbHUk8GonjREiWWYq4YucHnGaddjfI4iySfvD1x/wDWoSAqRxfZ7p1LbkPVOuRUIljRgTCXCPvOOQewqW5E0kMTxYViSpPqPeq81uYLyQpI7RMMFjgZO3r9K0SQmxGbN40zoAAWYp6E1RdX2jLBFbOcnpjpViBJkvFiaQyoF3fKODnsagRk+0TFi22Qn5Tz3pklmZY54oi6qrMmFPt7+9Ubm4McDwoWeNZNwYDjj0/Grc1ukagShjsww9Me1RWx35QcorbY4+2T3qhNEQEPls8YcSbMLngD1zSw6YJIkjZ9k7fdweHBPJP0FT7pZd1ux/dK5JZRzn3NSRrIkitH+9eRMD60mxWI7G1MkoXKxryitng9qnvwi3EkdugIKBAR1460+3tZHnTy5RhQWHHCnHpVeISvOX3MTt2u/p60mxj43MuQwCD5foAO9JHFbJcyhEZjj5XPTPr7Un2nIiLruRfkAA/hHc0+Bd0Y3DCq+SR3HpQAyfzZklmmbABAwvqOgqSF4HjJmUcsSW6lif4fwqK8mCxNgF4EAxnAPJ6n1qVUjVGlVxuKBmHYHPb8KNhkdvJHBM54yxIU9cGoVfy1ljjI8uZSr5HOB6VLOnlxiNMbD82/POagcrE0JLLIXXAA/hPvQhDVeIQxZYPFxnPUAdqmgLmctHGZNzALF1Y5OBj8arrtNs5jZA7cbf7vrWloBW11SzmkmAQMUaQfwZBAb8CQaGBLcaVCsxguNUs4bsZPl4YqhzyDIBtGOnoKqESwXbW0kLRTxkoy9SD6g+/rXSTWkw1axuA88clvEImsUgZ2dQMFEIG1kfk7if4ua5nxDIUu4EglR5LeGOCVozkblHIB74+7n2p2JUm2dHe/6i0ccMM4x2qK3JeMzFiJcsdw60UVmbF4SmLyAFQ/aIwHLLk8Ht6Ve0GFLm9tTcAyb/MdgTwSpGB9OaKKXUHsPvgovbiWJRDjftWPgKM4wPaoIFA8yTqywkjPQciiikwWxNfRhNL89c+aZME/8BzS6OqO581BIDGDhicZI60UUhojtY1a1k3chFAA9qvQAzSBHZtojyAOPpRRQMz5ZGGpBBjC/uxwMkYzz61MkjBmXJIOFOf96iigaFmAjvXdRgqzKPy6/Wq5HkXkscZO0nvyegoopDZK7mfW2Dhfnxu2jGcAVLOqwarsQAgJgbucZODiiim9yTI1JAiXjKSGjddpH1pZiUltGU8yfK3uKKKuOwGJeYRmRQABG4/U1T09m8qFdzEEf0oorWImZ2oSsGtVAAPnbN2OcdKWYfZ76Mxk4mG1weQRn0ooq47kyNiaNTZ/bRkTmfyyR0IwO3rVGeVkLOMFnTJz2OccUUVYlsVrKJZLiJnyTIuW+ua2oyFhVwq7nZGbjqaKKwmMsNIYLpxFhd5Cn6HrUV+7NPsZiVV1A+lFFQhl2EkzbSSQ82w/SrF27FrNicneU/D0oopPcBqkeVbR7VKkE5PWqpndoJNxznbn3ooqWA2WdpnVmVBtnKLgfdGOgp13kXkkuSXCAj6nrRRVIGQzDD3JGfuI2O2TVeTh7odthbHvRRVLYhharuljUlgHQqcHsOlVhCirKyjDAcH8KKKYApPkxAkncOc+9V4JHju4EVjtQlh9aKKoDTswEiu3CjLK2R261Ws52muGMgUkx46YwKKKliY6RyPtAXACABcduKfCSLEJnKu+5vfrRRSGSxW8aWzsByI+PzqLyxNDtbOM9qKKfUCreoBI65OAM1Xu0+SE7m5UZ560UU2Ayd2haERkjdyaqwDckm4kkHcPrRRSiJmpKVYQhkQjbkjHWqlsxAkUYClugoooYIsrqN7Fpxgju7hYG4MYkO3HpisqcA2ca44Y84oopoD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Palpable purpuric lesions are present on the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Palpable purpura",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Palpable purpura are present on the legs of this patient with cutaneous small vessel vasculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:",
"     <a href=\"file://www.visualdx.com\" target=\"_blank\">",
"      www.visualdx.com",
"     </a>",
"     . Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Leukocytoclastic vasculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous petechiae are present on the lower leg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutaneous leukocytoclastic vasculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vesicles overlying purpuric macules are present on the lower leg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cutaneous small vessel vasculitis with ulcer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A small ulcer and areas of hyperpigmentation are present in this patient with cutaneous small vessel vasculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_26_44458=[""].join("\n");
var outline_f43_26_44458=null;
var title_f43_26_44459="Technique of central venous catheterization";
var content_f43_26_44459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Technique of central venous catheterization",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Identify vessel or pertinent landmark",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prepare the site by scrubbing widely with antiseptic solution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drape the site with sterile towels and surgical drapes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infiltrate the skin with 1 percent lidocaine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cannulate the vein using the introducer needle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Confirm position of needle by easy aspiration of venous blood; if doubt exists regarding venous versus arterial cannulation, transduction of pressures or blood gas analysis is recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Remove syringe from needle hub",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insert J-tipped guidewire through the needle into the vein and gently advance the wire;",
"        <strong>",
"         never",
"        </strong>",
"        force the wire",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Remove the needle while maintaining control of the guidewire",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Make a small skin nick contiguous with the wire using an upward-facing scalpel blade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Advance the dilator over the wire using a twisting motion; always hold the guidewire",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Withdraw dilator while guidewire is stabilized",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thread the catheter over the guidewire; always hold the guidewire",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stabilize the catheter and remove the guidewire",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evaluate ease of aspiration and flushing from each port of catheter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suture the catheter securely, dress site with sterile technique and topical antiseptic ointment",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_26_44459=[""].join("\n");
var outline_f43_26_44459=null;
var title_f43_26_44460="Factors affecting exhaled NO";
var content_f43_26_44460=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors affecting exhaled and nasal nitric oxide measurement",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Increased nitric oxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Papaverin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Sodium nitroprusside",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            L-arginine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Enalapril",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"1\">",
"            Air pollution exposure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ingestion of arginine or nitrite/nitrate rich foods",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Chemical exposure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Fluoride",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ozone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Chlorine dioxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Latex",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Formaldehyde",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Upper respiratory tract infections",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Decreased nitric oxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Oxymetazoline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            NOS inhibitors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Repeated spirometry",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Exercise",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Menses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sputum induction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Reduction in body temperature",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Chemical exposure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Water vapor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Nitrous oxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Heptane",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Carbon dioxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            100% oxygen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Smoking",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Caffeine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Alcohol ingestion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Moderate altitude",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Kharitonov, SA, Barnes, PJ, Am J Respir Crit Care Med 2001; 163:1693.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_26_44460=[""].join("\n");
var outline_f43_26_44460=null;
var title_f43_26_44461="Drugs used to treat pericardial disease in pregnancy";
var content_f43_26_44461=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Anti-inflammatory and immunosuppressive drugs potentially useful in the treatment of pericardial disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Drug",
"      </td>",
"      <td class=\"subtitle1\">",
"       Pregnancy category*",
"      </td>",
"      <td class=\"subtitle1\">",
"       Transplacental passage",
"      </td>",
"      <td class=\"subtitle1\">",
"       Teratogenicity",
"      </td>",
"      <td class=\"subtitle1\">",
"       Potential fetal-neonatal adverse effects",
"      </td>",
"      <td class=\"subtitle1\">",
"       Long-term effects offspring",
"      </td>",
"      <td class=\"subtitle1\">",
"       Fertility impairment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Aspirin (analgesic dosed) and non-selective NSAIDs",
"      </td>",
"      <td>",
"       <p>",
"        C (1st, 2nd T)",
"       </p>",
"       <p>",
"        D (3rd T)&bull;",
"       </p>",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       <p>",
"        No pattern of birth defects established. Use in late pregnancy avoided due to concerns over premature constriction of ductus arteriousus, reduction in renal blood flow and alteration of maternal and neonatal hemostasis (3rd T).",
"       </p>",
"       <p>",
"        Rare reports of cardiac defects, gastroschisis, low birth weight, or prolonged gestation may be exposure related (all T).",
"       </p>",
"      </td>",
"      <td>",
"       Unknown (none detected with low dose aspirin)",
"      </td>",
"      <td>",
"       Case descriptions of follicle rupture inhibition associated with prolonged use. May increase risk of spontaneous abortion if used at time of conception.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Celecoxib",
"      </td>",
"      <td>",
"       <p>",
"        C (1st, 2nd T)",
"       </p>",
"       <p>",
"        D (3rd T)",
"       </p>",
"      </td>",
"      <td>",
"       Expected",
"      </td>",
"      <td>",
"       <p>",
"        Unknown (human)",
"       </p>",
"       <p>",
"        Yes (animal)",
"       </p>",
"      </td>",
"      <td>",
"       Unknown. Interferes with embryonic development in rats and rabbits.",
"      </td>",
"      <td>",
"       Unknown",
"      </td>",
"      <td>",
"       Unknown. Interferes with fertility in murine models.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prednisone",
"      </td>",
"      <td>",
"       <p>",
"        D (1st T)",
"       </p>",
"       <p>",
"        C (2nd, 3rd T)&Delta;",
"       </p>",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       May increase risk of orofacial clefting (1st T) and restrict fetal growth (all T).",
"      </td>",
"      <td>",
"       None detected",
"      </td>",
"      <td>",
"       Experience does not suggest impairment.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Colchicine",
"      </td>",
"      <td>",
"       C",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       <p>",
"        No (human)",
"       </p>",
"       <p>",
"        Yes (animal)",
"       </p>",
"      </td>",
"      <td>",
"       Experience (treatment of pregnant women with FMF) does not suggest adverse embryonic effects. However, prenatal diagnosis for chromosomal abnormalities should be offered.",
"      </td>",
"      <td>",
"       Unknown",
"      </td>",
"      <td>",
"       Experience in women does not suggest impairment. Rarely causes infertility in men.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Azathioprine",
"      </td>",
"      <td>",
"       D",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       <p>",
"        No (human)",
"       </p>",
"       <p>",
"        Yes (animal)",
"       </p>",
"      </td>",
"      <td>",
"       Experience does not establish an increased risk of birth defects or miscarriage. Reports of hematologic abnormalities, immune impairment, growth restriction and prematurity may be exposure related.",
"      </td>",
"      <td>",
"       Unknown",
"      </td>",
"      <td>",
"       Experience does not suggest impairment. May interfere with efficacy of intrauterine contraceptive devices.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Methotrexate",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       Spectrum defects include skull, facial feature and limb anomalies when exposed during organogenesis (1st T). CNS abnormalities also reported. Growth retardation and mortality may be elevated in 2nd and 3rd T exposure. Some clinicians offer folinic acid to women who stop methotrexate during pregnancy.",
"      </td>",
"      <td>",
"       Developmental delay and intellectual impairment reported",
"      </td>",
"      <td>",
"       Oligospermia in men and amenorrhea in women when used for cancer chemotherapy in combination with other agents.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cyclophosphamide",
"      </td>",
"      <td>",
"       D",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       Skeletal, palate, ocular and limb defects associated with exposure during 1st T. 2nd and 3rd T exposure associated with smaller risk of malformations but hematologic abnormalities and growth restriction reported may be exposure related.",
"      </td>",
"      <td>",
"       Unknown",
"      </td>",
"      <td>",
"       Gonadal toxicity established in dosage regimens for cancer chemotherapy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cyclosporine",
"      </td>",
"      <td>",
"       C",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       Experience, based on limited case reports, does not establish an increased risk of birth defects. Reports of growth restriction, miscarriage, and preterm delivery may be exposure related.",
"      </td>",
"      <td>",
"       Unknown",
"      </td>",
"      <td>",
"       Experience does not suggest impairment.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IV Immunoglobulins",
"      </td>",
"      <td>",
"       C",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       Experience does not suggest an increased risk of congenital anomalies or other adverse embryonic effects. Preparations that do not contain thimerosal are preferred in pregnancy.",
"      </td>",
"      <td>",
"       Unknown",
"      </td>",
"      <td>",
"       Unknown",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     T: trimester of pregnancy; NSAID: nonsteroidal anti-inflammatory drug; FMF: familial Mediterranean fever.",
"     <br>",
"      * For description of US FDA pregnancy categories, see \"FDA pregnancy categories\" table. Also see: file://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093310.htm concerning ongoing revision of US FDA pregnancy risk labeling and phased elimination of lettered categories (A through D and X).",
"      <br>",
"       &bull; According to US FDA product information for aspirin containing combinations, risk category is D all trimesters due to aspirin component (aspirin and dipyridamole: file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=12170 [Accessed 01/02/2010]; aspirin and oxycodone: file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=13309).",
"       <br>",
"        &Delta; According to US FDA product information, prednisone is risk category C or no lettered risk category is designated depending on specific product (prednisone: file://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=prednisone&amp;x=21&amp;y=11 [Accessed 01/04/2010]).",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      1. Briggs, GG, Freeman, RK, Yaffe, SJ. Drugs in pregnancy and lactation 8th ed. file://www.briggsdrugsinpregnancy.com (Accessed 01/02/2010).",
"      <br>",
"       2. REPROTOX&reg; database. file://www.reprotox.org/Default.aspx (Accessed 01/02/2010).",
"       <br>",
"        3. US FDA product information. file://dailymed.nlm.nih.gov/dailymed/about.cfm (Accessed 01/02/2010).",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_26_44461=[""].join("\n");
var outline_f43_26_44461=null;
var title_f43_26_44462="Exostosis of the external auditory canal";
var content_f43_26_44462=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Exostosis of the external auditory canal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Exostoses are multiple benign bony growths of the external auditory canal that most commonly occur in individuals who have had repeated exposure to cold water.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from Nikolas H Blevins, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_26_44462=[""].join("\n");
var outline_f43_26_44462=null;
var title_f43_26_44463="Approach to axillary adenopathy in children";
var content_f43_26_44463=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 631px\">",
"   <div class=\"ttl\">",
"    Suggested approach to axillary adenopathy in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 611px; height: 688px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CBC: complete blood count; ESR: erythrocyte sedimentation rate; PPD: purified protein derivative test for tuberculosis.",
"     <br>",
"      * Empiric antibiotic therapy should include coverage for common pathogens such as group A streptococcus and",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      (eg, clindamycin in areas with a high prevalence of community-associated methicillin-resistant",
"      <em>",
"       S. aureus",
"      </em>",
"      (CA-MRSA) or a first-generation cephalosporin (eg, cephalexin) or amoxicillin-clavulanate in areas with a low prevalence of CA-MRSA).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Based on information from:",
"     <br>",
"      <ol>",
"       <li>",
"        Soldes OS, Younger JG, Hirschl RB. Predictors of malignancy in childhood peripheral lymphadenopathy. J Pediatr Surg 1999; 34:1447.",
"       </li>",
"       <li>",
"        Slap GB, Brooks JS, Schwartz JS. When to perform biopsies of enlarged peripheral lymph nodes in young patients. JAMA 1984; 252:1321.",
"       </li>",
"      </ol>",
"      <br/>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_26_44463=[""].join("\n");
var outline_f43_26_44463=null;
     